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Background: Metastatic dissemination often occurs at early stages of breast cancer 
progression implying that disseminated cancer cells (DCCs) evolve outside the 
primary tumor in a process of selection and adaptation. To identify metastasis founder 
cells in humans we strived to construct cell lineage trees by longitudinally tracking 
genetic changes in cancer cells isolated from patients at various disease stages.  
 
Methods: We used sample triplets comprising primary tumor, bone marrow DCCs 
isolated at presumably curative surgery and CTCs/DCCs at a further time point before 
and after progressing into metastasis. To prepare samples for single cell lineage tree 
analysis we developed robust methods for isolation of single cells of high DNA quality 
from all tissues, including - (i) Isolation of single cells from flash frozen tumor tissue; 
(ii) Laser capture microdissection to isolate DCCs from diagnostic cytospins; (iii) 
Isolation of blood CTCs from CellSearch cartridges. In addition, we isolated CD3+ T 
cells, CD68+ macrophages and oral epithelial cells to serve as outgroups for cell 
lineage tree analysis. Cell lineage tree reconstructions are based on short tandem 
repeats (STRs) mutations reflecting cell divisions which determine cellular descent by 
tracing random mutational events. Around 12000 STR loci are sequenced after target 
enrichment using a patient-generic panel of duplex molecular inversion probes. 
 
Results: Detection, isolation and whole genome amplification from all sample sources 
could be successfully established. Results of STR based lineage tree analysis showed 
a significantly separate clustering of advanced primary tumor cells from metastatic 
cells. Interestingly these metastatic cells have detectable early DCC ancestors.  
 
Conclusions: The data allows reconstructing the genomic make-up of metastases 
founder cells from the available phylogenetic trees.  Longitudinal analysis of systemic 
breast cancer evolution may provide insights for diagnostic monitoring and inform the 









1.1. Cellular organization of the mammary gland 
 
The human adult mammary gland consists of branching ducts and lobules which are 
ectodermal in origin and stromal tissue which is mesodermal in origin, consisting mostly of 
adipocytes (Javed and Lteif 2013). Mammary glands mature at puberty by a process called 
branching morphogenesis (Lyons 1958), when the ductal epithelium grows into the adipose 
tissue in response to hormonal cues (Inman et al. 2015). Small morphogenetic changes at 
menstrual cycles to major remodelling events during pregnancy are orchestrated by cell 
differentiation, proliferation and apoptosis (Inman et al. 2015). A mature mammary duct is bi-
layered (Figure 1) and comprises myoepithelial cells, which are in contact with the basement 
membrane, and luminal epithelial cells, which line the ducts (Inman et al. 2015). The mammary 
epithelium also consists of stem and progenitor cells which can give rise to both basal and 
luminal cell types and thereby maintain the epithelium (Visvader and Stingl 2014). During 
pregnancy the mammary epithelium rapidly proliferates to give rise to secretory alveoli. During 
lactation, the luminal cells secrete milk while the basal cells contract to help transport the milk 
through the ductal structures to the nipples. At weaning, the mammary epithelium undergoes 
massive apoptosis in a process called involution to return to its ‘pre-pregnant’ state (Inman et 
al. 2015). These complex tissue remodelling processes are tightly regulated in the healthy 
state, understanding of which can provide insights into diseases like breast cancer which 
occur due to disregulation of normal mammary gland development pathways (Visvader and 



























Figure 1. Breast anatomy. Mammary epithelium consists of a bilayer of two types of cells. Outer layer is made up 
of basal cells also called myoepithelial cells and inner layer consists of luminal epithelial cells. The basal layer also 
consists of stem and progenitor cells which gives rise to both cell types in the bilayer. The basement membrane 




1.2. Breast Cancer 
 
Breast cancer is one of the most common malignancies in women around the world. In 2018, 
more than 2 million diagnoses of breast cancer (11.6% of all diagnosed cancers worldwide) 
and 626,679 deaths (6.6% of global cancer related deaths) were estimated (Bray et al. 2018). 
In females, breast cancer accounts for 24.2% of all diagnosed cancers and contributes to 15% 
of all cancer related deaths (Torre et al. 2016; Seely and Alhassan 2018; Bray et al. 2018). It 
has been estimated from the current incidences that 1 in 8 to 10 women will develop breast 
cancer during their lifespan (Harbeck and Gnant 2017). The incidence of breast cancer in 
males is very low and accounts for <1% of all breast cancers and <1% of all diagnosed cancers 
in males (Abdelwahab Yousef 2017). Only female breast cancer has been addressed in this 
dissertation.  
 
1.2.1. Breast cancer classification 
 
Breast cancer can be classified broadly as either carcinoma in situ or invasive carcinoma 
(Malhotra et al. 2010) on the basis of histology. Carcinoma in situ is a non-obligate precursor 
of invasive carcinoma, refers to a stage where the cancer cells have not crossed the basement 
membrane to invade the surrounding tissues and includes ductal carcinoma in situ (DCIS) and 
lobular carcinoma in situ (LCIS) originating in the ducts and lobules respectively (Wen and 
Brogi 2018; Jaffer and Bleiweiss 2002). DCIS accounts for around 20% of breast tumors 
detected by mammography (Narod et al. 2015), however, LCIS cases are rare (0.5-2.5%) and 
are usually identified incidentally in breast biopsies (Wen and Brogi 2018). Similarly, invasive 
carcinoma includes both ductal and lobular types. Invasive ductal carcinoma (IDC) also called 
‘no special type’ (NST) accounts for around 75% of breast carcinoma diagnoses (Li et al. 2003; 
Li, Uribe, and Daling 2005). Invasive lobular carcinoma (ILC) accounts for around 15% of all 
breast cancers (Arpino et al. 2004) and is characterized by small, round cells infiltrating the 
stroma in an irregular sheet-like pattern, instead of forming a tumor mass (Li, Uribe, and Daling 
2005). ILCs are hard to detect by standard diagnostic tools including mammography and 
ultrasound (Hogan et al. 2015; Li, Uribe, and Daling 2005). Other classes of breast carcinoma 
include six rare histological subtypes namely inflammatory, medullary, papillary, mucinous, 
tubular and comedo carcinomas, each of which show differences in clinical characteristics, for 
example inflammatory carcinomas show poor survival rates (Li, Uribe, and Daling 2005).  
 
Another important classifier reported by pathologists is the tumor grade, which is determined 
histologically according to growth patterns and degree of differentiation in the tumor tissue, 
where grade 1 refers to a well-differentiated tumor closely resembling normal breast tissue 
and grade 3 refers to a poorly differentiated tissue (Rakha et al. 2010). The degree of 
differentiation is calculated on the basis of three morphological features which include degree 
of tubule formation, cellular pleomorphism, and mitotic count (Rakha et al. 2010).  
 
Assessment of anatomical extent of the disease is performed according to the TNM 
classification system which basically characterizes breast cancer on the basis of three major 
parameters, i) T denotes the features of the primary tumor, mostly size and local invasion and 
varies from T1-T4 with ascending order of severity; ii) N denotes the presence of disseminated 
cancer cells (DCCs) or micro-metastases in the lymph nodes, whereby N0 implies no 
involvement of lymph nodes, while N1-N3 indicate spread in increasing order; iii) M indicates 
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the absence or presence of distant metastasis, which could be either M0 or M1, respectively 
(Rosen and Sapra 2020). The combination of the above parameters defines the stage of the 
disease (Rosen and Sapra 2020). Stage 0 is assigned to non-invasive cancers like DCIS, 
stage I-III are considered early breast cancer without distant metastasis and stage IV refers 
to metastatic breast cancer. More recently, tumor grade and biomarkers including receptor 
status has also been incorporated in the staging system (O'Sullivan et al. 2017; Giuliano, 
Edge, and Hortobagyi 2018; Cserni et al. 2018). 
 
Breast tumors are clinically categorized depending on the expression of estrogen (ER), 
progesterone (PR) and human epidermal growth factor 2 (HER2) receptors. 1) ER, PR positive 
and HER2 negative cancers account for around 70% of all breast cancers; 2) HER2 enriched 
cancers, account for 15-20% of tumors; 3) Around 15% tumors do not express any of these 
cell surface receptors and are thus called triple-negative breast cancers (Waks and Winer 
2019; Howlader et al. 2014). Hormone receptor positive status is identified by the expression 
of ER or PR in at-least 1% of the tumor cells (Hammond et al. 2010), found by 
immunohistochemistry (IHC). HER2 receptor status is also determined by IHC; for a positive 
status >10% tumor area must stain for HER2. In uncertain cases, this method is 
complemented by in-situ hybridization to identify amplification of the HER2 gene (Wolff et al. 
2013).  
 
Gene expression studies led to molecular subtype classification (Perou et al. 2000; Sorlie et 
al. 2001), which largely identified four clinically relevant subtypes of breast cancer namely 
luminal A, luminal B, HER2-enriched, and basal-like each of which has distinct prognosis, 
treatment strategies and response to therapies (Harbeck and Gnant 2017). The hormone 
receptor (HR)  positive cancers, also known as luminal-like cancers are further classified as 
Luminal A and Luminal B, both showing expression patterns similar to the luminal cells in the 
breast epithelium (Sorlie et al. 2001). Luminal B cancers have higher expression of cell 
proliferation markers and lower expression of hormone receptors (Sorlie et al. 2001; Brenton 
et al. 2005; Prat et al. 2013). Ki67 is a cell proliferation marker and is used to clinically identify 
luminal B cancers by immunohistochemistry (Ades et al. 2014). Next, basal-like tumors have 
a gene expression pattern similar to basal/myo-epithelial cells of the breast epithelium 
(Sotiriou and Pusztai 2009). Around, 80% of triple-negative breast cancers (TNBCs) are basal 
like (Weigelt, Baehner, and Reis-Filho 2010; Prat et al. 2015). Another major subtype 
belonging to the TNBCs group include claudin-low tumors, which display enhanced 
mesenchymal and stem-like properties (Foulkes, Smith, and Reis-Filho 2010).  
 
Furthermore, on the basis of distinct copy number alterations (CNAs) and expression profiles, 
up to ten different subtypes have been reported (Curtis et al. 2012). Thus, breast cancer is 
highly heterogenous and demands a personalized approach to diagnostics and therapy. 
 
1.2.2. Breast cancer treatment 
 
Primary breast cancer is treated loco-regionally by  surgical resection of tumor and removal of 
adjoining lymph nodes, which is sometimes followed up with post-operative radiation therapy 
(Waks and Winer 2019).  Systemic therapy includes cytotoxic chemotherapy and targeted 
therapies which are determined on the basis of the diagnosed molecular subtype. For 
example, HR positive breast cancers are treated by downregulation of ER receptor signaling 
(endocrine therapy) with tamoxifen or aromatase inhibitors, which is sometimes combined with 
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chemotherapy if the cancer is luminal B or has a higher nodal status (Waks and Winer 2019), 
trastuzumab, an anti-HER2 antibody is prescribed for HER2-positive breast cancer with 
chemotherapy, sometimes in combination with endocrine therapy if HR positivity exists 
(Slamon et al. 2011; Romond et al. 2005). TNBCs however cannot benefit from targetted 
therapies due to the lack of ER, PR or HER2 receptors and only rely on chemotherapy for 
tumors larger than 5mm (Waks and Winer 2019).  
 
Unfortunately,metastatic breast cancer is considered incurable with current treatment regimes 
and treatment is mostly palliative (Harbeck and Gnant 2017). Systemic therapy is usually 
prescribed to manage metastatic disease and very rarely locoregional intervention takes place 
(Waks and Winer 2019). Metastic relapse is treated by sequential addition of new therapeutic 
agents, for example metastatic HR positive/HER2 negative disease, is treated at first with 
endocrine therapy along with cyclin-dependent kinase (CDK) 4/6 inhibitors. After development 
of resistance, chemotherapeutic agents are introduced sequentially to minimize toxicity (Waks 
and Winer 2019). Metastatic HER2 positive cancers are treated with chemotherapy with 
continuation of HER2 targeted therapy (von Minckwitz et al. 2009). Metastatic TNBCs  (without 
BRCA1/2 mutations) are also treated with sequentially varying  chemotherapeutic agents 
(Waks and Winer 2019). Some therapeutic decisions are also based on the genomics of the 
cancer cells, for example BRCA1/2 are tumor supressor genes and approximately 5% of 
breast cancer patients have mutations in these genes, and BRCA1/2 mutated cells can be 
targeted by FDA approved poly(adenosine diphosphate-ribose) polymerase (PARP) 
inhibitors which leads to cell death (Robson et al. 2017). Immunotherapy using anti-PDL-1 
antibodies has also been used for treatment of metastatic breast cancers having microsatellite 
instability (Waks and Winer 2019). 
 
1.2.3. Breast cancer prognosis and survival 
 
Multiple factors influence the prognosis and survival of breast cancer patients, mainly 
histological type, grade, stage and molecular subtypes. Breast cancer specific mortality 
(percentage of deaths after diagnosis) for DCIS (Stage 0) and small invasive breast cancer 
(node negative) patients after 15 years of diagnosis was 2% and 4.1%, respectively 
(Giannakeas, Sopik, and Narod 2018). Histological grade is also an important parameter to 
predict survival as the ten year survival rate (percentage of patients alive) of breast cancer 
patients among different grades with identical TNM stages shows significantly different 
prognosis where higher grade corresponded to poor prognosis (Schwartz et al. 2014). 
Moreover, the higher the stage at diagnosis the poorer the survival (Polyak and Metzger Filho 
2012).  Ten years after diagnosis the survival rates for early (Stage 0-I), locally advanced 
(stage II-III) and stage IV breast cancer were 94%, 75% and 9%, respectively (Vondeling et 
al. 2018). Additionally, molecular subtypes display different survival, which is highest for 
luminal A, followed by luminal B and HER2-enriched cancers (Fallahpour et al. 2017). Triple-
negative breast cancers have the poorest prognosis of all subtypes (Fallahpour et al. 2017; 
Haffty et al. 2006) and there is a sharp increase in relapse within three to five years of 
diagnosis (Foulkes, Smith, and Reis-Filho 2010). Apart from the clinical parameters, various 
other factors like genetic predisposition, age at diagnosis, socio-economic condition, and 
lifestyle choices also contribute to differences in incidence and overall survival rates of breast 
cancer (Vondeling et al. 2018; Oh et al. 2015; Foulkes, Smith, and Reis-Filho 2010; Shariff-
Marco et al. 2015).  
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Around 90% of cancer related deaths are caused by metastatic disease (Brabletz et al. 2013).  
Although, advances in diagnostics have led to improved early detection of primary tumors so 
that more than 90% of breast cancers are now diagnosed at an early stage (Waks and Winer 
2019), approximately 30% of women diagnosed with early stage breast cancer would relapse 
months to decades after curative surgery (O'Shaughnessy 2005; Tjensvoll et al. 2019). 
Unfortunately, the five year survival rate of metastatic breast cancer to date is a dismal 25% 
(Rabbani and Mazar 2007; Valastyan and Weinberg 2011). Median overall survival of 
metastatic breast cancer varies from approximately 1 year in TNBCs to 5 years in HR positive 




Metastasis is the process of dissemination of cancer cells from the primary tumor site to 
sucessful colonization of distant organs (Figure 2) and is the primary cause of cancer lethality 
(Valastyan and Weinberg 2011). It is a dynamic and multistep process in which the tumor cells 
enter circulation (blood or lymph) by various mechanisms like collective migration, undergoing 
epithelial to mesenchymal transition (EMT) or by passive shedding (Bill and Christofori 2015). 
Next the circulating tumor cells (CTCs) need to survive in the vasculature amid shear forces, 
anoikis and immune surveillance (Al-Mahmood et al. 2018; Blomberg, Spagnuolo, and de 
Visser 2018). CTCs are found associated with platelets which guard them from the immune 
system (Gay and Felding-Habermann 2011). Finally, the CTCs extravasate into distant organs 
or eventually get trapped in small capillaries (Bill and Christofori 2015). These extravasated 
cancer cells are then found in the distant sites as single cells or a micrometastasis which can 
remain quiescent (Valastyan and Weinberg 2011) or proliferate after undergoing 



























Figure 2: The process of metastasis. 1, Collective invasion of cells into surrounding tissue; 2, Single cells that 
underwent EMT enter circulation; 3, Passive shedding of metastatic cells; 4, Circulating tumor cells are found 
associated with thrombocytes in the circulation protecting them from shear forces and enhancing their sensitivity 
towards chemokine gradients (Al-Mahmood et al. 2018); 5, At distant sites circulating tumor cells extravasate 
through interactions with endothelial cells or; 6, get stuck in thin capillaries at distant sites; 7, The tumor cells 
start proliferating and colonizing by a process called mesenchymal to epithelial transition (MET). In the legend, 
E, epithelial characteristics; E/M having both epithelial and mesenchymal characteristics; M, mesenchymal 
characteristics. Figure taken from (Bill and Christofori 2015) 
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Breast cancer cells preferentially metastasize to bones, liver, brain and lung. Such preferential 
colonization can be seen in other cancers types as well, for example, prostate and colorectal 
cancer metastasize predominantly to bone and liver, respectively (Chambers, Groom, and 
MacDonald 2002). Various theories have been published about the reason for organotropism. 
The ‘seed and soil’ hypothesis (Paget 1989) proposed that a cancer cell (seed) is able to 
colonize a distant organ (soil), when the host microenvironment provides favourable growth 
conditions. Various microenvironmental factors, which supported this hypothesis, were 
subsequently found. For example, breast cancer cells carry CXCR4, which is the receptor for 
the chemokine CXCL12 (also called SDF1) secreted in bone marrow, thus making bone 
marrow a preferred niche for breast cancer metastasis (Luker and Luker 2006; Eckhardt et al. 
2012). Paget’s hypothesis was later challenged by James Ewing, who proposed that 
circulatory patterns from primary site to distant organs dictated the pattern of metastasis 
(Chambers, Groom, and MacDonald 2002). However, many autopsy studies subsequently 
found that both the theories hold ground and contribute to tumor metastasis (Chu and Allan 
2012). 
 
1.3.1. Fate of tumor cells in ectopic sites 
 
Cancer cells residing at distant organs are termed disseminated cancer cells (DCCs). DCCs 
must acquire adaptive mechanisms within the new environment to become proliferative and 
give rise to metastases (Nguyen, Bos, and Massague 2009). In breast cancer, metastasis can 
occur months to decades after removal of the primary tumor (Pan et al. 2017; Fallahpour et 
al. 2017). This could be explained by DCCs remaining in a state of dormancy which alters 
their metabolic profiles and enables evasion of apoptosis (Senft and Ronai 2016; Havas et al. 
2017; van der Toom, Verdone, and Pienta 2016). Alternatively, DCCs could exist in steady-
state proliferation, meaning that the proliferation rate is balanced by the rate of cell death 
induced by immune surveillance or lack of angiogenesis (Endo and Inoue 2019). Interestingly, 
recent study in our lab showed that around 50% of DCCs in early breast cancer patients are 
in a state of proliferation, thus supporting this hypothesis (Irlbeck 2019).  
 
Various factors contribute to the survival of DCCs and latency of breast cancer. Immune 
system (Suhail et al. 2019), anti-tumor therapy (Chatterjee and van Golen 2011) and the 
endothelial cells of the vasculature have been found to assist in keeping tumor cells dormant 
(Ghajar et al. 2013; Chatterjee and van Golen 2011; Sosa, Bragado, and Aguirre-Ghiso 2014). 
Bone marrow provides a permissive microenvironment for the DCCs to lay dormant until the 
arrival of an opportune moment to proliferate and colonize (Psaila and Lyden 2009; Psaila et 
al. 2006; Gomis and Gawrzak 2017; Linde, Fluegen, and Aguirre-Ghiso 2016). One such 
moment could be stochastic removal of immune surveillance that can bring dormant DCCs 
into proliferation (Malladi et al. 2016). However, it is not yet clear which combinations of 











1.3.2. Models of metastasis 
 
The linear progression model (Figure 3) of cancer evolution, holds that the metastasis founder 
cells (MFCs) evolve mostly within the primary tumor by sequentially acquiring somatic 
mutations (Lambert, Pattabiraman, and Weinberg 2017) and are among the most advanced 
clones which disseminate late during the progression of the primary tumor (Valastyan and 
Weinberg 2011). However, various clinical observations and data from animal models have 





















Many studies from as early as the 1950s pointed out that the late dissemination model of 
MFCs could not explain the growth rates of metastasis (Collins, Loeffler, and Tivey 1956; Klein 
2009). By assessing the growth kinetics from mammography studies it was shown that 
manifestation of metastasis would take six to twelve years, if cancer cells disseminated from 
primary tumor at an advanced stage shortly before surgery, however median metastasis free 
survival of patients with tumors <2 cm is 35 months, which indicated that primary tumors and 
metastasis must develop in parallel (Klein 2009). Also, metastases are detected at diagnosis 
in 5% of patients with small primary (T1 and T2) tumors (Engel et al. 2003) and in cancer of 
unknown primary (CUP) where there is no clinically detectable primary tumor (van de Wouw 
et al. 2002). Furthermore, no significant difference was found in the tumor size and the 
presence of DCCs in bone marrow of breast cancer patients (Klein and Holzel 2006). 
Interestingly, DCCs were also observed in bone marrow of ductal carcinoma in-situ (DCIS) 
patients, which by definition is considered as a precursor of invasive breast cancer (Banys et 
al. 2012; Sanger et al. 2011; Husemann et al. 2008).  
 
According to the SEER study involving 108,196 breast cancer patients, where decades long 
follow-up data is available, 54.1% of DCIS patients who died of breast cancer did not have an 
invasive in-breast recurrence prior to death (Narod et al. 2015), which indicates that DCIS 
cells have the intrinsic abilities to migrate and colonize. This phenomenon was also 
Figure 3: Linear vs. parallel progression. Top: The late dissemination model proposes that DCCs evolve largely 
within the primary tumor, gradually acquire somatic mutations there and resemble the most advanced clone in the 
primary tumor. In this scenario the DCC’s genomic profile must be similar to that of the primary tumor and therapy 
decisions based on the primary tumor should curb relapse. Bottom: In the early dissemination model, DCCs leave 
the primary tumor at a genomically immature state and evolve outside the primary tumor by acquiring somatic 
mutations at the distant sites. In such a scenario the metastases could be irresponsive to the therapy strategies 
based on primary tumor characteristics. Figure adapted from (Klein 2008) 
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demonstrated in mouse models of breast cancer where the majority of the metastases were 
generated from the pre-malignant tumors (Hosseini et al. 2016; Harper et al. 2016; Husemann 
et al. 2008). A similar demonstration of early dissemination was also seen in melanoma and 
pancreatic cancer models (Muzumdar et al. 2016; Eyles et al. 2010). 
 
Finally, genomic analysis of the disseminated cancer cells in carcinoma patients from our 
laboratory and others confirmed that dissemination of cancer cells to distant sites occurs early 
and long before the diagnosis of a primary tumor (Schardt et al. 2005; Klein et al. 1999; Klein 
2009) suggesting a parallel and non-linear evolution of primary tumor and metastases (Figure 
3). Metastases might therefore be resistant to targeted therapies based on the biomarkers of 
the primary tumor (Klein 2008). Hence understanding the mechanisms of parallel evolution by 
analysis of the residual disease (DCCs) would improve therapy decisions. 
 
1.4. Disseminated Cancer Cells  
 
1.4.1. Detection of DCCs  
 
Carcinoma cells can be detected in the bone marrow, lymph nodes and blood by 
immunocytochemical staining against epithelial markers, since these tissues are of 
mesenchymal origin and lack epithelial cells (Klein 2013; Schlimok et al. 1987). Many 
antibodies targeting various epithelial cell markers have been tested over the years, of which 
monoclonal antibodies against cytokeratins (CK) have been found to reliably detect DCCs 
(Pantel and von Knebel Doeberitz 2000). Using a consensus protocol where 2 million bone 
marrow cells were screened per patient, one to ten CK-positive cells can be found in 
approximately 30% of M0 patients (Fehm et al. 2006). 
  
The epithelial cell adhesion molecule (EpCAM) is another common epithelial marker used for 
detection of DCCs (Schlimok et al. 1987). Although EpCAM is not as specific as CK, being a 
cell surface marker it allows isolation of live cells for transcriptomic analysis (Guzvic et al. 
2014; Klein, Seidl, et al. 2002). EpCAM is also used for enrichment of tumor cells in bone 
marrow prior to CK staining (Woelfle et al. 2005). The FDA approved CellSearch system which 
enumerates CTCs in blood, is based on ferromagnetic enrichment of CTCs using anti-EpCAM 
antibody (Allard et al. 2004; Cristofanilli et al. 2005).  
 
1.4.2. Prognostic significance of detected DCCs 
 
Multiple studies have shown that the detection of DCCs in bone marrow leads to poor 
prognosis in carcinoma patients (Tjensvoll et al. 2010; Domschke et al. 2013; Hartkopf et al. 
2014; Janni et al. 2011). In breast cancer, approximately 30% of patients were found to be 
DCC-positive, and among the patients with small tumors (<2 cm and lymph node negative), 
DCC-positive patients had more than three times increased breast cancer specific mortality 
rates within the first five years of diagnosis than the DCC negative counterparts (Braun et al. 
2005). Recently, a multi-centre study involving 10,320 early breast cancer (T1–4, N0–2, M0) 
patients showed that detection of DCCs in bone marrow (27.4% of all patients) was an 
independent prognostic marker for reduced overall survival and distant disease-free survival 






1.4.3. Genomic analysis of DCCs 
 
CK positive cells in the bone marrow were found to harbor tumor specific chromosomal 
aberrations by fluorescence in-situ hybridization experiments, thus proving their malignant 
origin (Muller et al. 1996; Klein 2000). Single cell profiling by comparative genome 
hybridization (CGH) of DCCs from breast, prostate and oesophageal cancer patients without 
clinically detectable metastases revealed substantial heterogeneity (Klein, Blankenstein, et al. 
2002; Schardt et al. 2005; Schmidt-Kittler et al. 2003; Stoecklein et al. 2008; Weckermann et 
al. 2009). M0 DCC genomes show early genomic separation from the predominant clone of 
the primary tumour (Klein 2013). Characteristics of most M0 DCC genomes include fewer 
chromosomal aberrations compared to M1 DCC genomes and absence of typical cancer type 
specific aberrations and point mutations (Weckermann et al. 2009; Schmidt-Kittler et al. 2003; 
Klein, Blankenstein, et al. 2002; Irlbeck 2019). Data from breast cancer patients can be seen 
in Figure 4. Advanced, PT specific gains and losses like in 8q, 8p are missing in majority of 
the M0 DCCs (Hosseini et al. 2016). 
 
In contrast, DCC genomes are highly similar in patients with clinical metastases, suggesting 
expansion of an aggressive clone and a preference for a shared state of genomic changes 
(Klein 2013). It was observed that this acquired state of genomic aberrations is relatively 
stable, and is maintained in patient DCCs even after several cycles of chemotherapy (Klein, 
Blankenstein, et al. 2002; Klein 2013). This preferred genomic state is also seen in peripheral 
blood derived CTCs from M1 patients (Magbanua et al. 2013; Magbanua et al. 2012; Polzer 
et al. 2014). Interestingly, the genomes of DCCs and CTCs from M1 patients resemble those 
found in corresponding primary tumours (Weckermann et al. 2009; Schmidt-Kittler et al. 2003; 
Klein, Blankenstein, et al. 2002; Heitzer et al. 2013). The genomic difference between DCCs 
isolated from M0-stage patients and M1-stage patients raises questions on the evolution of 
systemic cancer. Are there some cell intrinsic properties that could potentiate the genomically 













In the M0 stage, when the primary tumor has been surgically removed, M0 DCCs must 
overcome several obstacles to evolve to the M1-DCC-like karyotype to give rise to lethal 
metastasis. Matched primary tumors and single cell CTC analysis of metastatic breast cancer 
patients indicate that important driver mutations of breast cancer like HER2 or PIK3CA could 
be acquired outside the primary tumor (Polzer et al. 2014). HER2 amplification was also found 
in some DCCs while their matched primary tumors did not have the amplification (Schardt et 
al. 2005).  In mouse models of breast cancer (Hosseini et al. 2016) and human melanoma 
Figure 4. M0-DCCs are genomically   
immature. Copy number alterations 
found in primary tumors of breast 
cancer (n=1637 from Progenetix 
database) compared to that of M0 
DCCs (n=94) and M1-DCCs (n=91). 
The ordinate depicts the percentage of 
cells with aberrations at the given 
chromosomal locus. Figure adapted 
from (Hosseini et al. 2016) 
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(Werner-Klein et al. 2018) it was shown that typical driver alterations required for colonization, 
are acquired outside the primary tumor. Thus DCCs which are capable of colonization must 
be characterized, to identify early events in the evolution of metastasis which could be relevant 
for therapeutic intervention (Schardt et al. 2005).  
 
It is noteworthy that the current data on genomic aberrations of M0-DCCs and M1-DCCs do 
not comprise longitudinally collected samples, i.e. no matched pairs of DCC from both M0 and 
M1 stage after detection of systemic metastasis of one individual patient have been obtained 
and analyzed so far. Phylogenetic analysis of longitudinally collected samples could help 
identify the metastasis founder cells (MFCs). 
 
1.5. STR based cell lineage tracing 
 
As multicellular organisms are products of multiple cell divisions of one single cell, the ‘zygote’, 
cell lineage tracing could allow identification of progenies of putative founder cells enabling us 
to understand various concepts in development and diseases like cancer (Shapiro 2018). 
While lineage tracing by direct observation is possible in the nematode C.elegans (Sulston et 
al. 1983; Sulston and Horvitz 1977) and transplantation and genetic engineering based 
invasive maneuvers could be performed in animal models (Kretzschmar and Watt 2012; 
Frieda et al. 2017; McKenna et al. 2016; van de Moosdijk et al. 2017), in human patients one 
could only probe retrospectively (Shapiro 2018). Human cell lineage reconstructions can be 
made by tracing somatic mutations which naturally occur in genomic loci during cell divisions. 
Such genomic regions include short tandem repeats (STRs), single nucleotide polymorphisms 
(SNPs), L1 retro transposable elements and copy number alterations (Behjati et al. 2014; 
Evrony et al. 2015; Lodato et al. 2015; Woodworth, Girskis, and Walsh 2017) 
 
STRs - also called microsatellites - consist of repeats of one to six base pairs, which are 
frequently mutated during mitosis, due to polymerase slippage at replication (Frumkin et al. 
2005). These mutations can be linked to cell divisions because each progeny acquires a 
distinct mutational signature (Frumkin et al. 2005). Among all naturally occurring somatic 
mutations, STRs possess one of the highest mutation rates of around 10-3 to 10-5 per locus 
per generation in humans (Willems et al. 2016). The higher the mutation rate, the lower is the 
number of genomic loci required to be sampled for obtaining reliable cell lineage trees 
(Frumkin et al. 2005). Owing to this fact, lineage relationships of cells with microsatellite 
instability are easier to resolve due to high STR mutation rates (Frumkin et al. 2005). 
 
Most STRs are present in non-coding regions of the genome hence these mutations are silent 
and do not affect the phenotype and are not under selection pressure, unlike driver mutations 
in cancer (Frumkin et al. 2005). STR based cell lineage reconstructions have been applied to 
questions of development (Reizel et al. 2011; Reizel et al. 2012; Salipante et al. 2010) and 
tumor evolution (Frumkin et al. 2008) in mouse models. In human cancers like leukemia, STR 
based phylogenies have revealed diverse mechanisms for relapse initiation (Shlush et al. 











1.6. Aims of the thesis 
 
In order to identify the MFCs and obtain novel insights into the evolution of metastatic breast 
cancer, we strived to obtain cell lineage trees by longitudinal tracking of breast cancer patients 
progressing from M0-stage to M1-stage disease (Figure 5). Hence we had two aims; i) 
Establishment of a cohort of breast cancer patients with triplet samples of primary tumor, M0-
DCCs at the time point of surgery and M1-CTCs at a time point after progression to metastatic 























Figure 5: Longitudinal tracking of breast cancer patients. A. Bone marrow is sampled at the time of primary 
tumor surgery for isolation of M0 DCCs. B. Primary tumor is analyzed. C. After the patient is diagnosed with 






2.1. Patient samples and collaborations 
 
2.1.1. Clinical cooperation  
 
To generate the triplet cohort of patients we collaborated with the Department of Gynecology, 
University of Tübingen, owing to their huge archive of BM slides in collaboration with Dr 
Andreas Hartkopf. For establishing the protocol several unrelated patients bone marrow 
cytopsins were tested which, also included samples from Department of Gynecology and 
Obstetrics, LMU Munich in collaboration with Dr Nadia Harbeck. 
 
2.1.2. Inclusion criteria 
 
Inclusion criteria for the study were i) Female breast cancer patients, ii) M0 at primary tumor 
surgery, iii) Detection of CK positive cells in bone marrow aspirate at primary surgery, iv) bone 
marrow derived archived frozen cytospins available for isolation of DCCs, v) progression to 




Written informed consent was obtained from all patients involved in the generation of the triplet 
cohort for lineage tree analysis. The study was approved by the local ethics committee of 
University of Regensburg (ethics vote numbers 07-079, 18-948-1) and University of Tübingen 
(ethics vote number 535/2016BO2).  
 
2.1.4 Bioinformatics Collaborations 
 
Cell lineage trees were generated in collaboration with Dr Ehud Shapiro, Department of 
Computer Science and Applied Mathematics, Weizmann Institute of Science, Israel. 
 
2.2. Single cell isolation techniques 
 
2.2.1. Standard Micromanipulation 
 
Single cells were isolated from adhesion slides or cell suspensions using a micromanipulator 
(PatchMan NP2, Eppendorf) coupled to an inverted fluorescence microscope (Olympus IX81). 
Cells were aspirated with the help of a 30 µm diameter glass capillary as previously described 
(Klein et al. 1999) and transferred to a separate field (called picking field) in an 8 chambered 
slide containing 200 μl PBS. Finally, the cell is aspirated in 1 μl PBS from the pick field into a 
200 μl PCR tube (Axygen, MAXYMum Recovery) containing 2 μl cell lysis buffer for whole 








2.2.2. Laser Microdissection (LMD) 
 
2.2.2.1. Sample preparation for LMD 
 
The entire slide undergoing LMD was stained in addition to the immunohistochemical staining 
of cells of interest. For counterstaining, the slides were incubated with Mayer’s hematoxylin 
for 2 minutes followed by washing 2 times with 1X PBS (pH 7.4) for 2 minutes. The cuvette 
containing the slides was left in 4 °C for at least 30 min for bluing. Next, the slides were 
dehydrated by dipping into pre-chilled (-20 °C) solutions of 70%, 90% ,100% ethanol and 
acetone for 5 seconds each (dehydration at RT should be avoided). Slides were used for LCM 




LMD was performed on Zeiss PALM Microbeam system consisting of a 355 nm pulsed 
frequency tripled solid state laser which can be controlled by the PALM Robo software. The 
beam diameter could be focused to <1 µm which allowed precise microdissection of single 
cells, the higher the magnification of the objective, the smaller would be the beam diameter. 
The sample to be micro-dissected was placed on the PALM RoboMover stage (which could 
be controlled using the PALM Robo software), after selection of the desired area of interest 
on the software the robotic stage automatically moved to the selected area. Default factory 
settings were loaded on the software followed by calibration of the laser marker (to calibrate 
a point seen on the screen as the point where laser should hit the sample) according to 
manufacturer’s instructions. Calibration of laser marker was repeated before microdissection 
of each cell to ensure precision. Cells of interest were micro-dissected with the laser cutting 
function with energy levels varying from 35-55% focused through a 40X objective to ensure 
sharp and precise cutting along the edges of the cells. Next two methods were possible for 





After laser cutting, single cells were catapulted into a silicon filled adhesive cap of a 200 μl 
PCR tube (Carl Zeiss) containing 4.5 μl of lysis buffer for WGA (see chapter 2.9.2). Due to the 
silicon filling in the cap the flight distance of a catapulted cell was reduced and due to the 
adhesive properties of silicon the cells would stick to the cap, thus augmenting the success of 
cell isolation. LPC energy was set to the minimum energy required to detach and successfully 
catapult the cells into the cap of the tube, which varied from 55-65% depending on the type of 
sample preparation. Various sample preparation methods were tested by Eva Maria Hecht, 




In this method, after laser cutting, cells were isolated from the slide using standard 
micromanipulation instead of LPC. A large amount of surrounding area was ablated using 
higher laser cutting energy (50-65%). Higher energy allows bigger cutting widths which is 
required to clear a larger area around the cell. In order to create space for contamination free 
standard micromanipulation, laser ablation was carried out in a radius of 25-50 μm around the 
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cell. (Supplementary Figure 1B). For standard micromanipulation the slide was dipped shortly 
in 1X PBS for rehydration, followed by incubation with a detergent cocktail (10 μl 10X OPA 
buffer, 2.6 μl 10% Tween, 2.6 μl Igepal, 69.6 μl PCR water) for 5 minutes. After a short wash 
in 1X PBS the slide was ready for standard micromanipulation as described in chapter 2.2.1. 
 
 
2.3. Isolation of DCCs from frozen archived cytospins 
 
2.3.1. Cytospin preparation 
 
Frozen cytospin slides collected over the last decades at the Department of Gynecology, 
University of Tübingen were sent to our lab on dry ice for this project. The slides were prepared 
according to a previously published protocol (Bauer et al. 2000). Briefly, 10-20 ml of bone 
marrow (BM) was aspirated from the anterior iliac crest during primary tumor surgery and 
processed within 24 hours. MNCs were isolated by density gradient separation using Ficoll 
(Biochrom, Berlin, Germany,1.077 g/ml). The isolated MNCs were counted and resuspended 
in 1X PBS to obtain a solution containing 1.5 million cells/ml. To prepare cytospins, 1 ml cell 
suspension was spun down at 1600 rpm for 2 min onto a glass slide using a cytocentrifuge 
(Hettich, Tuttlingen, Germany). The slides were allowed to dry at room temperature and 
thereafter stored at -20 °C.  
 
2.3.2. Detection and isolation of DCCs  
 
For detection of DCCs, frozen cytospins were stained for epithelial marker cytokeratin as 
described previously (Klein, Blankenstein, et al. 2002) with some modifications. Frozen 
cytospins were allowed to equilibrate to room temperature and incubated with blocking 
solution (10% AB serum/1X PBS) for 30 min. The blocking solution was discarded followed by 
incubation with A45-B/B3 antibody (Micromet, Munich, Germany) at a concentration of 2μg/ml. 
After 60 min, the primary anitbody was discarded and the slides were washed 3 times with 1X 
PBS. Next, slides were incubated for 30 minutes with secondary antibody anti-mouse AP-
Polymer solution followed by washing 3 times with 1X PBS. For development, BCIP/NBT 
solution (AP Conjugate Substrate Kit; Bio-Rad Laboratories) was prepared according to 
manufacturer’s instructions with 0.5% levamisole followed by incubating the slides for 12 min. 
After development the slides were washed again for 3 times with 1X PBS. Fixation with PFA 
was not performed for slides undergoing LCM. Screening of positive cells was performed 
using upright Olympus microscope (BX43). For cytopsins undergoing LCM, screening was 
performed under the PALM microbeam microscope (PALM Zeiss) where the location of 
positive cells could be saved as elements in the slide specific elements file on the PALM Robo 
Software. After screening, the slides were counterstained and dehydrated (chapter 2.2.2.1) 
followed by isolation by LCAM (chapter 2.2.2.2). 
 
2.4. Isolation of vimentin positive cells 
 
2.4.1. Preparation of adhesion slides from fresh blood  
 
MNCs from fresh blood were isolated as previously described (Klein, Blankenstein, et al. 
2002). Briefly, 5-10 ml of blood was washed with Hanks buffer solution and subjected to 
density gradient separation with 60% Percoll. The interphase cells were collected and 
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counted. Cells were diluted to a concentration of 500,000 cells/ml in 1X PBS and 1ml was 
dispensed per adhesion slide (Menzel, Braunschweig, Germany) at a density of 0.16*106 cells 
per 14 mm diameter spot. The cells were allowed to sediment for 1 hour followed by discarding 
the supernatant PBS. The slides were allowed to air dry at RT and then stored at -20 °C. 
 
 
2.4.2. Detection and isolation of vimentin positive cells  
 
Adhesion slides from healthy donor PBL or frozen archived patient cytospins were stained for 
mesenchymal marker vimentin using monoclonal Mouse Anti-vimentin antibody (clone V9, 
Agilent DAKO). The rest of the staining protocol is as in chapter 2.3.2. Vimentin positive cells 
were isolated by standard micromanipulation or LPC as described in chapters 2.2.1 and 2.2.2 
respectively. 
 
2.5. Isolation of MCF10a spiked-in mouse BM-MNCs 
 
2.5.1. Preparation of cytospins from mouse BM-MNCs with spiked in MCF10a cells 
 
Balb/C BM-MNCs were isolated as previously published (Hosseini et al. 2016). MCF10a cells 
were cultured as described (Grujovic 2019), harvested at 70-80% confluence, resuspended in 
1X PBS and counted. MCF10a cells were spiked into Balb/C BM-MNCs in a ratio of 1:100 to 
obtain a final suspension of 1.5*106 cells/ml. Cytospins were made using the Hettich 
Centrifuge Rotofix 32A by centrifuging 100 µl of cell suspension at 1000 rpm for 5 minutes 
over a spot of 30 mm2. After centrifugation the supernatant was carefully removed with a 
Pasteur pipette. The slides were allowed to dry at RT overnight. After drying, the slides were 
stored at -20 °C. 
 
2.5.1. Detection and isolation of MCF10a cells from mouse BM-MNC cytospins 
   
Frozen cytospins were allowed to equilibrate to room temperature and incubated with blocking 
solution (10% AB serum/1X PBS) for 30 min. The blocking solution was discarded followed by 
incubation with biotinylated A45-B/B3 antibody and biotinylated MOPC-21 antibody (isotype 
control) at a dilution of 1:150. Meanwhile ABC-AP complexes (VECTASTAIN® ABC-AP KIT) 
were prepared according to manufacturer’s instructions. After 45 min, the biotinylated 
antibodies were discarded and the slides were washed 3 times with 1X PBS. Next, slides were 
incubated for 30 minutes with ABC-AP complexes followed by washing 3 times with 1X PBS. 
For development, BCIP/NBT solution (AP Conjugate Substrate Kit; Bio-Rad Laboratories) was 
prepared according to manufacturer’s instructions with 0.5% levamisole followed by incubating 
the slides for 12 min. After development the slides were washed again for 3 times with 1X 
PBS. For isolation of MCF10a, slides were screened on the PALM Microbeam microscope 
and the coordinates of MCF10a cells were saved. Next the cytopsins were counterstained by 











Two samples of 7.5 ml blood were collected from patients in Cellsave tubes at University of 
Tübingen, sent to our laboratory at RT and analyzed within 72 hours of sample collection. 
Cellsearch was used for detection and enumeration of CTCs as described previously (Polzer 
et al. 2014). Briefly, CTCs were captured by ferrofluid coated with EpCAM-antibody, followed 
by staining for cytokeratin, CD45 and DAPI by an automated workflow. It is to be noted that 
for the first CellSave tube, the assay was conducted according to manufacturer’s instruction 
but from the second tube, plasma was isolated first, followed by diluting the cellular fraction 
with dilution buffer to reach the original volume of 7.5 ml, which was then prepped according 
to manufacturer’s instruction. 
 
2.6.2. Cell extraction  
 
When CTCs were detected in a Cellsearch run, cell suspension from Cellsearch cartridge was 
extracted into a 1,5ml Eppendorf LoBind tube using a 200 μl gel-loading pipette tip pre-coated 
in 2% BSA (to prevent cells from sticking to the tip, to avoid cell loss). Next, the cartridge was 
carefully rinsed with 325μl 1xPBS by pipetting on the inner walls repeatedly using a pre-coated 
gel-loading pipette tip for a total of two times. The entire fluid was collected in the 1,5ml 
Eppendorf LoBind tube. The sample was centrifuged with a swinging-bucket rotor centrifuge 
for 5 min at 1000 g, 20°C. The supernatant was discarded very carefully from above until 
approximately 100 μl was left in the tube. The cells are resuspended and immediately used 
for single cell picking.  
 
2.6.3. Single cell isolation from suspension 
 
The entire 100μl cell suspension containing CTCs was pipetted onto a chamber of an 8-
chambered slide pre-coated with BSA. Next, 100μl PBS was used to rinse the tube containing 
cells and was added to the sample in the chamber to reach a final of 200 μl in one chamber. 
The cells were allowed to settle. Next, the sample was screened manually on the fluorescence 
microscope. Single cells positive for cytokeratin (Cy3), DAPI and negative for CD45 (APC) 
were isolated using standard micromanipulation as described in chapter 2.2.1. Additionally, 
two normal cells were picked per sample (APC positive, DAPI positive, Cy3 negative), a cell 
pool (blindly picking 1 μl of cell suspension) as positive control and 1 μl of PBS from the picking 
field was collected as reagent control for each sample. 
 
2.7. Primary tumor material 
 
2.7.1. Isolation of primary tumor single cells from cryo sections 
 
Sections of 20-25 µm from cryopreserved PT tissues were placed on glass slides coated with 
poly L-lysine. The slides were immediately fixed in 0.5% PFA solution for 5 minutes followed 
by washing 3 times in 1X PBS for 3 minutes. The slides are then incubated with blocking 
solution (10% AB serum/1X PBS) for 30 minutes followed by staining for cytokeratin as 
described in chapter 2.3.2. After the development step, the section is incubated for 1h in a 1:1 
mixture of collagenase A (33mg/ml) and hyaluronidase (10mg/ml) at 37°C in an oven for 
enzymatic digestion. To avoid drying of the tissue during incubation, the slide was placed in a 
pre-heated humid chamber in the oven (made by adding water to paper towels). After 
 23 
incubation, the slide was shortly dipped into 1X PBS to wash away the enzymes. Next, 250-
300 µl of 0.5M maltose solution was pipetted onto the slide and left for at-least 45 minutes to 
create a hypertonic environment for the cells. Next, the slide was scratched with a 200 µl 
pipette tip and the contents were collected in a microfuge tube already containing 250 µl of 
0.5M maltose solution. The entire solution was pipetted vigorously several times to obtain a 
single cell suspension. For single cell picking, 50 µl of single cell suspension in maltose was 
added to 150 µl of pick PBS in one of the chambers of the 8 chambered slide pre-coated with 
BSA. Cell isolation was carried out as mentioned in section 2.6.3. 
 
2.7.2.  Isolation of primary tumor single cells from FFPE sections 
 
2.7.2.1. Tissue deparaffinization and dissociation 
  
For isolation of single cells from FFPE sections a protocol from Menarini Silicon Biosystems 
was used, now commercially available as DEPArray™ FFPE SamplePrep Kit. FFPE tissue 
section (40- 60 μm thick) was sealed inside a nylon biopsy bag. The sealed bag containing 
the tissue sample was placed in a 50ml falcon tube. The tissue was washed with zylene three 
times for 10 min each at RT for deparaffinization. To rehydrate, the tissue was washed with a 
decreasing ethanol series, 3 times with 100%, 3 times with 70% and 2 times with 50% ethanol, 
for 5 min per wash at RT. Next, the sample was washed once for 5 minutes with Milli-Q water 
at RT. For antigen retrieval, at first 1X HIAR buffer was added to the sample. After 5 min the 
1X HIAR buffer at RT was changed with pre warmed (80 °C) 1X HIAR buffer and the sample 
was incubated at 80 °C in a water bath for 1 h. After incubation, the sample was allowed to 
cool to RT. Next 1X HIAR buffer was discarded and the sample was washed three times for 5 
minutes with RPMI 1640 medium at RT under sterile conditions. To dissociate the tissue, 
RPMI 1640 medium was discarded and 10ml 1X Dissociation solution pre-warmed at 37 °C 
was added to the sample followed by incubation at 37 °C in a water bath for 45 min, with gentle 
agitation of sample after every 15 minutes. To stop dissociation, the sample was placed on 
ice, and was resuspended gently by pipetting with a 10ml serological pipettes. The dissociated 
sample was filtered through a 30μm mesh nylon filter into a 15ml conical tube and centrifuged 
at 1.000g for 5 minutes at 4 °C. The supernatant was discarded and the pellet was washed 
two times in 5ml ice-cold PBATw buffer by centrifugation at 1.000g for 5 minutes at 4 °C. 
Finally, the pellet was resuspended in 1ml ice-cold PBATw buffer and transferred to a 1,5ml 
Eppendorf protein LoBind tube. The cells were counted under fluorescence lamp in a Neubaur 
chamber by staining 10 µl of cell suspension with DAPI at a final concentration of 0.2 µg/ml.  
 
2.7.2.2. Immunofluorescence staining  
 
For immunofluorescence staining, 1 µl of anti-cytokeratin antibody (A45/Bb3) was added to 
100 µl of ice-cold cell suspension (500.000 cells in PBATw buffer) and incubated for 1 h with 
gentle agitation every 15 minutes. Next 1ml of ice-cold PBATw was added to the cells and the 
solution was centrifuged at 1.000g for 5 minutes at 4 °C.  This step was repeated for a total of 
two washes. Finally, the supernatant was discarded, and the cells were incubated with 
secondary antibody Alexa Fluor. 488 goat anti-mouse IgG1 (2mg/ml) diluted in ice cold 
PBATw buffer (1:500) for 30 minutes with gentle agitation every 15 minutes. Again, the cells 
were washed twice with 1ml ice cold PBATw buffer by centrifugation at 1.000g for 5 minutes 
at 4 °C. The supernatant was discarded and filled again with ice cold PBATw buffer, to which 
DAPI was added at a final concentration of 0.2 µg/ml and incubated for 15 minutes. The cell 
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suspension was again washed with ice cold PBATw buffer two times by centrifugation at 
1.000g for 5 minutes at 4 °C. The cell pellet was finally diluted in 1 ml ice cold PBATw buffer 
and directly used for single cell isolation. 
 
2.7.3. Isolation of primary tumor gDNA from FFPE tumor blocks 
 
Tumor containing areas in PT blocks were determined by pathologist Dr Florian Weber and 
marked on hematoxylin and eosin sections (H and E sections). These sections were 
superimposed on the block to locate the tumor regions. Tumor regions were punched out 
using disposable biopsy punch (1.5mm). Next the punched-out regions were placed on UV 
sterilized glass slide, and the excess paraffin was cut out using a scalpel. Another UV sterilized 
glass slide was used to squeeze the tissue, followed by cutting the tissue into pieces in all 
directions with a scalpel. The tissue bits were transferred from the glass slide to a 1.5 ml tube 
using the scalpel. The tube was centrifuged shortly to collect all the tumor material at the 
bottom. Next, gDNA was isolated from the tumor material using QIAamp FFPE Tissue Kit 
according to the manufacturer’s instructions. The isolated gDNA was quantified using 
NanoDrop ND-1000. 
 
2.8. Isolation of outgroup cells 
 
2.8.1. T cells and macrophages. 
 
2.8.1.1. Preparation of adhesion slides from fixed blood  
 
Blood samples from patients were collected in CellSave tubes (Menarini Silicon Biosystems).  
Approximately 7.5 ml of blood was washed with PBS in a 50 ml falcon tube and centrifuged at 
200g for 10 min at 4 °C. The cell pellet was diluted in Hanks solution and centrifuged at 1000g, 
for 20 min at 4 °C on a 60% Percoll density gradient. The interphase was collected and washed 
in 1X PBS by centrifugation at 200g for 10 min at 4 °C and resuspended in 1X PBS, counted 
and transferred onto adhesion slides at a density of 0.16*106 cells per 14 mm diameter spot. 
The cells were allowed to sediment on the slide for 1 hour at RT. The residual PBS was 
discarded and slides were allowed to air-dry overnight at RT and then stored at -20°C.  
 
2.8.1.2. Detection and isolation of T cells and macrophages 
 
Adhesion slides stored at -20 °C were thawed at RT and blocked with 1x PBS/10% AB-serum 
(Bio-Rad) for 30 min, followed by incubation with polyclonal rabbit anti-CD3 antibody (C7930, 
Sigma Aldrich) and  monoclonal mouse anti-human CD68 antibody (clone KP1, M0814 Dako) 
in 1X PBS/10% AB-serum for T-cells and macrophages respectively, for 60 minutes each at 
room temperature. Next, slides were washed with 1x PBS and incubated with ready to use 
solutions of AP-polymer anti-rabbit (ZUC031-006, Zytomed Systems) and AP-Polymer anti-
mouse (ZUC077-100, Zytomed Systems) respectively for 30 minutes at room temperature and 
developed using BCIP-NBT detection system (Bio-Rad Laboratories) with leavamisol (0.5%) 







2.8.2.1. Preparation of adhesion slides from buccal swabs 
 
Buccal swabs collected from patients were immediately stirred into 1ml 1X PBS. The cell 
suspension thus obtained was pipetted onto adhesion slides. The cells were allowed to 
sediment for 1 hour at RT, and the residual PBS was discarded. The slides were allowed to 
air dry overnight at RT and then stored at -20 °C. These slides were prepared at the University 
of Tübingen and were shipped to us on dry ice. 
 
2.8.2.1. Detection and isolation of OECs 
 
Adhesion slides with buccal swabs were incubated with Mayer’s hematoxylin for 2 min 
followed by washing in 1X PBS for 5 minutes. Next, the slide was dipped in fresh 1X PBS and 
was taken for picking by standard micromanipulation as described in chapter 2.2.1. Cells with 
a polygonal morphology with a distinct nucleus were isolated. 
 




WGA protocol used to amplify single cells or minute amounts of DNA was originally published 
as SCOMP (Stoecklein et al. 2002; Klein et al. 1999) and now commercially available as 
Ampli1™ WGA Kit. The method is based on a ligation mediated adaptor linker PCR (Figure 
1) wherein the template DNA is deterministically fragmented using MseI restriction digestion, 
to obtain fragments that are around 150-1500 bp in length. Following restriction digestion, the 
DNA fragments are ligated to asymmetric double stranded adaptors (which are prepared 
separately in a step called pre-annealing). One of the oligonucleotide strands (ddMse11; 5’-
TAACTGACAGddC-3’) lacks phosphate group at the 5′-end which blocks its ligation to the 
Mse1 digested DNA fragments. This strand is later removed by denaturation. Since it also 
consists of a di-deoxy nucleotide at the 3′-end it is not able to prime amplification during PCR 
amplification of the fragments. The overhangs of the other strand (Lib1; 5’-
AGTGGGATTCCTGCTGTCAGT-3’), is filled in by DNA polymerase during PCR amplification. 


















































2.9.2. Experimental Procedure  
 
Composition of all master mixes are provided in Table 1. All steps were carried out in a PCR 
cycler. Single cells/cell pools were collected in lysis buffer containing proteinase-K (PK). The 
samples were incubated at 42 °C for 15 hours (for cell isolated by LCAM, LPC or FFPE) or for 
10 hours (for cell picked from adhesion slides,cell suspensions). PK was inactivated at 80 °C 
for 10 min, and then allowed to cool to 4 °C. After PK digestion, the DNA was subjected to 
MseI restriction digestion by incubation at 37 °C for 3 h.  Simultaneously, double stranded 
adaptors were prepared by pre-annealing at 65 °C and gradually decreasing temperature by 
1 °C per minute till the sample reached 15 °C. Next ATP (10 mM) and T4 ligase (5U/μl) were 
added to the pre-annealing mixture. After 3 h of digestion, MseI was inactivated at 65 °C for 5 
min and the sample was allowed to cool to 4 °C. The pre-annealing mixture containing ATP 
and T4 ligase was added to the MseI-digested samples, followed by overnight incubation at 
15 °C for ligation. On the following day, the samples were incubated after addition of primary 






Figure 2: Principle of Ampli1™ WGA. The WGA protocol comprises of five steps including cell lysis, DNA 
digestion using MseI restriction enzyme, pre-annealing (where  ddMse11 and Lib1 adaptors hybridize), ligation, 
where the double stranded adaptors ligate to digested DNA fragments, an PCR amplification, Chemical groups 
at the ends of the DNA fragments are indicated with coloured dots; blue, 5′ phosphate group; green, 3′ de-dioxy 
oligonucleotide; red, 3′-hydroxyl group. Figure adapted from (Czyz and Klein 2015). 
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Master Mix Constituents *Volume per sample (μl)    **Volume per sample (μl)    
Proteinase-K digestion OPA 10x 0.2 0.5 
 Tween 10 % 0.13 0.13 
 Igepal 10 % 0.13  0.13  
 Proteinase K (10mg/ml) 0.26   0.26   
 PCR-water 1.28   3.48 
MseI digestion OPA 10x 0.2  -- 
 MseI 50,000 U/μl 0.2   0.25 
 PCR-water 1.6   0.25 
Pre-annealing OPA 10x 0.5  0.5  
 Lib1 100 μM 0.5  0.5  
 ddMse11 100 μM 0.5  0.5  
 PCR-water 1.5  1.5  
Primary PCR Buffer 1 3  3  
 dNTPs 10 mM 2  2  
 DNA Pol Mix 1  1  
 PCR-water 34 34  
Table 1: Composition of master-mix prepared for WGA.  
* Indicates amounts for standard WGA 
** Indicates amounts for WGA of cells isolated by LPC 
 
Step Temperature Duration Cycles 
Step 1 68.0 °C 3 min  
Step 2 94.0 °C 40 s  
Step 3 57.0 °C 30 s  
Step 4 68.0 °C 1:30 min extend 1s/cycle 
Step 5   GOTO 2, 14 times 
Step 6 94.0 °C 40 s  
Step 7 57.0 °C 30 s Increase 1.0°C/cycle 
Step 8 68.0 °C 1:45 min extend 1s/cycle 
Step 9   GOTO 6, 8 times 
Step 10 94.0 °C 40 s  
Step 11 65.0 °C 30 s  
Step 12 68.0 °C 1:53 min extend 1s/cycle 
Step 13   GOTO 10, 22 times 
Step 14 68.0 °C 3:40 min  
Step 15 4.0 °C infinite  




















2.9.2. WGA of single cells isolated from FFPE sections 
 
To improve the quality of DNA derived from FFPE sample, a DNA repair enzyme mix from 
NEB was used which constitute a mixture of various DNA repair enzymes (Taq DNA Ligase, 
Endonuclease IV, Bst DNA Polymerase, Fpg, Uracil-DNA Glycosylase, T4 Endonuclease V 
and Endonuclease VIII). The DNA repair step was introduced prior to MseI restriction digestion 
step in the WGA protocol. Single cells from FFPE tissue were collected in PK-lysis buffer, 
followed by incubation at 42 °C for 15 hours. Next, the DNA was treated with FFPE repair mix 
(NEB), by incubating at 37 °C for 20 min, followed by inactivation of the repair enzymes at 80 
°C for 20 min. The samples were allowed to cool to 4 °C followed by MseI digestion (with half 
the quantity as standard WGA). Rest of the WGA protocol was similar as in chapter 2.9.1. The 
master mix composition for FFPE repair mix and MseI digestion mix is provided in Table 3. 
 
Master Mix Volume of constituents per sample 
FFPE Repair  0.4 μl FFPE Repair buffer (10x) 
 0.1 μl FFPE Repair Mix 
 0.5 μl PCR-water 
MseI digestion 0.1 μl OPA 10x 
 0.1 μl MseI 50,000 U/μl 
 0.8 μl PCR-water 
 
Table 2: Composition of master-mixes for FFPE repair and modified MseI restriction digestion 
 
2.9.3. Quality control (QC) PCR for WGA samples  
 
Quality of WGA samples was assessed by a multiplex endpoint PCR consisting of primers 
(KRAS, CK 19, TP53 Exon2/3, D5S2117) to amplify four genomic regions corresponding to 
different MseI fragments, as previously described (Polzer et al. 2014) and commercially 
available as Ampli1TM QC kit. Primer sequences, amplicon lengths and corresponding MseI 
fragment length is provided in Table 3. Master mix for the multiplex PCR was prepared 
according to Table 4, 9 μl of the master mix was used for every 1 μl of template DNA (WGA 
product/reamplified WGA product). As negative control 1 μl of PCR water was used instead 
of template DNA, and a previously assessed good quality sample was used as a positive 
control. The multiplex PCR program is described in Table 5. The products of the PCR reaction 
were visualized by agarose gel electrophoresis (see chapter 2.9.5). The number of bands 
displayed on the gel corresponded to the genome integrity index (GII) of the sample. Samples 
with GII>2 were considered to be of good quality. Since KRAS corresponds to a small MseI 
fragment, it is usually amplified in the QC PCR if a cell was isolated, irrespective of its DNA 
quality. Absence of all the bands GII=0, thus means that the starting material might not have 


















KRAS_91bp_5' 12p ATAAGGCCTGCTGAAAATGAC 192 91 
KRAS_91bp_3'  CTGAATTAGCTGTATCGTCAAGG   
*D5S2117_5' 5q CCAGGTGAGAACCTAGTCAG 1376 140 
D5S2117_3'  ACTGTGTCCTCCAACCATGG   
CK19 5'  6q GAAGATCCGCGACTGGTAC  1146 621 
CK19 3'  TTCATGCTCAGCTGTGACTG   
TP53 Exon2/3 5' 17p GAAGCGTCTCATGCTGGATC 1374 301 
TP53 Exon2/3 3'  CAG CCC AAC CCTTGTCCTTA   
 
Table 3: QC-Multiplex PCR Primers and amplicon description 
*D5S2117 is a microsatellite marker, homozygous samples show one band, heterozygous samples show two 




Reagent Volume per sample  
10x FastStart PCR Buffer (with 20mM MgCl2) 1 μl 
Primer mix (4 μM per primer) 1 μl 
dNTPs (from FastStart kit) 0.2 μl 
BSA (20 mg/ml) 0.2 μl 
FastStart Taq Polymerase (5 U/μl) 0.1 μl 
PCR-water 6.5 μl 
 
Table 4: Master mix composition for QC-Multiplex PCR  
 
Step Temperature Duration Cycles 
Step 1 95.0 °C 4 min  
Step 2 95.0 °C 30 s  
Step 3 58.0 °C 30 s  
Step 4 68.0 °C 1:30 min  
Step 5   GOTO 2, 32 times 
Step 6 72.0 °C 7 min  
Step 7 4.0 °C forever  
 
Table 5: Multiplex QC PCR program  
 
 
2.9.4. Quality control (QC) PCR for FFPE WGA samples 
 
Since FFPE DNA is damaged and heavily fragmented, longer Mse1 fragments are scarcely 
present in WGA samples, owing to which FFPE samples have lower GII values. Therefore, 
different sets of primers targeting MseI fragments of various lengths, mostly including smaller 
and medium length MseI fragments were designed to judge the suitability of the FFPE DNA 
for downstream analysis. FFPE QC PCR consist of a total of 12 primer sets constituting three 
different multiplex PCRs. Primer sequences, amplicon lengths and corresponding MseI 
fragment length is provided in Table 6. Master mix for the multiplex PCR was prepared 
according to Table 7 and 9 μl of the master mix was used for every 1 μl of template DNA. As 
negative control 1 μl of PCR water was used instead of template DNA, and a previously 
assessed good quality sample was used as a positive control. The multiplex PCR program is 
as described previously in Table 5. The products of the PCR reaction were visualized by 
agarose gel electrophoresis (see chapter 2.9.5). 
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1 KRAS_91bp_5' ATAAGGCCTGCTGAAAATGAC 192 91 
 KRAS_91bp_3' CTGAATTAGCTGTATCGTCAAGG   
 BRAF_Exon 15_5’ CTCTTCATAATGCTTGCTCTG 264 171 
 BRAF_Exon 15_3’ TCCAGACAACTGTTCAAACTG   
 PIK3CA_Exon20 (HS2)_5’ TCTAGCTATTCGACAGCATGC 296 221 
 PIK3CA_Exon 20 (HS2)_3’ TTGTGTGGAAGATCCAATCCAT   
 EGFR_Exon 19_5’ TCCTCGATGTGAGTTTCTGC 425 350 
 EGFR_Exon 19_3’ ATGCCTCCATTTCTTCATCC   
 TP53_Exon 7_5’ GAGGCTGAGGAAGGAGAATG 724 400 
 TP53_Exon 7_3’ AGTATGGAAGAAATCGGTAAGAGG   
2 NRAS_Exon 2_5’ ACACCCCCAGGATTCTTACA 221 174 
 NRAS_Exon 2_3’ TCCGCAAATGACTTGCTATT   
 TP53_Exon 8_5’ AGGTAGGACCTGATTTCCTTACTG 558 245 
 TP53_Exon 8_3’ AGGCATAACTGCACCCTTG   
 EGFR_Exon 21_5’ CAGCGGGTTACATCTTCTTTC 427 418 
 EGFR_Exon 21_3’ AAACAATACAGCTAGTGGGAAGG   
 EGFR_Exon 18_5’ TTGTCCTTCCAAATGAGCTG 743 496 
 EGFR_Exon 18_3’ TGCCTTTGGTCTGTGAATTG   
3 TP53_Exon 5/6_5’ ACGCATGTTTGTTTCTTTGC 507 1034 
 TP53_Exon 5/6_3’ ACCCCTCCTCCCAGAGAC   
 EGFR_Exon 20_5’ AAACGTCCCTGTGCTAGGTC 442 1324 
 EGFR_Exon 20_3’ CATGGCAAACTCTTGCTATCC   
 CKND2A _Exon 3_5’ TGGCTCTGACCATTCTGTTC 380 1367 
 CKND2A _Exon 3_3’ TGGAAGCTCTCAGGGTACAA   
 
Table 6: FFPE WGA Multiplex QC-PCR Primers and amplicon description 
 
Multiplex Reagent Volume per 
sample  
1 10x FastStart PCR Buffer (with 20mM MgCl2) 1 μl 
 Primer mix 1(KRAS_Ex1, PIK3CA_Ex20, EGFR_Ex19, 8 μM per primer) 1 μl 
 Primer mix 2 (BRAF_Ex15, TP53_Ex7, 8 μM per primer) 1 μl 
 dNTPs (from FastStart kit) 0.2 μl 
 BSA (20 mg/ml) 0.2 μl 
 FastStart Taq Polymerase (5 U/μl) 0.1 μl 
 PCR-water 5.5 μl 
2 10x FastStart PCR Buffer (with 20mM MgCl2) 1 μl 
 Primer mix (EGFR_Ex18, EGFR_Ex21, TP53_Ex8, NRAS_Ex2, 8 μM per primer) 1 μl 
 dNTPs (from FastStart kit) 0.2 μl 
 BSA (20 mg/ml) 0.2 μl 
 FastStart Taq Polymerase (5 U/μl) 0.1 μl 
 PCR-water 6.5 μl 
3 10x FastStart PCR Buffer (with 20mM MgCl2) 1 μl 
 Primer mix (CKND2A_Ex3, EGFR_Ex20, TP53_Ex 5/6, 8 μM per primer) 1 μl 
 dNTPs (from FastStart kit) 0.2 μl 
 BSA (20 mg/ml) 0.2 μl 
 FastStart Taq Polymerase (5 U/μl) 0.1 μl 
 PCR-water 6.5 μl 
 







2.9.5. Agarose gel electrophoresis 
 
PCR products from WGA Multiplex QC PCR and FFPE WGA Multiplex QC PCR were 
visualized with gel electrophoresis, on 1.5% agarose and 2% agarose respectively. The 
agarose gel was prepared in 1X TBE buffer with ethidium-bromide (0,5 μg/ml). PCR product 
(10 μl) was mixed with loading dye (3 μl), loaded into the wells of the gel and were allowed to 
run for 45 min at 160V. Finally, the gel was imaged on a UV transilluminator. 
 
2.10. Lineage tree analysis 
 
2.10.1. Reamplification of Ampli1™ WGA products  
 
WGA products were reamplified using a master mix shown in Table 8. For each sample 49 μl 
of the master mix, was used for 1 μl of primary WGA product to reach a final volume of 50 μl. 
The re-amplification was performed in a PCR cycler according to the program described in 
Table 9. Samples undergoing lineage tree analysis were reamplified using both the variations 
of the programs (Reamp 65 and Reamp 68), followed by mixing the products of both the 
reactions in 1:1 ratio. Samples undergoing Ampli1™ LowPass CNA analysis were reamplified 
using Reamp 68 only. A WGA-QC PCR was performed to check if the reamplification reaction 
was successful according to the protocol described in 2.9.3. 
 
Master Mix Volume of constituents per sample 
Expand Long Template Buffer 1 (Buffer 1) 5 μl  
Lib1 (10 μm) 5 μl 
dNTPs (10 mM) 1.75 μl 
BSA 1.25 μl 
DNA Pol mix 0.5 μl 
PCR water 35.5 μl 
 
Table 8: Master mix composition for Reamp 65/68  
 
 
Step Temperature Duration Cycles 
Step 1 95.0 °C 1 min  
Step 2 60.0 °C 30 s  
Step 3 65.0 °C or 68.0 °C 2 min  
Step 4 94.0 °C  30 s  
Step 5 60.0 °C 30 s  
Step 6 65.0 °C or 68.0 °C 2 min extend 20 s/cycle GOTO 4, 10 times  
Step 7 4.0 °C forever  
 
Table 9: Reamp 65/68 program  
 
2.10.2. Double strand synthesis of Ampli1™ WGA products  
 
Double strand (ds) DNA synthesis of WGA products was performed as one of the approaches 
to optimize processing of Ampli1™ WGA products for lineage tree pipeline. Currently dsDNA 
synthesis is skipped during processing samples for lineage tree. Components of the master 
mix is provided in Table 10. For dsDNA synthesis of 10 μl WGA/ reamplified WGA sample, 2 
μl of the master mix was used. The samples were incubated at 68 °C for 2 h, and then cooled 
till 12 °C in a PCR cycler. 
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Master Mix Volume of constituents per 10 μl WGA sample 
Expand Long Template Buffer 2 (Buffer 2) 0.2 μl  
Lib1 (100 μm) 0.2 μl 
dNTPs (10 mM) 0.2 μl 
DNA Pol mix 0.1 μl 
PCR water 1.3 μl 
Table 10: Master mix composition for dsDNA synthesis  
 
2.10.3. Purification of reamplified WGA products 
 
Samples meant to undergo Duplex MIPs-based targeted enrichment pipeline (at Dr Ehud 
Shapiro’s laboratory) for lineage tree analysis were purified using AMPure XP beads 
(Beckman Coulter) according to manufacturer’s protocol to eliminate residual PCR reagents. 
Briefly, 27 μl (1.8X) of AMPure XP beads were mixed with 15 μl of sample (1:1 mixture of 
reamp 65 and reamp 68 products or primary WGA product) and incubated for 5 min at RT to 
allow the DNA to bind to the beads. Next, the samples were put on a magnetic rack where the 
beads are separated and the supernatant containing the impurities was discarded. While on 
the magnetic rack, the beads were washed two times for 30s with 80% ethanol, followed by 
air drying of the residual ethanol for 5-10 minutes making sure that beads were not overdried 
(cracks should not appear on beads). Next, the samples were removed from the magnetic 
rack and the DNA was eluted by adding 13 μl of nuclease free water on the beads followed 
by vortexing and incubating for 5 min. The samples were put back on the magnetic rack and 
the beads were allowed to separate for 5 min or until the solution was clear. The supernatant 
was collected in a fresh eppdendorf Lobind tube/96-well plate and sent to our collaborators on 
dry ice for downstream analysis.  
 
2.10. Lineage tree analysis 
 
All steps involving target enrichment of STR loci by molecular inversion probes (MIPs), 
sequencing and data analysis were performed at the Weizmann Institute of Science, Israel 
according to a published pipeline (Tao et al. 2018). FastTree2 algorithm was used for final 





WGA libraries were PCR labelled or RP labelled (random primer based labelling with exo-
Klenow fragment) and hybridized on oligonucleotide-based 4x180K Agilent Microarrays 
(design code: 022060) as previously published (Czyz et al. 2014; Polzer et al. 2014). 
Microarrays were scanned using Agilent Microarray Scanner Type C and the image was 
processed by Agilent Genomic Feature Extraction Software 10.7 and analyzed using Agilent 
Genomic Workbench Software 6.5 lite. Aberration calls were defined using ADM-2 algorithm 
with a threshold at 7.0. For centralization a threshold of 6.0 and a bin size of 10 was used. 
The minimum number of probes in the aberrant interval was set to 50 and a log2 ratio of 0.25 







2.13. Shallow sequencing of MCF10a cells spiked in Balb/C bone marrow MNCs  
Ampli1™ WGA products were subjected to dsDNA synthesis according to the protocol in 
chapter 2.10.2. Lib1 adaptor was released by Tru1I digestion at 65 °C for 3 h followed by an 
AMPureXP-purification (1.8X) and the DNA was fragmented using Covaris ultrasonication for 
obtaining average insert size of 350 bp. Next, Illumina TruSeq DNA PCR-free library prep was 
used to make libraries according to manufacturer’s instructions. Quality of resulting libraries 
was evaluated by Bioanalyzer 2100 using the HS DNA kit, and high-quality libraries were 
quantified by qPCR (KAPA library quantification kit) and pooled in equimolar amounts for 
sequencing on the Illumina MiSeq platform with 150bp paired-end reads. The sequenced data 
was analyzed using BioBloom Tools (Chu et al. 2014) to evaluate the amount of mouse DNA 
contamination in the sample. 
2.14. Ampli1 LowPass CNA Analysis 
 
Genome wide CNA sequencing was performed using Ampli1 LowPass Kit according to the 
manufacturer’s instructions (Menarini Silicon Biosystems). Briefly, Ampli1™ WGA products 
were reamplified using Reamp68 protocol (chapter 2.10.1.), 5 μl of reamplified WGA product 
was diluted in 5 μl NGS water and purified with 1.8X SPRIselect or AMPure XP beads 
(Beckman Coulter). Next, 3 μl of purified sample was used to obtain barcoded libraries, which 
were quantified using the Bioanalyzer 2100 HS DNA kit (Agilent) and Qubit HS DNA kit 
(ThermoFisher Scientific) according to manufacturer’s instructions followed by pooling the 
libraries in equimolar amounts (4nM). Sequencing was performed in single-end mode using 
Illumina Miseq or Novaseq 6000 according to the manufacturer’s instructions. A maximum of 
32 samples were pooled in one Miseq run and 96 samples were pooled in one Novaseq 6000 
run. It should be noted that a custom primer for Read1 was used for sequencing which was 
provided in the Ampli1™ LowPass kit and PhiX DNA was not spiked-in. To obtain copy-
number aberration (CNA) calls a modified version of the open source software Control-FREEC 



























3.1. List of reagents 
 
Reagent Manufacturer Catalog Number 
1kb Plus DNA Ladder New England Biolabs N3200L 
AB serum, human Bio Rad 805135 
Acetone VWR Chemicals MFCD00008765 
Adenosine triphosphate (ATP) 100 mM Roche Diagnostics 11140965001 
Agarose LE Anprotec AC-GN-00009 
AMPure XP purification beads Beckman Coulter A63882 
Bovine serum albumin (BSA) (20 mg/ml) (for PCR) Roche Diagnostics 10711454001 
BSA Fraction V Sigma Aldrich 05479 
CellTracks AutoPrep Instrument Buffer Menarini Silicon Biosystems 7901003 
Collagenase A Sigma Aldrich  C0130 
Collagenase 1a Sigma Aldrich C9891 
Dispase Life Technologies 17105-041 
BCIP/NBT detection system Bio-Rad 1706432  
BSA (for cell picking) Sigma Aldrich B8667-5ml 
dNTP Set; 





Ethanol absolute Mol. Bio.Grade 250 ml VWR Chemicals 437443T 
Ethanol absolut ≥99.8% VWR Chemicals 20821.330 
Ethidium Bromide Solution (10 mg/ml) Sigma-Aldrich E1510-10ML 
Expand Long Template Buffer 1 Roche Diagnostics 11759060001 
FastStart DNA Polymerase Roche Diagnostics 4738420001 
Fetal bovine serum (FBS) sera Plus PAN Biotech P30-3702 
FFPE repair mix NEB M6630S 
Formaldehyde, 37% Merck 104003 
Hank’s balanced salt solution (HBSS) 10x Biochrom L2045 
Hyaluronidase Sigma-Aldrich H4272  
Igepal CA-630  Sigma-Aldrich I3021-50ml 
Levamisol  Sigma Aldrich  L9756 
Mayer’s hematoxylin Sigma-Aldrich MHS16  
MseI New England Biolabs R0525M 
NaCl 0.9% Braun 3570160 
Orange G Sigma-Aldrich O3756 
Percoll™ GE Healthcare 17089101 
Pick PBS  Gibco 10-010-023 
RPMI 1640 Pan-Biotech P05-17500  
SPRI Select beads Beckman Coulter B23317 
Tris EDTA 1x pH 8.0 low EDTA for mol. Biology AppliChem A8569,0500 
Trypan blue Sigma Aldrich T8154-20ml 
Trypsin/ EDTA (10x)  PAN Biotech P10-024100 
TWEEN 20 Sigma-Aldrich P9416-50ml 
Water, aqua ad iniectabilia (NGS-water) Braun 2351744 
Water for Chromatograhy 1l (PCR-water) VWR Chemicals 1.153.331.000 









3.2. List of Antibodies 
 
Antibody Manufacturer Catalog No. 
Monoclonal Mouse Anti-Human Pan cytokeratin, Clone A45B/B3 Micromet, Germany N.A. 
A45B/B3 biotinylated in house biotinylated  N.A. 
Monoclonal Mouse Anti-vimentin,clone V9 Agilent DAKO M0725 
Monoclonal Mouse Anti-human CD68, clone KP1 Agilent DAKO GA609 
Anti-CD3, T Cell antibody produced in rabbit Sigma Aldrich C7930 
Alexa Fluor. 488 goat anti-mouse IgG1 Life Technologies A-21121 
IgG1, Kappa from murine myeloma, Clone MOPC 21 Sigma Aldrich  M9269 
MOPC21 biotinylated in house biotinylated  N.A. 
Rabbit IgG isotype control Southern Biotech 0111-01 
AP-polymer anti-rabbit Zytomed Systems ZUC031-006 
AP-polymer anti-mouse Zytomed Systems ZUC077-100 
 
 
2.15.3. List of custom-made buffers 
 
Buffer Composition 
AB serum 10 % 5 ml AB serum human, in 45 ml 1X (PBS) pH 7.4 
Citric acid monohydrate 0.1M 2,1g citric acid monohydrate dissolved in 100 ml Milli-Q water 
Collagenase solution (2%) 0.1g of Collagenase Ia, 5ml RPMI 1640 
Dispase solution (2%) 0.1g of Dispase, 5ml RPMI 1640 
Dissociation solution 10X 5ml 2% Dispase solution, 5ml 2% Collagenase solution 
HIAR Buffer 10X 
0,1M citric acid monohydrate is added drop by drop, to 100ml of 0,1M 
sodium citrate tribasic dihydrate, under constant swirling conditions, 
until the pH reaches pH 6,40. 
Igepal 10 % 2 ml 100 % Igepal in 18 ml PCR water 
Maltose 0.5M 1.7115 g maltose, Milli-Q water (final volume 10 ml) 
One Phor All (OPA) buffer 10X 5 ml 1 M Tris acetate, 5 ml 1 M Magnesium acetate ,1 ml 5 M Potassium acetate, PCR-Water (final volume 1l) 
PBATw buffer 1,0g of bovine serum albumin (BSA) fraction V in washing buffer (final volume 100 ml) 
PBS pH 7.4 10X 
450 g Sodium chloride, 71.65 g Disodium phosphate (Na2HPO4), 13.35 
g Monopotassium phosphate (KH2PO4),  
Milli-Q water (final volume 5l) 
Percoll 60 % 60 ml Percoll 100 % ,40 ml NaCl (0.9% Braun) 
PFA 0.5% 1.35 formaldehyde solution, Milli-Q water (final volume 100 ml) 
Sodium citrate tribasic dihydrate 
0.1M 2.9g sodium citrate tribasic dihydrate dissolved in 100 ml Milli-Q water 
Tris/Borate/EDTA (TBE) buffer 10x 539 g Tris, 275 g Boric acid, 37 g EDTA, Milli-Q water (final volume 5l) 
Tween 10 % 2 ml 100 % TWEEN. 20 in 18 ml PCR water 





3.4. List of commercial kits 
 
Kit Manufacturer Catalog Number 
ABC (Avidin-Biotin Complex)  Linaris  AK-5000 
Agilent High Sensitivity DNA Kit Agilent Technologies 5067-4626 
Ampli1TM LowPass Kit (SET 
A+Set B) 2 x 48 reactions Menarini Silicon Biosystems WGLPAB 
BCIP/NBT (AP conjugate substrate Kit) Bio-rad 170-6432 
CellSearch Circulating Tumor Cell Kit Menarini Silicon Biosystems 7900001 
CellSearch Circulating Tumor Cell Control Kit Menarini Silicon Biosystems 7900003 
DNeasy Blood & Tissue Kit Qiagen 69504 
Expand Long Template PCR System Roche Diagnostics 11759060001 (Sigma Aldrich) 
FastStart™ Taq DNA Polymerase, dNTPack Roche Diagnostics 4738420001 (Sigma Aldrich) 
KAPA Library Quantification Kit Roche Diagnostics 07960298001 
MiSeq. Reagent Kit v3 (150 cycles) Illumina MS-102-3001 
Qubit dsDNA BR Assay Kit Thermo Fisher Scientific Q32853 
Qubit dsDNA HS Assay Kit Thermo Fisher Scientific Q32854 
QIAamp DNA FFPE Tissue Kit Qiagen 56404 
TruSeq DNA PCR-Free Kit Illumina 20015962 
VECTASTAIN® ABC-AP KIT Linaris AK-5000 
 
 
3.5. List of consumables 
 
 
Product Name Company Catalog Number 
AdhesiveCap 200 clear Carl Zeiss 415190-9191-000  
Adhesive sealing sheets Thermo Fisher Scientific AB0558 
CellSave Preservative Tubes Menarini Silicon Biosystems 7900005 
Cellstar. serological pipette 2 ml  Greiner Bio-one 710180 
Cellstar. serological pipette 5 ml  Greiner Bio-one 606180 
Cellstar. serological pipette 10 ml  Greiner Bio-one 607180 
Cellstar. serological pipette 25 ml  Greiner Bio-one 760180 
Centrifuge tube 15 ml Greiner Bio-One 188271 
Centrifuge tube 50 ml Greiner Bio-One 227261 
Diagnostic adhesion slides Thermo Fisher Scientific ER-203B-CE24 
Eppendorf twin.tec®-PCR-Platte 96 LoBind, 
skirted, 
Eppendorf 0030129512 
Eppendorf. protein LoBind tube 0.5ml Eppendorf 0030 108.094 
Eppendorf. protein LoBind tube 1,5ml Eppendorf 0030108.116 
Eppendorf. protein LoBind tube 2ml Eppendorf 0030 108.132 
Eppendorf. protein LoBind tube 5ml Eppendorf 0030 108.302 
LabTek Chamber Slides, glass, 8 fields Nunc 11367764 
MAXYMum Recovery™ 0.2 ml Axygen Scientific 11370145 
Micro-hematocrit capillary Brand 749321 
Microcentrifuge tube 1.5 ml Greiner Bio-One 616201 
Microcentrifuge tube 2 ml Greiner Bio-One 623201 
Multichannel Reagent reservoirs  Integra 4331 
Nylon biopsy bag Thermo scientific 6774010 
Nylon mesh filters 30μm Partec CellTrics. 04-004-2326 
PCR tube 0.2 ml 4titude Deutschland 4ti-0795 
PCR SingleCap 8er-SoftStrips 0.2 ml Biozym 710970 
SafeSeal Surphob filertips 1250μl Biozym VT0270 
SafeSeal Surphob filertips 2oo μl Biozym VT0240 
SafeSeal Surphob filertips 2o μl Biozym VT0220 
SafeSeal Surphob filertips 1o μl Biozym 770010 
Superfrost® Plus slides Thermo Fisher Scientific 10149870 




























































Bioanalyzer 2100 Agilent Technologies 
Cell culture incubator  Heraeus, Hanau  
Cell culture laminar flow  Heraeus, Hanau  
CellTracks Autoprep® System Menarini Silicon Biosystems 
CellTracks Analyzer II® System Menarini Silicon Biosystems 
Centrifuge 5424 Eppendorf, Hamburg  
Centrifuge 5810R Eppendorf, Hamburg  
Centrifuge Rotina 380R Hettich 
Centrifuge Rotofix 32A Hettich  
DMZ Universal Puller Zeitzt 
Gel electrophoresis chamber  Biostep, Jahnsdorf  
Gel electrophoresis power supply  MRC Lab 
Herasafe™ KS (NSF) biological safety workbench class II  Thermo Fisher Scientific 
Inverted microscope  Leica  
Laboratory Incubator Mammert 
Laser Microdissection microscope Zeiss PALM Microbeam 
Microscope IX81 Olympus 
Magnetic stirrer  VELP Scientifica  
Magnetic Rack (FastGene MagnaStand 0.2) Nippon Genetics Europe 
Micromanipulator PatchMan NP2 Eppendorf  
MJ Research Peltier Thermal Cycler Tetrad  Bio-Rad  
MJResearch Peltier Thermal Cycler PTC-200  Bio-Rad  
MiSeq Illumina 
Multipipette Stream  Eppendorf, Hamburg  
NanoDrop ND-1000 Thermo Fisher Scientific 
Neubauer chamber   Schubert und Weis, Munich  
Novaseq 6000 Illumina 
PCR bench UVT-S-AR Thermo Fisher Scientific 
PCV-2400 Combined Centrifuge/vortex mixture Grant-bio 
pH-meter  Eutech Instruments, The Netherlands  
Pipettes (single and multi-channel) Gilson 
Qubit3 fluorometer Thermo Fisher Scientific 
Screening microscope Olympus microscope (BX43) 
ThemoMixer Eppednorf, Hamburg 
UV illuminator  Intas, Gottingen  
Vortex mixers  VELP Scientifica, Italy  






Longitudinal tracking of patients required development of robust methods to isolate single cells 
of high DNA quality from all tissues, which included (i) Laser microdissection to isolate DCCs 
from diagnostic cytospins; - (ii) Isolation of single cells from flash frozen/FFPE tumor tissue; 
(iii) Isolation of blood CTCs from CellSearch cartridges. Additionally, for every patient CD3+ T 
cells, CD68+ macrophages and oral epithelial cells (OECs) were isolated to serve as 
outgroups for cell lineage tree analysis. The development of these protocols and their 
successful usage on patient samples are illustrated in the sections 4.1. through 4.5. of this 
section. The samples were then shipped to our collaborator Dr Ehud Shapiro at the Weizmann 
Institute of Science, for generating metastatic phylogenies based on STR mutations which 
determines cellular descent by tracking random mutational events. The results of these 
phylogenetic analysis are elaborated in Section 4.6. The workflow of my PhD thesis is 

































Figure 1 PhD thesis workflow.  DCCs, disseminated cancer cells; CTCs, circulating tumor cells. 
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4.1. Isolation of disseminated cancer cells (DCCs) from archived frozen cytospins 
 
To acquire bone-marrow (BM) DCCs we collaborated with the Department of Gynecology, 
University of Tübingen and the Department of Gynecology and Obstetrics, LMU Munich. 
These BM preparations had been collected from breast cancer patients over the last 20 years 
and hence a long patient follow-up data exists. However, the slides were prepared as 
cytospins at high cell densities. So far studies involving single cell DNA analysis of DCCs in 
our laboratory (Klein et al. 1999; Klein, Seidl, et al. 2002) used standard micromanipulation to 
isolate single cells from adhesion slides on which cells were sedimented at low densities 
(Figure 2A). This allowed ample space for contamination free isolation of single cells. 
However, isolation of single cells by standard micromanipulation from cytospins (Figure 2B) is 
unfeasible due to high cell density and strong adherence of cells to the slide. Consequently, 




















4.1.1. DNA quality assessment of cells isolated from frozen archived cytsopins  
 
At first, we wanted to find out if single cells isolated from old frozen archived cytospins have 
good DNA quality after whole genome amplification (WGA). Applying standard 
micromanipulation to cells from low-density areas (Figure 3A) revealed that the DNA quality 
of aged samples is well suited for WGA and downstream analyses as seen after WGA QC 
multiplex PCR (Figure 3B). The number of bands in the WGA QC multiplex PCR (methods 
section, 2.9.3) is referred to as the genome integrity index (GII) which predicts the sample’s 
DNA quality. A GII of 0 (no bands visible in QC-PCR) means the cell was not successfully 
collected in the tube, while a GII>2 refers to cell with sufficient quality (Polzer et al. 2014). 
From 123 such patients’ BM samples, which had been prepared up to 18 years ago, we found 
that median 60% of single cells isolated per sample showed a GII>2. Detailed WGA QC 
multiplex PCR results of all the samples have been summarized in Appendix 1. Dividing the 
samples by age of preparation in brackets of 5 years and applying non-parametric Kruskal-
Wallis Test shows that there is no significant difference among the samples prepared up to 10 
years ago (Figure 3C), nevertheless the cell quality slightly drops beyond 10 years of slide 
preparation. Copy number alteration (CNA) analysis by Ampli1TM LowPass (methods section 
2.14) of marker negative cells from archived patient samples (8 years and 11 years ago) also 
A B 
Figure 2: Cell density is crucial for micromanipulator assisted isolation. BM-DCCs can be detected with 
anit-cytokeratin antibody A45-B/B3 on adhesion slides and cytospins. A: BM mono-nuclear cells sedimented on 
adhesion slide at a density of 0.16*106 per 14 mm diameter spot are amenable to standard micromanipulation. 
B: BM mono-nuclear cells centrifuged at a density of 1.5*106 per 16 mm diameter spot on adhesion slide lay flat 
and adhere strongly to the glass surface making standard micromanipulation unfeasible. 
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showed comparable balanced profiles to cells picked from fresh adhesion slides, prepared 
less than a year ago (Figure 3D). Thus, frozen archived cytospins can be used for isolating 
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Figure 3: Single cell DNA quality of archived frozen cytospins. A: Example of cells at the boarders of high density 
cytospins. Marked cells could be easily isolated by standard micromanipulation for testing the single cell quality in 
such cytospins. B: Representative image of a multiplex QC PCR gel.  Genome integrity index (GII) is the number of 
bands (0-4). C: Cytospin samples were divided according to age of preparation in groups of 5 years and the WGA 
results of cells isolated by standard micromanipulation are plotted on the ordinate. Kruskal Wallis Test suggests a 
significant difference (p value=0.0027) between the samples. We obtained a significant difference between the 0-5 
years and the 11-15 years group (P value=0.0003) D: Ampli1TM Lowpass whole genome CNA sequencing of marker 
negative cells with GII>2 from <1year old adhesion slides compared to cells from 8 and 11 year old slides. 
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4.1.2. Laser Microdissection as a solution for DCC isolation 
 
 
Laser microdissection (LMD) has emerged as a promising technique through the last decades 
for contamination free isolation of single cells (Ahmed 2006), but in order to obtain good quality 
nucleic acid post LMD the samples should be prepared on UV absorbing polyethylene 
nephthalate (PEN) membrane slides (Ahmed 2006; Vogel et al. 2007). The high optical 
absorption coefficient of the membrane makes LMD possible at lower laser power (Figure 4A), 
enables sharp laser focusing, acts as a scaffold and protects the specimen from UV laser 
energy during laser pressure catapulting (LPC) (Vogel et al. 2007). Since, our archived 
samples were not prepared on membrane slides, we tested various methods to increase laser 
precision and protect cellular DNA from laser-induced damage. Since unstained cells have 
the lowest optical absorption coefficient (Figure 4A), we tried to increase the absorption 
coefficient in the sample by using histological dyes as counterstains. We also tested DNA 
binding fluorochromes and other UV absorbing molecules in our attempts to compensate for 
the absence of PEN membrane (Table 3).  
 
Next we optimized the sample dehydration procedure to prepare samples for LMD. For the 
acquisition of cells, we tested two protocols, 1. Laser cutting followed by laser pressure 
catapulting (LPC) which allowed rapid contact-free isolation (Figure 4B and C) and 2. Laser 


















































































Figure 4: Possibilities of cell isolation by laser microdissection. A: Thresholds values of irradiance (laser 
power per unit area) for ablation and plasma formation at 337 nm for glass, unstained cells, H and E stained 
sections and PEN foil; lower optical absorption coefficient (extinction coefficient) relates to higher irradiance 
thresholds; laser ablation is required for laser cutting and plasma formation is required for LPC; PEN foil offers the 
lowest threshold for laser ablation followed by stained sample (figure adapted from Vogel et al., 2007). B: The 
steps and possibilities leading to successful laser microdissection. C: Protocol 1, Laser Pressure Catapulting 
(LPC) where at first laser cutting is used to isolate the cell from the surroundings followed by acquisition of the cell 
by laser force from the bottom of the specimen, the cell is collected in a cap of a tube kept above the specimen. 
D: Protocol 2, Laser cutting assisted micromanipulation (LCAM), where laser cutting is used to clear a larger area 




4.1.2.1 Sample preparation 
 
Counterstaining: After screening for positive cells, the specimen had to be counterstained 
with an intense dye in order to obtain sharp laser focus during laser cutting at minimum laser 
power. Additionally, the stain should not chemically hinder any step of WGA. As shown in 
Figure 5, common histological stains were tested by Eva Maria Hecht as part of her master 
thesis (Hecht 2016). Mayer’s hematoxylin performed best in terms of both staining intensity 
and Ampli1TM WGA compatibility (Table 1) and was our choice of counterstain for future 






























Table 1: Summary of results from Figure 8 
#LPC isolation was assessed by the ability to catapult a cell into the cap of a tube with lowest possible laser power, 
+++ (varied from 55-65%), + (values higher than 70% / inability to LPC intact cells), - (LPC was not possible at all) 
* depicts percentage of cells displaying GII>2 from cells isolated by standard micromanipulation; shows that the 











LPC# % cells with GII>2, picked manually * 
Mayer’s 
hematoxylin  +++ 100 
Weigert’s 
hematoxylin  +++ 0 
Crystal Violet +++ 50 
Chlorazol Black E  +++ 78 
Methyl Green  + 80 
Giemsa +++ 0 
Figure 5: Various hiostological stains tested for LMD. Cells stained with, A:  Mayer’s Hematoxylin. B: 
Weigert’s Hematoxylin. C: Crystal Violet. D: Chlorazol Black E. E: Methyl Green. F: Giemsa. All images are 




Dehydration: Samples had to be dehydrated for LMD. We used an increasing ethanol series 
followed by a short dip in acetone to dehydrate the samples, at RT and -20 °C (methods 
section 2.2.2.1). Patient cytospin samples which were prepared through the last decade were 
used for the experiment. Figure 6A displays the results of WGA QC PCR of cells picked from 
slides of various time points treated with the following protocols: 1) fresh (picked right after 
hematoxylin staining without dehydration); 2) after dehydration at RT and 3) after dehydration 
at -20 °C. Since the same slide cannot be dehydrated twice, a separate slide from the same 
BM sample was used for probing the effect of dehydration at -20 °C. The quantification of 
WGA QC PCR is shown in Figure 6B.  We saw that dehydration at RT is detrimental for WGA 
of single cells for majority of samples, possibly because DNA when exposed to ethanol at RT 
shows decreased sensitivity to restriction digestion (Svaren et al. 1987) and since Ampli1TM 
WGA is based on Mse1 restriction digestion, dehydration temperature could be critical at a 
single cell level. However, dehydration at -20 °C provides results not different to that of fresh 
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Figure 6  Dehydration temperature is crucial for obtaining good quality DNA from archived frozen cytospins. 
A: Results of WGA QC PCR, obtained from cells of 6 different BM cytospin samples prepared 9 - 4 years ago. Five 
cells were isolated per condition. Fresh, Cells picked right after hematoxylin staining; -20 Dehydration, Cells picked 
after dehydrating the slide at -20 °C; RT Dehydration, Cells picked after dehydrating at RT; Left to right from 9 – 4 
years old samples. B: Quantification of A showing the percentage of cells with GII>2 per sample, per treatment, 
Wilcoxon signed rank test is used to compare the fresh and dehydrated at RT sample pairs  (p value 0.03) and fresh 
and dehydrated at -20 °C sample pairs (p value 0.99, n.s.).  
y=year 
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4.1.2.2.  Laser pressure catapulting of single cells (LPC) 
 
 
LPC allows automated and contactless isolation of single cells wherein the cells are catapulted 
from the glass surface by laser force into the cap of a 200 µl microfuge tube (Figure 7A). We 
first tried if cells could be removed from glass slides without the presence of a PEN membrane. 
As, shown in Figure 4A stained cells have a higher UV extinction coefficient, and hence the 
plasma formation threshold power, which is required for catapulting a cell, is lower. We 
observed that darker stained cells could be successfully catapulted (Figure 4C). 
Counterstaining as mentioned in section 4.1.2.1 and seen in Figure 7B, increases the staining 
intensity of a DCC along with staining the surrounding cells which aids in laser cutting. 



























Initially in order to develop the protocol, we used patient BM cytospins which were irrelevant 
to the project and contained more than 10 DCCs per slide. We detected the DCCs using a 
pan cytokeratin antibody A45-B/B3 and developed using BCIP/NBT (described in methods 
section 2.3.2) The slides were counterstained with hematoxylin (Figure 7B). We performed 
laser cutting followed by LPC to isolate DCCs from two patient derived cytospins. Surprisingly 
both the processes worked well despite that there was an absence of PEN membrane on 
patient slides. Isolated cells were subjected to WGA and thereafter a WGA QC PCR. As 
controls we isolated some cells from low-density areas of the same cytospins by standard 
micromanipulation. We found that the quality of cell isolated by LPC was low, as only 35% and 




Figure 7: LPC from glass slides  
A: The process of LPC (PALM Zeiss), figure 
adapted from (Vandewoestyne et al. 2013) . 
Cells are catapulted against gravity onto a cap 
placed above the specimen B: Cytokeratin 
positive DCCs developed with BCIP/NBT as 
substrate and counterstained with Mayer’s 
Hematoxylin, hence the cells are darker than 
the background (Image captured at 40X 
magnification). 
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the majority (100% and 88% for T1 and T2 respectively) of cells showed good DNA quality. 














Table 2 Summary of results from Figure 8 
 
Next, we analyzed the cells with GII>2 from patient T1 and T2 (Figure 8) by array CGH 
(comparative genome hybridization) as described in method’s section 2.12. We found that the 
DCCs isolated by LPC had higher DLRS values (which is a measure of hybridization noise) 
and displayed artefacts in the genomes as compared to the genomes of DCCs isolated by 
standard micromanipulation (Figure 9). These results lead us to speculate that LPC might 
have an impact on the DNA quality of the cell, as seen by the artefacts introduced at the array 

























isolated by LPC 
Cells with GII>2 
(percent) 
Cells successfully isolated by 
micromanipulation 
Cells with GII>2 
(percent) 
T1 14 5 (35%) 7 7 (100%) 
T2 4 1 (25%) 9 8 (88%) 
Figure 8: LPC from patient cytospins 
  
Patient T1: Top. WGA QC PCR results of 
DCCs collected by LPC. Bottom. WGA 
QC PCR results of control cells collected 
by standard micromanipulation.  
Patient T2: Top. WGA QC PCR results of 
DCCs collected by LPC. Bottom. WGA 
QC PCR results of control cells collected 
by standard micromanipulation  




Figure 9 : Array CGH of patient DCCs isolated by LPC and by standard micromanipulation. Top to bottom, 
Patient T1 DCC isolated by LPC displays noisy profile (DLRS spread 0.99); Patient T2 DCC isolated by LPC 
shows huge aberrations and has a high DLRS spread of 2.44; Patient T2 DCC isolated from the same slide by 
standard micromanipulation has lower hybridization noise (DLRS spread 0.90).  
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Since tumor cells intrinsically have aberrant profiles, we wanted to exclude this bias while 
further testing and developing our protocol. Therefore, we focused on non-tumor cells and 
used both, patient BM cytospins and healthy donor PBL adhesion slides, for isolating healthy 
mono-nuclear cells (MNCs). For simulating the scenario of isolating a CK positive DCC we 
stained patient derived bone marrow cytospins and healthy donor blood PBL adhesion slides 
against mesenchymal marker vimentin (methods section 2.4), which should be expressed by 
the mesenchymal cells of BM/blood and should have a normal karyotype. BCIP/NBT was used 
as a development substrate to mimic the staining of the DCCs and the background was 
counterstained with Mayer’s hematoxylin. After dehydration at -20 °C, test cells and controls 
were isolated by LPC and standard micromanipulation, respectively, and were subjected to 
WGA and thereafter WGA QC PCR (Figure 10). We again observed low single cell DNA 
quality, as only 40% of patient BM MNCs and 25% of healthy donor PBLs isolated by LPC 
























Table 3: Summary of results from Figure 10. 












isolated by LPC 
Cells with GII>2 
(percent) 
Cells successfully isolated by 
micromanipulation 
% Cells with GII>2 
(percent) 
T3 8 4 (40%) 8 8 (100%) 






Figure 10: Vimentin positive cells isolated by LPC and standard micromanipulation. A: WGA QC PCR 
results of vimentin positive MNCs isolated by LPC from patient T3 cytospin, control cells isolated by standard 
micromanipulation are shown below. B: WGA QC PCR results of vimentin positive MNCs isolated by LPC from 
healthy donor adhesion slide, control cells isolated by standard micromanipulation are shown below.  
* Cells analyzed by array CGH 
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Next, we performed array CGH of high-quality cells (GII>2) isolated by LPC and standard 
micromanipulation of both patient and healthy donor MNCs. Again, the cells isolated by LPC 
displayed noisy array CGH profiles and artefacts in otherwise normal genomes when 


















































Figure 11: Array CGH of vimentin positive cells isolated by LPC and standard micromanipulation. A: 
Top, patient BM MNC isolated by LPC displays huge aberrations and has a higher DLRS value despite having 
a GII of 4 as compared to bottom profile, an MNC isolated by standard micromanipulation. B: Top, healthy 
donor MNC also shows aberrations and higher DLRS values despite having a GII of 4 as compared to; bottom, 
an MNC isolated by standard micromanipulation. 
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Efforts to improve LPC 
 
Since we observed that cells with GII>2 showed artefacts in the DNA at array CGH resolution, 
we speculated that laser energy could be destroying the DNA. Therefore, we wanted to reduce 
the laser power required to isolate single cells by LPC, hypothesizing that the lower the power 
needed to catapult the cell, the better would be the DNA quality. A high optical absorption of 
the sample would mean usage of lower LPC power to isolate a cell. In order to achieve that 
we tested various UV absorbing molecules which could increase the optical absorption 
coefficient of the sample and thereby reduce the threshold energy needed to catapult the cells.  
 
The tests were performed on cytospins prepared with MCF10a cell line cells and the results 
are summarized in the Table 3. MCF10a cells were used because of their mammary epithelial 
origin and cytokeratin positivity. The experiments were performed by Eva Maria Hecht, as part 
of her Masters project (Hecht, E.M. 2016). Briefly, after treating the slides with the known UV 
absorbing chemicals namely a 1:1 mixture of SYBR Gold:DAPI and DNA intercalating dye 9-
amino acridine the percentage of LPC isolated cells with good DNA quality increased as we 
were able to isolate up to 80% of cells with a GII>2 (Table 4). But unfortunately, the array CGH 
results revealed that the DNA of treated single MCF10a cells isolated by LPC again had 
artefacts (Figure 12). 
 
We could finally conclude that DNA quality of cells isolated by LPC directly from glass slides 
in the absence of PEN membrane is sub-optimal and LPC could not be used for isolation of 
DCCs from frozen archived cytospins. 
 
Protocol LPC# % cells with GII>2 of 
manually 
micromanipulated cells* 
% cells with 
GII>2 of LPC 
cells** 
ArrayCGH *** 
Mayer’s hematoxylin (In combination 
with BCIP/NBT staining) 
+++ 100 30-60 failed 
UV absorbing compounds      
Avobenzone - n.d. n.d. n.d. 
Gumrosine - n.d. n.d. n.d. 
DNA binding fluorochromes 
with UV-A excitation  
    
DAPI (In combination with BCIP/NBT 
staining) 
+++ 100 60 n.d. 
SybrGold (In combination with 
BCIP/NBT staining) 
+++ 100 40 n.d. 
DAPI+SybrGold (In combination with 
BCIP/NBT staining) 
+++ 100 80 failed 
9AA +++ 100 50 failed 
  
Table 4: Protocols tested to isolate single DTCs by LPC   
#LPC isolation was assessed by the ability to catapult a cell into the cap of a tube with lowest possible laser power, 
+++ (varied from 55-65%), + (values higher than 70% / inability to LPC intact cells), - LPC was not possible at all 
*depicts percentage of cells displaying GII>2 from cells isolated by standard micromanipulation. These controls 
show i) That the specific dye or the stain does not interfere with the WGA protocol; ii) That the slide that was used 
for testing have good quality cells to begin with. This step was only performed when LPC was successful. 
**depicts % of cells displaying GII>2 from cells isolated by LPC. 







Figure 12 Array CGH of MCF10a cells isolated by improved LPC. Top to bottom. ArrayCGH profile of MCF10a 
cell stained against cytokeratin and developed with BCIP/NBT and a 1:1 mixture of fluorochrome DAPI and 
SybrGold isolated by LPC; ArrayCGH profile of MCF10a cell stained against cytokeratin with BCIP/NBT and DNA 
intercalating acridine dye 9AA isolated by LPC; ArrayCGH of MCF10a bulk genomic DNA shown as control. 
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4.1.2.3. Laser cutting assisted micromanipulation (LCAM) 
 
Since we failed to obtain cells with intact DNA after isolation by LPC, we tested the next 
approach - laser cutting assisted standard micromanipulation (LCAM) which is a combination 
of laser cutting and standard micromanipulation (Figure 4B and D). At first laser cutting is used 
to isolate the cell of interest from the surrounding cells by destroying a larger area around the 
cell with laser in order to make room for standard micromanipulation of the cell of interest by 
a glass capillary. Before standard micromanipulation the slide is rehydrated in a buffer 
containing detergents to wash any stray cellular elements resulting from laser ablation  
(described in methods section 2.2.2.2.). WGA quality of MNCs and DCCs isolated from patient 
BM cytospins having gone through the entire workflow of LCAM is shown in Figure 13. Some 
cells are isolated by standard micromanipulation only from the low-density regions of the 
slides, to serve as controls. Up to 85% of cells isolated by LCAM have a GII>2 as compared 






















Table 5 Summary of results from Figure 13 
 
Next, we wanted to check the DNA profiles of these cells by array CGH. We saw that marker 
negative cell isolated from patient T4 cytospin by LCAM displayed balanced array CGH 
profiles (Figure 14A) similar to that of a control cell picked by standard micromanipulation. We 
then also tested a DCC from patient T5 for which we could use a DCC cluster as a positive 
control (Figure 14B) and saw that the samples shared majority of aberrations. As the DNA 
quality of cells obtained by LCAM was optimal for array CGH analysis, we could conclude that 





isolated by LCAM 
Cells with GII>2 
(percent) 
Cells successfully isolated by 
micromanipulation 
% Cells with GII>2 
(percent) 
T4 9 5 (55%) 6 6 (100%) 







Figure 13: LCAM from patient cytospins. A: Left, WGA QC PCR results of marker negative cells collected by 
LCAM from patient T4. Right- WGA QC PCR results of controls collected by standard micromanipulation from the 
same slide. B: Left, WGA QC PCR results of DCCs collected by LCAM from Patient T5. Right, WGA QC PCR 
results of control cells collected by standard micromanipulation.  

























Assessment of possible DNA contamination introduced by LCAM 
 
Lastly, we wanted to evaluate the amount of stray DNA left in the surroundings after laser 
cutting. Presence of DNA contamination could introduce artefacts in downstream analysis. To 
test that LCAM performs as good as standard micromanipulation, we prepared cytospins of 
mouse BM MNCs with spiked in MCF10a cells (described in methods section 2.5) and stained 
for human cytokeratin (described in methods section 2.5.1). MCF10a cells were isolated from 
these cytospins by LCAM (Figure 15) and also by standard micromanipulation from regions of 
low density as controls. We also isolated cells from slides containing only MCF10a cells to 



















Figure 14: ArrayCGH of cells isolated by LCAM. A. Top: ArrayCGH profile of bone marrow MNC isolated from 
archived patient cytospins by standard micromanipulation; Bottom: arrayCGH profile of bone marrow MNC isolated 
from archived patient cytospins by LCAM. B: Top: ArrayCGH profile of CK positive DCC isolated from archived 
patient cytospins by LCAM; Bottom: ArrayCGH profile of DCC cluster isolated by standard micromanipulation from 







Figure 15: MCF10a cells spiked in BALB/C mouse bone marrow cells. A: MCF10 cells detected after CK 
staining (with biotinylated A45/Bb3 antibody) in BALB/C mouse bone marrow cells. B: Isotype Control. C: MCF10 
cell prepared for LCAM (Image captured at 20X magnification. 
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In order to investigate DNA contamination shallow whole genome sequencing of the WGA 
products (Figure 16A) was performed at ITEM-R by Dr Stefan Kirsch’s group and analyzed by 
BioBloom Tools (methods section 2.13). There was no difference in contamination levels for 
all the samples as evaluated by Mann Whitney test (Figure 16B).  We also checked the CNA 
profiles of cells isolated by LCAM to look for the presence of artefacts by Ampli1TM Lowpass 
sequencing. However, the profiles appeared identical to the cells isolated by standard 
micromanipulation (Figure 16 C and D). Thus, we could conclude that there is no stray DNA 















































Figure 16: Assessing possible contamination due to LCAM. A: Sequential filtering was performed for the 
contamination estimation as shown in the legend order. Red, human; violet, mouse; the rest of the legend included 
common contaminants of molecular biology reagents. Ordinate shows the proportion of identified sequences from 
different organisms in the sample. Samples S01-S07 and S08-S14 are isolated by LCAM and standard 
micromanipulation respectively. Samples S15-S16 were isolated by standard micromanipulation from pure MCF10a 
slides. Samples S15/S16 show no mouse contamination (as expected for pure MCF10a), sample 
S02/S03/S05/S10/S12 show little contamination (<3.5%), samples S06/S07/S11/S13 show moderate contamination 
(<10%), samples S04/S08/S09/S14 show strong contamination (<20%), sample S01 shows very strong 
contamination (>35%), S00 is the "negative" control, i.e. the sequence reads from the spiked in PhiX. B: Median 
contamination in both LCAM and control group is <10%, Mann Whitney test for the contamination levels in both 
groups is non-significant, p value 0.76. C: Lowpass whole genome CNA sequencing of sample S04 and S05 isolated 









4.1.3. Summary of DCCs isolated from cytospins 
 
After thorough investigation as seen in Section 4.1.2. LCAM was used as the method for 
isolation of DCCs from high density BM frozen archived cytospins. A laser microdissected 
DCC from patient 01 can be seen in Figure 17. In total 182 DCCs were isolated from 23 
patients, out of which 143 (78%) had a GII≥2. Table 6 provides a summary of all DCCs isolated 



















Table 6: Summary of DCCs and NZs isolated from patient cytospins from Tübingen cohort. 
*NZ stands for marker negative cells isolated by standard micromanipulation 
 
 
Patient ID DCCs successfully 
isolated by LPC 
Cells with GII≥2 
 
*NZs successfully isolated by 
micromanipulation 
Cells with GII≥2 
 
03 12 9 5 3 
05 3 2 10 10 
04 3 2 8 7 
09 10 7 8 8 
11 11 11 7 5 
14 8 7 6 5 
02 2 2 9 8 
08 2 2 10 7 
01 2 2 10 10 
12 2 1 -- -- 
13 6 3 2 2 
15 2 0 2 1 
16 4 4 4 4 
17 2 2 1 1 
18 3 3 2 2 
06 49 29 2 0 
06-2 8 8 2 2 
10 33 33 4 4 
19 7 4 9 7 
20 5 5 3 3 
21 3 3 2 2 
22 2 2 2 2 
23 3 2 0 0 





Figure 17: Patient DCC isolated by LCAM. A: DCC detected by A45/Bb3 PAN-cytokeratin staining; B: DCC after 
laser cutting, ready to be picked by standard micromanipulation. 
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4.2. Isolation of primary tumor DNA 
 
Primary tumors are available as either fresh/frozen or formalin-fixed paraffin-embedded 
(FFPE). Only a handful of tumor tissue is available as fresh/frozen since their procurement is 
not part of routine diagnostics in most of the clinics. Consequently, we had three kinds of 
primary tumor material. 1) For the primary tumors from which cryo tissue was available, we 
developed a protocol to isolate single cells from tissue sections. 2) For the FFPE tumor blocks 
we tried to isolate single cells, however in majority cases FFPE tissue blocks did not have 
good quality. 3) Bulk genomic DNA was isolated from the tumor containing regions of the 
FFPE tissue block. 
 
 




In order to obtain single cells from cryopreserved primary tumor tissue, sections of 20-25 µm 
thickness were fixed in PFA and stained for epithelial marker cytokeratin (CK). After staining, 
an enzymatic digestion with collagenase and hyaluronidase was performed on the slide. 
Additionally the slide was incubated with a hypertonic solution of maltose (Goodenough and 
Gilula 1974; Mitra, Mishra, and Li 2013) based on reports about the use of osmotic pressure 
to disrupt the zona occludentes and gap junctions. Next, the slide was scratched with a 200 
µl pipette tip and the contents were collected in microfuge tube containing maltose solution 
with pipetting vigorously for several times to obtain a single cell suspension (described in 
methods section 2.7.1). CK positive single-cells were picked with the manual-
micromanipulator. 
 
For testing the protocol, we used healthy mammary breast tissue sections (Figure 18A and B) 
and tested the DNA quality of cells after WGA with WGA QC-PCR (Figure 18D). We could 
obtain good quality single cells after the isolation protocol (9 out of 9 cells picked successfully 
showed GII4). Next we wanted to check if the protocol introduces any artefacts in the genome. 
We performed array CGH profiling of normal mammary cell as control and found that the 
genomic profile is balanced (Figure 18E), this means that if we would isolate tumor cells using 
this protocol, the aberrations detected in the tumor cells would be true. 
 
Hence, we used this protocol for isolation of single cells from cryopreserved tumor tissues of 















































Isolation of single cells from patient cryopreserved tumor sections 
 
Using the method developed for isolation of single cells from frozen tissue sections (Figure 
18), we isolated cells from the cryopreserved tumors of patient 01 and patient 02. We found 
that 57% and 59% of single cells isolated from patient 01 and patient 02 respectively had good 
DNA quality (GII>2). The results per patient are summarized in Table 7.  
 
Patient Picked single cells Cells with GII>2 Success rate 
01 89 51 57% 
02 66 39 59% 




Figure 18: Isolation of single cells from flash frozen tissues. A: CK stained mammary tissue section 25 µm 
thickness), B: CK stained tissue section after enzymatic digestion, C: Cell isolation from single cell suspension 
by standard micromanipulation. D: Multiplex QC PCR results of cells picked using the method, the pool is picked 
up blindly, since the concentration of cells in the picking field is very low and digested/broken stromal cells 
could be picked up which could explain the GII of 1, E: Array CGH profile of a single cell isolated from healthy 
mammary tissue using the above protocol 
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4.2.2. FFPE tumor tissue 
 
4.2.2.1.  Single cell isolation from FFPE tissues 
 
Single cell isolation was performed from 40-60 µm sections of tumor tissue using a protocol 
established by Menarini Silicon Biosystems described in detail in methods section 2.7.2. 
Briefly the tissue sections were deparaffinized, followed by antigen retrieval and enzymatic 
digestion. The single cell suspension was stained with anti-cytokeratin antibody and DAPI to 
















Figure 19: CK positive cell obtained from FFPE tissue.  
 
Although the morphology of FFPE specimen is preserved, the proteins and nucleic acids are 
crosslinked and denatured during the fixation process and various chemical modifications take 
place which leads to introduction of artefacts in the DNA. Single cell WGA from such tissues 
is challenging. Pre-Cr enzyme mix from NEB is reversing those chemical modifications of DNA 
introduced by formalin fixation (except for DNA fragmentation) and the enzyme mix could be 
used for WGA of single cells (Martelotto et al. 2017). Dr Giancarlo Feliciello from ITEM-R 
tested the enzyme mix on single cells derived from FFPE blocks by introducing the enzyme 
repair step before MseI DNA digestion in the Ampli1 WGA protocol (marked in Figure 20A, 
described in details in methods section 2.9.2). The WGA products were evaluated by a QC 
PCR (Figure 20A) designed for FFPE samples (Developed by Dr Zbigniew Czyz in the 
laboratory, details in methods section 2.9.4). It was found that the addition of a repair step 






















































We found that NEB offers the same enzyme mix as PreCR with a buffer optimized for NGS 
purposes sold as FFPE Repair mix. We tested this mixture on breast cancer single cells 
isolated from a previously tested good quality FFPE tumor block and found that there were no 
significant differences in the DNA quality of single cells treated with FFPE Repair mix or PreCR 
mix used by Dr Giancarlo Feliciello (Figure 21). Hence FFPE Repair mix was the choice of 
repair enzyme for future experiments. 




Figure 20: DNA repair prior to WGA. A: After cell lysis, the DNA repaired step is introduced, indicated by the 
arrow, following which DNA digestion with MSEI is continued, rest of the  Ampli1 WGA protocol remains constant 
where the repaired and digested DNA is ligated to the adaptors followed by gap filling and PCR amplification 
similar, figure adapted from (Czyz and Klein 2015). B: FFPE QC multiplex, comprises of set of 3 multiplex PCR; 
blue, FFPE single cells undergoing standard WGA; red, FFPE single cells undergoing DNA repair prior to WGA. 
P.C. is the pool of cells as positive control C: Quantification of figure B, there is a significant difference between 


















Isolation of single cells from patient FFPE tumor sections 
 
Next, we used the FFPE Repair mix on two patient blocks from the Tübingen breast cancer 
collective. This experiment was performed by Vincent Walter as part of his medical thesis 
project. Alas, we did not find any significant improvement facilitated by the FFPE Repair mix 
over the untreated WGAs when applied to patient tumor cells (Figure 22A). We also performed 
Ampli1TM Lowpass CNA analysis and we were not able to observe any improvement between 
the cells processed with or without the repair step before WGA (Figure 22B). All profiles are 




























Figure 21: PreCR repair mix vs FFPE Repair mix. A: FFPE QC multiplex, comprises of set of 3 multiplex PCR, 
left: FFPE single cells undergoing DNA repair with PreCR repair mix before WGA, right: FFPE single cells 







Figure 22: DNA repair on patient samples of Tübingen cohort. A: Quantification of FFPE QC PCR results, no 
significant difference was found in the single cells undergoing WGA with FFPE repair treatment or without repair 
treatment, Mann-Whitney Test p value 0.512. B: Ampli1TM Lowpass CNA profiles, Top: without treatment, Bottom: 




4.2.2.2.  Bulk genomic DNA isolation from FFPE tissues 
 
As gDNA isolation of since single cells from FFPE tissue appeared sub-optimal for NGS 
purposes (indicated by the noisy CNA profiles in Figure 22B), we investigated bulk DNA 
extraction using the FFPE DNA isolation kit from Qiagen. Details are provided in the methods 
section 2.7.3. Briefly, tumor areas were marked by pathologist Dr. Florian Weber using 
hematoxylin and eosin sections, and the respective areas were isolated and digested following 
the manufacturer’s instructions. The gDNA concentrations obtained from FFPE tumor blocks 
are summarized in Table 7. We were able to obtain good quality DNA from 9 out of 17 (53%) 
of FFPE tumor blocks tested so far from the Tübingen cohort as implicated from the 260/280 
ratios, where a value of ~1.8 indicates good DNA quality.  
 
 
Block ID Concentration (ng/µl) 260/280 ratio 
13 136.8 1.83 
12 42 1.75 
08 31.1 2.04 
05 32.3 2.01 
04 Region 1 67.1 1.87 
04 Region 2 51.6 1.87 
06-29551 161.6 1.86 
06-22516-Region 1 27.7 1.89 
06-22516-Region 2 48.5 1.48 
06-24920 31.7 1.73 
02-Region 1 120.3 2.03 
02-Region 2 12.7 1.93 
09 53.8 1.89 
10 Recurrence 11.5 2.11 
10 SN 2.4 2.05 
11 29 2.02 
03 7.3 2.42 
 





















4.3. Isolation of M1- Circulating Tumor Cells 
 
To acquire tumor cells from patients with metastatic disease (M1), we obtained blood samples 
instead of bone marrow because bone marrow isolation is a highly invasive procedure. The 
CellSearch system was used for enrichment and enumeration of CTCs. For each patient we 
receive 3 CellSave tubes. The first tube goes directly into CellSearch, from the second tube 
plasma is isolated from the blood at first and the residual cell fraction goes into CellSearch, 
for the third tube, MNCs are isolated from the blood and adhesion slides are prepared for the 
isolation of macrophages and T-cells which serve as outgroups for cell lineage analysis 









































Figure 23: Blood samples from breast cancer patients. Tube CS1: Goes directly into Cellsearch. Tube CS2: 
Goes into into Cellsearch after plasma isolation. CS3: The blood is put through density gradient separation using 
Percoll to isolate PBL for preparation of HOTS (adhesion slides) 
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When a CellSearch run was positive, meaning CTCs were detected in the run (Figure 24A), 
the cartridge was flushed and the cells were manually screened (method’s section 3.5). A CTC 
was selected when being CK+, DAPI+, CD45- (Figure 24B) and isolated by standard 
micromanipulation. Isolated CTCs went through Ampli1 WGA followed by QC PCR (Polzer et 
al. 2014). DNA quality of CTCs after WGA was good (Figure 24C). CNA analysis of isolated 

































When a patient sample is negative for CTCs, blood is collected again at their upcoming 
doctor’s visits. We had 88 samples (from 33 patients) in total, of which 31 (35%) were positive 
for CTCs (from 17 patients). Out of 33 patients enrolled in the study, during the span of 3 years 
from 2016 to 2019 we have been able to isolate CTCs from 11 patients (33%). Patient wise 
number of CTCs isolated are summarized in Table 9.  
 
Patient ID 08 05 06 02 01 04 13 22 03 09 18 
CTCs 75 51 48 27 18 9 7 7 3 1 1 
 










Figure 24: CTCs isolated from M1 breast cancer patients of the Tübingen breast cancer cohort. A: CTC 
recognized by the CellSearch machine. Cell is positive for cytokeratin (green) and DAPI (purple). B: CTC 
screened during manual isolation, Red (Cy3) for cytokeratin, Blue (DAPI) for nucleus. C: Cell quality of CTCs 
isolated from CellSearch cartridges. D: CNA profile of a CTC (patient 01) isolated from the CellSearch cartridge. 
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4.4. Triplet cohort of patients 
 
Bone marrow (BM) aspirates collected from 4864 M0 patients undergoing curative surgery at 
the Department of Gynecology, University of Tübingen between 2001 and 2016 were 
considered for the sample collective. Thirty-three patients (see Methods section 3.1) were 
finally enrolled in the study with the inclusion criteria of a long follow-up and availability of 
sample triplets comprising BM DCCs, primary tumor and CTCs/DCCs at a later time point 
before and after progressing into metastasis. Figure 25 delineates the steps through filtering 




























Patient ID Primary Tumor Classification Type ER PR Her2 Metastasis free survival (years) 
03 cT3 cN3 M0 G2 NST 1 1 0 3 
05 ypT1b ypN0 M0 NST 1 1 0 6 
04 ypT3 ypN3 M0 G2 ILC 1 1 0 7 
09 rpT1 Nx M0 G2 NST 0 0 1 15 
02 pT3 pN3a M0 G2 NST 1 1 0 3 
08 ypT3 ypN2a M0 G2 Inflammatory 1 1 0 1 
01 pT3 pN1a M0 G2 ILC 1 1 0 7 
18 ypT1c ypN2a M0 G3 NST 1 1 0 4 
06 pT3 pN3a M0 G2 ILC 0 1 0 5 
07 right ypT1 yN1 M0 G2, left: ypT3 ypN1 M0 G2 NST / ILC 1 1 0 14 
Figure 25: Steps leading to the current number of patients selected for cell lineage analysis. DCC positive M0 
patients were selected, next the availability of frozen cytospins for DCC isolation, primary tumors and progression to 
metastasis were looked at. Fraction of the selected patients were visiting the University Hospital in Tübingen and 
consented for blood sample for CTC isolation from which till now we have good quality DNA samples from 10 patients. 
 
Table 9 Characteristics of the patients eligible for cell lineage analysis. NST, invasive carcinoma of no special 
type or invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor (1=positive, 0=negative); 





4.5. Generation of metastatic phylogenies 
 
We have started to generate cell lineage trees from single cells of primary breast cancers, 
DCCs isolated from bone marrow at the time or surgery, circulating tumour cells derived from 
metachronous metastases and outgroup cells (i.e. control cells from non-malignant lineages) 
to identify the metastasis founder cells (MFCs) in individual patients. Single cells from patients 
from the triplet cohort (Section 4.4.) were used to generate cell lineage trees based on Short 
Tandem Repeats (STRs) also known as microsatellites. STRs are an abundant source of 
somatic mutations (Woodworth, Girskis, and Walsh 2017) reflecting cell divisions which 
determines cellular descent by including random mutational events. Approximately, 12000 
STR loci are targeted by duplex Molecular Inversion Probes (MIPs) and sequenced and 



































Figure 26: Duplex MIPs based cell lineage workflow. A: Design of duplex MIPs precursor: Precursors for 
desired STR targets are designed; B: Duplex MIPs preparation: duplex MIPs precursors are synthesized on a 
microarray, pooled and amplified by PCR, followed by removal of universal adaptors (red and green). The product 
is purified to obtain active duplex MIPs; C: Duplex MIPs are annealed (blue and yellow) to the flanking regions of 
the targets of the template, next the products are circularized. Linear DNA (excess MIPs and template DNA) is 
eliminated by exonucleases digestion. Next, Illumina sequencing libraries are generated for each sample by PCR 
amplification with respective barcodes and subsequently pooled and sequenced by Illumina NGS platform. Raw 
reads are analyzed to detect STR mutations for cell lineage tree reconstruction. Figure adapted from (Tao et al., 
2018). 
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Molecular Inversion Probes (MIPs) are single strand DNA molecules with two targeting ends 
containing a linker between them. MIPs allow high throughput targeting of STR loci and have 
high specificity (Nilsson et al. 1994). Our collaborators, developed STRs targeting platform 
with duplex MIPs enabling the capture of thousands of STR loci, produced from precursors 
synthesized on microarrays (Tao et al. 2018). 
 
Critical parameters beginning from sample preparation of Ampli1TM WGA products, selection 
of outgroups and optimizing the required sequencing depth have been addressed and 
resolved in conjunction with Prof Ehud Shapiro’s group in the recent years. Lowpass CNA 
analysis was performed for each cell in the lineage tree to authenticate the positioning of a 
cell in the tree. Bootstrapping analysis was performed to validate the clusters seen on the 
lineage tree.  In this section, the results of optimizations performed on patient 01 samples and 
the resulting cell lineage tree is described. 
 
4.5.1.  Outgroups and root approximating group  
 
In phylogenetics, outgroup rooting is an optional procedure that anchors the beginning of the 
timescale to the shared ancestor of that outgroup. Some reconstruction algorithms may use 
this notion of rooting as part of the reconstruction itself; such is the case with the later 
mentioned triplet max cut (TMC) algorithm. We used two hematopoietic lineage cell types 
(macrophages and T-cells isolated from blood) and one epithelial lineage cell type (oral 
epithelial cells isolated from buccal swabs) to serve as outgroups in our cell lineage analysis. 
The tumor cells are expected to cluster apart from the outgroups. Genomic DNA obtained from 
peripheral blood was used as root approximating group.  
 
To isolate hematopoetic lineage cells, blood was collected from patients in CellSave tubes 
and adhesion slides were prepared from blood PBLs for single cell isolation which were 
stained against CD68 and CD3 to detect macrophages and T-cells respectively (Figure 27 A1, 
B1), and Method’s section 3.5. The stainings were first tested in healthy donor samples. From 
patient’s samples the positive cells were isolated by standard micromanipulation followed by 
Ampli1 WGA and WGA-QC. Cells with GII>2 were selected for cell lineage analysis.  We could 
successfully isolate around 25 CD68+ and CD3+ from each patient (Table 10). 
 
Oral epithelial cells were added as an outgroup for serving as an epithelial lineage control 
which should ideally cluster separately from the hematopoietic lineage cells. To isolate oral 
epithelial cells (OECs), patients were requested to provide buccal swabs. We developed a 
protocol to isolate good quality cells from the buccal swabs and tested in healthy donor 
(method section 2.8.2) and thereafter requested our clinical collaborators at University 
Hospital Tübingen to execute the protocol. Briefly, the buccal swabs obtained from patients 
were immediately stirred into PBS and sedimented onto adhesion slides. Frozen slides were 
shipped to us from Tübingen. The cells were stained with hematoxylin (Figure 27C) and 
isolated by standard micromanipulation. We could successfully isolate 11-20 OECs from each 





























4.5.2.  Sample preparation for lineage tree 
 
As primary single cell WGA material is precious, we needed to optimize the use of reamplified 
WGA products for sequencing. Therefore, various sample preparation protocols were tested. 
Combinations of original, reamplified and double strand synthesized (ds) WGA products were 
hybridized with different batches of MIP probes (Table 11).  Groups C1-C4 were prepared 
entirely by our collaborators. We prepared groups C5-C9, with 20 good quality non-tumor 
single cells. Next, the samples were subjected to duplex MIP hybridization and sequencing at 
Dr Ehud Shaprio’s laboratory. 
 




C1 - + - old  
C2 - + - new 
C3 + - - old 
C4 + - - new 
C5 - + - new 
C6 + + - new 
C7 - - - new 
C8 + + + new 







Patient ID CD68+ cells CD3+ cells OECs  
01 25 25 11 
02 25 25 22 
06 24 21 20 





Table 11: Various protocols for sample preparation. C1-C2, original WGA product after DSS hybridized with old 
and new batches of MIP preparation respectively; C3-C4, reamplified WGA product hybridized with old and new 
MIP preparation respectively; C5, original WGA product after DSS hybridized with new MIP preparation; C6, 
reamplified and DSS and hybridized with new MIP preparation; C7, original WGA product hybridized with new MIP 
preparation; C8, reamplified, DSS and purified with AMPure-XP and hybridized with new MIP preparation, C9, 
reamplified and purified with AMPure-XP and hybridized with new MIP preparation.  
 
Figure 27 Outgroup cell 
isolation from patients.  
 
A1: CD68 staining (HD);  
A2: Mouse Isotype control; 
B1: Left: CD3 staining (HD); 
B2: Rabbit isoltype control; 






Table 10: Outgroup cells isolated from breast cancer patients.  
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Samples from all the groups C1 through C9 were sequenced and the mapping rates for each 
of the preparations were calculated (Figure 28). The results indicated that the AMPure XP 
purification step introduced for control groups C8 and C9 have the highest mapping rates 
(~93%). C9 was used as the protocol of choice for sample preparation, which involves 





















4.5.3. Sequencing depth  
 
Single cells from primary tumor, CTCs, DCCs, CD68+ macrophages and CD3+ T cells from 
patient 01 were initially sent for STR sequencing. Following a normalization MiniSeq run 84% 
of the samples fulfilled the passing criteria (which is >60% of the reads successfully mapped 
to target STR loci). The samples were sequenced iteratively. At first, the selected cells were 
sequenced to an average of ~1 million reads/cell, followed by ~4 million reads/cell and ~5 
million reads/cell, subsequently. It can be seen in Figure 29, that the number of STR loci 
covered by >30 reads increases with an increase in sequencing depth, while saturation is 









































Figure 29: Depth versus Micro-satellite loci 
covered by more than 30 reads. The first round of 
NextSeq sequencing resulted in 0.6 x 106 reads per 
cell, where the median loci covered by >30 reads was 
3,452. After two more round of NextSeq sequencing 
the average depth reached 3.8 x106 reads per cell, 
where the median loci covered by >30 reads was 
6,932. Followed by a NovaSeq run which helped to 
achieve an average depth of 4.8 x106 reads per cell, 
where the median loci covered by >30 reads was 
7,825. 
Figure 28 Optimization of sample preparation.  Mapping rates of the reads for different types of preparation. The 
highest amount of mapped reads are obtained in groups C8 and C9. 
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Lineage trees at ~1 million reads/cell and ~4 million reads/cell are shown in Figure 30A and 
B, respectively. T-cells are used as the root approximating group in the trees. The trees are 
plotted using the Triplets Max Cut (TMC) algorithm which puts out all leaves at equal depth 
(ultrametric). Thereafter, a post process for depth calculation was applied. To calculate the 
depth, the genomic values of the reconstructed intermediate nodes were inferred for 
parsimonious values according to STR mutation probabilities derived from somatic mutation 
rates in the ex-vivo tree of DU-145 prostate cancer cell line (Biezuner et al. 2016). To 
determine genomic loci that are considered "classifying”, a minimum group size of 3 was used, 
meaning an STR locus is included in the analysis if it presents at least two different signals 
and each of those two is attributed to at least three cells. Clustering of groups in the tree in 
Figure 30B is improved over Figure 30A, indicating the role of increased sequencing depth. 
Interestingly, in both trees it could be seen that the healthy cells (T cells and macrophages) 
cluster separately from the tumor cells. Within the tumor arm the M1-CTCs including the M0 







































Figure 30: STR based lineage tree of patient 01. Primary tumor (single cell from fresh frozen tissue section) and 
bone marrow DCC (single cell from cytospin) were sampled in 2009. In 2016 the patient developed metastasis and 
blood was taken for CTC analysis (single cell from CellSearch). A panel of ~12000 microsatellite loci are sequenced 
to obtain single cell lineage separation; olive green, T-cells; yellow, macrophages; deep blue, single cells from 
primary tumor; red, M1-CTCs isolated in year 2016; light green, M1-CTCs isolated in year 2017; pink, bone marrow 
DCCs. The thickness of matching colors on the edges reflect the hypergeometric score of the edge’s descendants, 
or how unlikely it is to draw X cells of a certain colour out of Y cells in total. A: sequencing depth at ~1 million 




4.5.4. Addition of germline DNA and outgroups 
 
In order to improve the lineage tree even further, germline DNA derived from blood MNCs was 
used for root approximation and OECs were introduced as an epithelial lineage outgroup. 
Simultaneously, improvements in tree reconstruction algorithms continued from our 
collaborators. A new likelihood-based approach was integrated together with a TMC algorithm. 
In this approach, likelihood-based heuristics decide on the topology of cells-triplets which are 
then fed to the TMC algorithm. The depth calculation algorithm remained the same as before. 
The resulting tree can be seen in Figure 31. We could again see that the healthy cells (T-cells, 
macrophages and OECs) cluster separately from the tumor cells, and interestingly the OECs 
form a separate cluster. Within the tumor arm the M1-CTCs including one of the M0 DCCs 
tend to form separate cluster from the primary tumor cells. However, the other M0 DCC 

























To improve the clustering further, another round of deep sequencing was performed to achieve 
an average of ~5 million reads/cell, which would mean an increased number (median 7,825) 
of informative STR loci would get covered by greater than 30 reads (Figure 29). Additionally, 
advancements in the tree reconstruction algorithm used by our collaborators were also made. 
FastTree2 algorithm was used to generate lineage trees (Price, Dehal, & Arkin, 2010), which 
is a hybrid approach of the classical neighbor joining and maximum likelihood methods. The 
resulting tree is shown in Figure 32. Although we see a separation of healthy cells from tumor 
cells and a separation of the metastatic and primary tumor cells, one of the M0 DCCs still 
remains with the healthy cells (see arrow in Figure 32) and the separation within the healthy 
cells (T-cells, macrophages and OECs) does not appear robust. Next, we tried to validate the 
clusters by CNA profiling of all the cells on the tree. 
 
 
Figure 31: STR based Lineage tree of patient 01 at ~4 million reads/cell with germline DNA as root 
approximating group and OECs as another outgroup. Brown, T-cells; olive green, macrophages; yellow, OECs 
(as Kera in the legend); deep blue, Germline (as Bulk in the legend); light blue, single cells from primary tumor; 
red, M1-CTCs isolated in year 2016; light green, M1-CTCs isolated in year 2017; pink, bone marrow DCCs. The 
germline DNA samples and the OECs are however shallow sequenced in the tree. The thickness of matching 
colors on the edges reflect the hypergeometric score of the edge’s descendants, or how unlikely it is to draw X 

























Since some tumor cells were clustering with the healthy cells (T-cells, macrophages and 
OECs) and we were not able to see clear separation of hematopoietic and epithelial lineage 
cells, we wanted to check the accuracy of the clusters on tree. We used CNA analysis to 
assess the genomic profiles of the cells in the tree and bootstrapping analysis as a 
bioinformatical tool to validate the robustness of the tree. 
 
4.5.5.1. CNA profiling of cells on STR based lineage trees 
 
CNA analysis was performed to achieve two aims, (i) To confirm that tumor cells are of cancer 
origin and outgroup cells don’t contain cancer cells: It is possible that single cells isolated from 
the cryo primary tumor blocks are healthy cells of the mammary epithelium and therefore might 
be false positives. (ii) To construct cell lineage trees from CNA data. This aim exceeds the 
scope of the thesis and therefore is not presented here. Ampli1TM LowPass-Sequencing 
Technology as described in the method’s section 2.14 was used for the CNA analysis which 
included all cancer cells and healthy cells in the lineage trees of patient 01. The results of CNA 
analysis for patient 01 are as follows: (i) Cancer cells: All tumor cells (Primary tumor single 
cells, DCCs and CTCs) displayed aberrant profiles. Some of the primary tumor cells (3 out of 
23 single cells) displayed poor quality in terms of noisy profiles (DLRS values>0.35) and hence 
were removed from the lineage tree analysis. (ii) Outgroup cells: Macrophages and T-cells 
exhibit balanced profiles, nevertheless 11% of cells displayed an X-chromosome loss, but 
these profiles were counted as healthy and were not excluded from the analysis. Three out of 
11 OECs (27%) displayed aberrant or noisy profiles (DLRS value>0.35). These three cells 
were discarded from the lineage tree analysis henceforth. Examples of CNA profiles are 
shown in Figure 33. All CNA profiles and a hierarchical clustering analysis with CNA data are 
provided in Appendix 3.  
 
Figure 32: STR based Lineage tree of patient 01 at ~5 million reads/cell. Colours indicate tissue origin of 
each cell types (deep blue, CD3+ T-cells; red, CD68+ macrophages; green, M1-CTCs isolated in year 2016; 
yellow, M1-CTCs isolated in year 2017; pink, bone marrow DCCs; olive green, germline gDNA isolated from 
bulk of blood cells; light blue, OECs; brown, single cells isolated from primary tumor). The thickness of matching 
colors on the edges reflect the hypergeometric score of the edge’s descendants, or how unlikely it is to draw X 








































The resulting lineage tree after filtering cells on the basis of CNA analysis can be seen in 
Figure 34. We see a separation of the cancer cells from the healthy cells. OECs form a 
separate cluster from the hematopoietic cells (CD3+ T-cells, CD68+ macrophages) which 
originate from distinct embryonic germ layers. Interestingly, we also note a significantly clear 
separation (as indicated by an asterisk on the tree; explained in the next chapter) of advanced 
primary tumor cells from metastatic CTCs. One of the M0-DCCs (isolated 7 years before 
emergence of the metastasis) clusters with the metastatic cells. Furthermore, the other M0-
DCC is again grouped with the healthy cells (shown by arrow), but from CNA analysis we can 
confirm that the DCC shares aberrant regions with the other DCC, M1-CTCs and primary 
tumor cells (Figure 33, 10). This could suggest that the cell escaped from the primary tumor 
much earlier than its counterpart and is more ‘normal-like’. Next, the significance of the 
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Figure 33: CNA profiles of cells on the STR cell lineage tree. CNA profiles of cells on the STR cell lineage 
tree. A: Ampli1 lowpass sequencing was conducted for all the cells of the lineage tree to validate the correctness 
of the tree. 1, 2 are T-cells; 3,4 are macrophages; 5,6 are OECs, 5 is an example of one of the OECs showing 























4.5.5.2. Bootstrapping analysis 
 
On the lineage tree in Figure 34, an asterisk denote that a particular branching is significant 
using bootstrapping analysis (Lemoine et al. 2018) which suggests that corresponding clades 
are true. Bootstrapping analysis refers to resampling of a dataset iteratively, conservatively, n 
loci are sampled with replacement out of n loci. To validate the robustness of clusters seen on 
the lineage tree, bootstrapping analysis was performed (1000 iterations) to assess if the 
proximity between cells within designated groups is substantially closer than within a randomly 
sampled group of cells (Figure 35A). Majority of the groups show consistent clustering, as 
seen from smaller edge count values (both mean and median) as compared to random 
sampling, which means the clusters seen in the lineage tree are not created by chance and 
are robust except for the M0-DCCs (n = 2 cells). We next took a closer look at the DCC cluster 
by plotting a histogram of distances (here as edge counts) between the two DCCs at all the 
1000 bootstrap iterations, Figure 35B. Interestingly, in 8.4% of the bootstrap iterations M0-
DCCs had edge count of 2 meaning that the two DCCs were reconstructed in the same 
branch. Thus, there is a subset of STR loci which support common ancestry, however current 















Figure 34: STR based Lineage tree of patient 01 after filtering cells by CNA profiles. Colours indicate tissue 
origin of each cell types (deep blue, CD3+ T-cells; red, CD68+ macrophages; green, M1-CTCs isolated in year 
2016; yellow, M1-CTCs isolated in year 2017; pink, bone marrow DCCs; olive green, germline gDNA isolated 
from bulk of blood cells; light blue, OECs; brown, single cells isolated from primary tumor). The thickness of 
matching colors on the edges reflect the hypergeometric score of the edge’s descendants, or how unlikely it is to 
draw X cells of a certain colour out of Y cells in total. Arrow indicates DCC clustering with T-cells and 
macrophages. *Indicates transfer bootstrap expectation (TBE) value of >70% (bootstrap proportions of ≥70% 
corresponds to a probability of ≥95% that the corresponding clade is real (Lemoine et al. 2018)).  
 
A B 
Figure 35: Bootstrapping analysis of patient 01 cells. A: Bootstrapping performed on the cell collective shown 
in Figure 34, The ordinate indicates the range of mean/median edge counts within group in the bootstrapping 
iterations. Note that for each group (except the group of DCCs comprising only two samples), the mean and 
median treesums are lower than random, indicating consistent proximity of the cells in a group. B. Histograms of 
distances (in edge counts) from the bootstrap iterations (1000 in total) within the two DCC. Edge count 2 would 





Various studies from our lab and from around the world have proved that dissemination of 
cancer cells is an early event as opposed to the classical linear progression model (Klein 
2013). However, are these early DCCs capable of giving rise to metastasis? In mouse models 
it had been proved that 80% of the metastases arose from the early DCCs (Hosseini et al. 
2016). Based on the growth rates of tumor and metastasis, mathematical model of early 
disseminating cells giving rise to metastasis can be deduced (Klein and Holzel 2006), however 
it is challenging to identify the actual MFCs in patients. In this study, we strived to obtain single-
cells by longitudinal sampling of primary tumor, M0-DCCs and M1-CTCs to establish cell 
lineage trees of breast cancer patients to identify MFCs. We addressed two aims, i) technical: 
We established a protocol to isolate DCCs from frozen archived cytospins and were able to 
mine the archive for selecting patients with a long follow-up; ii) biological: We were able to 
identify MFCs in a breast cancer patient with 7 years of progression using de novo STR 
mutations. 
 
Genomic analysis of paired metastases and primary tumor samples from carcinoma patients 
in many other studies concluded MFCs disseminated late from the primary tumor, supporting 
the linear progression model (Leung et al. 2017; Sanborn et al. 2015; Yates et al. 2017). A 
study involving whole genome sequencing of colorectal cancer samples indicated that 65% of 
somatic mutations were common in primary tumor and metastases which indicated linear 
progression (Ishaque et al. 2018). Also a breast cancer study involving whole exome 
sequencing of paired samples from 6 patients claimed the incidence of linear progression in 5 
out of 6 cases (Kroigard et al. 2017). Many facets including technical and clinical differences 
and also our understanding of the disease could account for such inconsistencies. Bulk 
sequencing might not be suitable to unravel the heterogeneity of tumors and metastasis. Also, 
most of these sequencing studies apply the infinite sites assumption as used in species 
evolution, which means that a genomic location can mutate only once during the lifetime of 
the cancer which might not be true as seen from single cell sequencing data (Kuipers et al. 
2017). Experimental and clinical factors could also influence the studies, for example in the 
breast cancer study (Kroigard et al. 2017), it was noted that majority of samples analyzed were 
from synchronous lymph node metastasis rather than distant metachronous metastasis (which 
is mostly common), and in 3 out of 5 patients showing late dissemination, only one metastasis 
was analyzed per patient.  
 
To our knowledge this is the first single-cell study where longitudinally collected samples of 
primary tumors, and individual pairs of DCC/CTC before and after detection of systemic 
metastasis of one individual patient have been acquired and analyzed by phylogenetics using 
STR mutations which don’t possess selection advantage. 
 
5.1. Patient cohort and method development 
 
Longitudinal tracking of patients is a challenging task which demands availability of good 
quality patient material at several time points through progression. The inclusion criteria of a 
long follow-up, M0 at surgery, and availability of sample triplets comprising BM DCCs, primary 
tumor and CTCs/DCCs at a further time point before and after progressing into metastasis 
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was used.  Bone marrow (BM) aspirates collected from 4864 M0 patients undergoing curative 
surgery at the Department of Gynaecology, University of Tübingen between 2001 and 2016 
were considered for the sample collective, out of which 1068 were DCC positive. Finally, 83 
patients were shortlisted for the project and 33 (0.03% of total DCC positive patients) were 
enrolled for donating blood sample at M1 stage. We have been successful in acquiring triplet 
samples from 10 patients so far. Reasons for patient drop-out included (i) no progression to 
M1 within follow-up time (most frequent); (ii) low DCC-DNA quality; (iii) patient lost in follow-
up; (iv) patient in M1 stage but no CTCs isolated.  
 
 
Isolation of DCCs from archived cytospins 
 
In 2006 a consensus protocol for the method was published, which includes the preparation 
of slides and analysis of 2 million bone marrow cells per patient (Fehm et al. 2006). Since 
DCCs are so rare, to increase the number of cells screened at minimum cost most 
investigators (Riethdorf, Wikman, and Pantel 2008) therefore prepared cytospins at high 
cellular density. Since thousands of slides are still stored and would be amenable for single 
cell genomic analysis, and a long patient follow-up is available we tried to establish a protocol 
for single cell isolation from archived, cryo-preserved bone marrow cytospins.  
 
The technical difficulty to isolate DCCs with high quality DNA was overcome so that we now 
can mine the sample base from various clinics. At first, we confirmed that BM-DCCs obtained 
from frozen cytospins display high quality DNA irrespective of the age of preparation. We could 
demonstrate this after micro-manipulator-assisted isolation and WGA of cells from areas of 
low cell density (Results section 4.1.1, Figure 3). However, isolation of single cells from 
cytospins by micromanipulation is normally impossible due to high density and strong 
adherence of cells to the slide. Several methods were set up and tested to isolate single DCCs 
of good DNA quality after WGA. We compared the Arcturus system which is an infrared based 
laser microdissection system and the PALM laser microdissection systems for isolation of 
single cells from cytospins and were only successful using the PALM (Sluka et al. 2008; 
Vandewoestyne et al. 2013), which is based on UV laser and offers laser pressure catapulting 
(LPC) for contact free isolation of single cells. The approach was then evaluated by the 
efficiency to isolate a cell and the quality of the DNA after WGA. Finally, good quality WGA 
samples were tested by array-CGH.  
 
We standardized sample preparation protocol, (i) Staining of the background was vital for 
obtaining precise laser cutting, as the sample needs to absorb laser energy in order to allow 
“getting cut/ablated” (Vogel et al. 2007) and (ii) Sample dehydration was improved for laser 
microdissection by using reagents at -20 °C, an improvement over the manufacturer’s protocol 
also shown by other group by using ice-cold reagents (Sturm et al. 2013). Single cells having 
gone through this sample preparation procedure showed good quality DNA. (Results section 
4.1.2.1)  
 
Next, we had to standardize LPC from archived cytospins. We reasoned that lower the laser 
power needed to catapult the cell, better the DNA quality. High UV extinction coefficient of a 
sample corresponds to a lower LPC power required to isolate the cell (Vogel et al. 2007). 
Therefore, we tested several measures to increase the UV extinction coefficient for cells on 
archived cytospins. These included dark dyes, applying UV absorbing dyes and UV filters. In 
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total we compared 7 different protocols (Results section 4.1.2.2, Table 4). Unfortunately, we 
learned that DNA damage by LPC could not be avoided, since array-CGH generated highly 
artificial profiles (Results section 4.1.2.2, Figure 9,11,12). We finally established a protocol 
that allows us to obtain high quality DNA from archived cytospins by using a combination of 
laser microdissection and manual micromanipulation, which we abbreviated as LCAM. Laser 
cutting was used to ablate the cells in the surroundings so that ample space remains for 
manual micromanipulation. The genome profiles of cells obtained by array-CGH were as good 
as cells picked by micromanipulation (Results section 4.1.2.2, Figure 14). We also checked if 
the method allowed a scope of contamination from stray DNA, and we found that 
contamination is minimal and at par with the cells isolated manually. (Results section 4.1.2.2, 
Figure 16). 
 
Finally, LCAM was applied to isolate M0 DCCs from the cohort of Tübingen patients, DCCs 
from 23 BM samples have been isolated so far out of which 2 patients dropped out due to 
poor quality. 
 
5.2. Isolation of CTCs from M1 patients 
 
We used M1-CTCs obtained from blood as proxy for the metastases tissues which could be 
a heterogeneous population of cells arising from different metastatic foci. Since primary tumor 
had been removed long ago, the CTCs in peripheral blood are most likely arising from the 
systemic metastases. Although, chances of finding metastatic cells would be higher in the 
bone marrow (Janni et al. 2000), we obtained blood samples since bone marrow extraction 
from patients (other than during surgery) would be too invasive and painful.  
 
We used the FDA approved CellSearch system which is the gold standard for detection of 
CTCs in breast cancer (Cristofanilli et al. 2005). A multi-centre analysis involving 1944 patients 
showed that nearly 70% of metastatic breast cancer patients were CTC positive, and the CTC 
numbers although varied with response to treatment, number of metastatic sites, serum tumor 
bio-markers, did not vary with the tumor subtype (Bidard, Proudhon, and Pierga 2016). Thus, 
we expected to obtain CTCs from all breast cancer subtypes. A previously published workflow 
for CTC isolation and single cell genome analysis was used (Polzer et al. 2014).  
 
We found 17 out of 33 M1 patients positive for CTCs which could be because of good 
therapeutic response of the patient leading to reduced CTCs in circulation. Also, the 
CellSearch system applies EpCAM based positive selection, which might lead to loss of 
possible EpCAM negative CTCs in some patients (Sieuwerts et al. 2009). We were successful 
in isolating CTCs from 11 patients (33%), which could be attributed to patients where few 
CTCs are detected, the cells could be lost during washing of the cartridge while retrieving the 
cell suspension to isolate cells.  
 
5.3. Isolation of single cells from primary tumour tissue 
 
For lineage tree analysis we ideally need cells from the primary tumor. In 2 cases out of 10, 
primary tumor tissue was available as cryopreserved, so high quality DNA could be obtained 
from such tissues. We succeeded in setting up a protocol to isolate intact single tumor cells 
from the flash frozen tumor tissues. After WGA, single cell DNA displayed high quality and 
was also suitable for genomic analyses like arrayCGH (Results section 4.2.1, Figure 18). 
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However, since the protocol is based on anti-cytokertain staining of the tissue sections, 
healthy, non-tumor cells from the breast could also be isolated, all cells taking part in cell 
lineage tree are subsequently analyzed for CNAs, hence confirming the tumor cells. 
 
Primary tumors are mostly available as FFPE (formalin-fixed and paraffin-embedded) tissues 
which is the standard in surgical pathology, however is characterized by degraded low-quality 
DNA (Hognas et al. 2018) owing to DNA fragmentation and chemical modifications, 
prevalence of  which varies with the pre-processing conditions, age of preparation etc  
(Hognas et al. 2018; McDonough et al. 2019). WGA of single cells from FFPE tissue was 
demonstrated in a study (Martelotto et al. 2017) where they used a cocktail of DNA repair 
enzymes from NEB (sold as either PreCr repair mix or FFPE DNA repair mix) supposedly to 
reverse the chemical modifications found in FFPE, however in this study the blocks used were 
pre-selected by a QC multiplex PCR. Due to the limitation of our triplet sample cohort, we did 
not have a choice to discard blocks. In the limited blocks we tested from our cohort, single 
cells performed the same way with or without treatment with FFPE repair mix (Results section 
4.2.2.1, Figure 22). Finally, for majority of our tumor blocks we performed bulk DNA isolation 
from tumor containing areas of the block. 
 
5.4. STR based cell lineage tree analysis 
 
Somatic mutations which spontaneously occur in over a million STR regions during mitosis 
renders cells with a unique genetic signature, which could be theoretically tracked to obtain 
cell lineage trees with a probability of 99.95% (Frumkin et al. 2005).  In our case, to obtain cell 
lineage trees from longitudinally acquired samples from breast cancer patients, around 12000 
STR loci were sequenced after target enrichment using a patient-generic panel of duplex 
MIPs.  STR loci are prone to stutter noise and it is difficult to correctly genotype short low-
complexity reads, however these could be mitigated by a targeted capture using MIPs and a 
special mapping strategy (Carlson et al. 2015; Raz et al. 2019). This technique was scaled up 
to a targeted capture of more than 10000 loci by Dr Ehud Shapiro’s group (Tao et al. 2018). 
Next, this MIP panel was tested on our Ampli1 WGA samples. 
 
Critical parameters beginning from selection of outgroup, sample preparation of high quality 
Ampli1TM WGA products to optimizing sequencing and tree reconstruction algorithms were 
addressed and resolved in conjunction with Ehud Shapiro’s group in this project. (i) Outgroups 
were included as ground truth within the cell lineage tree and we selected T-cells and 
macrophages from blood as hematopoietic lineage outgroup and oral epithelial cells (OECs) 
as epithelial lineage outgroup (Results section 4.5.1, Figure 27). Acquiring these cell types 
from patients was relatively easier as they could be requested for blood and buccal swabs at 
the same time at which blood is collected for M1-CTCs. (ii) We found out that reamplification 
and an AMpure XP bead purification enhances the performance of Ampli1 WGA products in 
the duplex MIP target enrichment pipeline (Results section 4.5.2, Figure 28). (iii) Sequencing 
depth was a crucial parameter, increasing sequencing depth, increased the number of 
accurately genotyped STR loci.  It was simulated previously that correctness of a triplet tree 
reconstruction increases with increasing number of STR loci being genotyped as a function of 
depth in between the cells (Spiro and Shapiro 2016). In other words, when cells are closely 
related, a greater number of STR loci would be required to reveal the clonal relationships with 
accuracy. This fact is vital for our early disseminating DCCs and normal outgroup cells, since 
they are closer to the germline unlike progressed cancer cells. We found that at a sequencing 
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depth of ~5 million reads/cells, the median genotyped STR loci reach ~8000 (Results section 
4.5.3, Figure 29). 
 
5.5. Cell Lineage Tree of patient 01 
 
We wanted to identify the metastasis founder cells in a lobular carcinoma patient, ER/PR 
positive and Her2 negative, diagnosed with clinical metastases after 7 years of primary 
surgery. STR based lineage tree analysis should ideally reconstruct the true phylogeny of cells 
and indeed it is reflected in our data. At first, we see a separation of the cancer cells from the 
healthy cells, which improves at every iteration of sequencing from ~1 million reads/cell, to ~5 
million reads/cell (Results section 4.5.3, Figure 30). Next, OECs form a separate cluster from 
the hematopoietic cells (CD3+ T cells, CD68+ macrophages) which originate from distinct 
embryonic germ layers (Results section 4.5.4, Figure 31,32). Interestingly, we also note a 
clear separation of advanced primary tumor cells from metastatic CTCs. Here, one of the M0-
DCCs (isolated 7 years before emergence of the metastasis) clusters with the metastatic cells, 
not with the advanced cells of the primary tumor.  
 
Furthermore, the other M0-DCC is grouped with the healthy cells, irrespective of the tree 
reconstruction algorithm used (TMC or FastTree2). One could speculate that the cell escaped 
from the primary tumour much earlier than its counterpart, and is more ‘normal-like’, owing to 
which the separation from healthy cells is imperfect. Three M1-CTCs also cluster with the 
hematopoietic normal cells. Which could also have been dormant DCCs/micro-metastases 
which started circulating recently. 
 
5.6. Accumulating evidences supporting patient 01 lineage tree 
 
We gathered a substantial amount of information from the CNA analysis (Results section 
4.5.5.1, Figure 33 and Appendix 3). We found that outgroup cells were indeed normal 
(balanced profiles) except for 3 OECs which could be attributed to bad sample quality as seen 
from the noisy profiles. We could obtain an overview of the tumor cells. (i) M0-DCCs are seen 
to be heterogeneous, the DCC (ID40240) clustering with the outgroup cells is particularly 
genomically immature, as has been reported earlier (Klein 2013). (ii) Despite clustering with 
the hematopoietic outgroup, this cell is a tumor cell since the CNAs are shared with both 
primary tumor cells and M1-CTCs. (iii) Three M1-CTCs found clustered with the hematopoietic 
outgroup, are also genomically immature than its counterparts which suggests that there is 
clonal heterogeneity within metastases, and these cells could be closest to the founders of a 
slow growing, low abundant clone (see appendix 3).  
 
Next, the robustness of clusters seen on the lineage tree could be quantified by bootstrapping 




There are various limitations of this study. More M0 DCCs should have been included in the 
analysis, but due to the retrospective nature of the study and to obtain patients with a long 
follow up we had to resort to using archived cytospins which are limited in quantity. However, 
this can be mitigated by analyzing more patients. We already have 9 more patients in the 
pipeline for lineage reconstruction. Next, there is a chance that single cells that we isolated 
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from the primary tumor might not be enough to capture the entire clonal heterogeneity of the 
primary tumor. Furthermore other methods of CTC isolation like cell morphology based 
approaches (Guo et al. 2019) could be explored to obtain EpCAM negative CTCs. Our cohort 
is biased towards luminal cancers (hormone receptor positive), attempts to analyze more 
patients of each subtype is underway to identify MFCs across all breast cancer subtypes.  
 
From the bioinformatics side, several aspects must also be improved. It is noteworthy that the 
STR signals could be ambiguous due to the presence of CNAs, especially if signals come 
from multiple alleles of an STR loci (Biezuner et al. 2016). This bias introduced by the CNAs 
might also lead to the placing of cancer cells with the hematopoietic lineage cells.  Hierarchical 
clustering analysis with our CNA data (Appendix 4) shows that the M0-DCC and M1-CTCs 
which have fewer CNAs cluster separately from the rest of the M1-CTCs, interestingly, the 
same cells are also clustered away from the M1-CTC cluster in the STR based cell lineage 
tree (see ID40248, ID40249, ID40240 in Results section 4.5.5.1 in Figure 34). Next, bi-allelic 
STR genotyping could be improved in future. Inclusion of STR loci with mono repeats which 





To conclude, we successfully obtained longitudinal samples from breast cancer patients 
before and after progressing to metastatic disease, with the help of existing and newly devised 
protocols. Lineage tracing using STR loci in patient 01 showed that all the metastatic cells 
cluster apart from the advanced primary tumor cells with a detectable M0-DCC ancestor, 
thereby contradicting the linear progression model of metastasis. STR based phylogenetics 
provides a more unbiased approach compared to studies relying on driver mutations or CNA 
data of paired metastasis and PTs to reconstruct cancer lineage trees (Navin et al. 2011; 
Ishaque et al. 2018), which do not take convergent evolution into account. Deeper genomic 
analysis of these M0 DCCs by whole exome sequencing could reveal mutational signatures 
decisive for progression and help understand the complex mechanisms of tumor evolution for 




















Abdelwahab Yousef, A. J. 2017. 'Male Breast Cancer: Epidemiology and Risk Factors', Semin 
Oncol, 44: 267-72. 
Ades, F., D. Zardavas, I. Bozovic-Spasojevic, L. Pugliano, D. Fumagalli, E. de Azambuja, G. 
Viale, C. Sotiriou, and M. Piccart. 2014. 'Luminal B breast cancer: molecular 
characterization, clinical management, and future perspectives', J Clin Oncol, 32: 
2794-803. 
Ahmed, F. E. 2006. 'Laser Microdissection: Application to Carcinogenesis', Cancer Genomics 
Proteomics, 3: 217-25. 
Al-Mahmood, S., J. Sapiezynski, O. B. Garbuzenko, and T. Minko. 2018. 'Metastatic and 
triple-negative breast cancer: challenges and treatment options', Drug Deliv Transl 
Res, 8: 1483-507. 
Allard, W. J., J. Matera, M. C. Miller, M. Repollet, M. C. Connelly, C. Rao, A. G. Tibbe, J. W. 
Uhr, and L. W. Terstappen. 2004. 'Tumor cells circulate in the peripheral blood of all 
major carcinomas but not in healthy subjects or patients with nonmalignant 
diseases', Clin Cancer Res, 10: 6897-904. 
Arpino, G., V. J. Bardou, G. M. Clark, and R. M. Elledge. 2004. 'Infiltrating lobular carcinoma 
of the breast: tumor characteristics and clinical outcome', Breast Cancer Res, 6: 
R149-56. 
Banys, M., I. Gruber, N. Krawczyk, S. Becker, R. Kurth, D. Wallwiener, J. Jakubowska, J. 
Hoffmann, R. Rothmund, A. Staebler, and T. Fehm. 2012. 'Hematogenous and 
lymphatic tumor cell dissemination may be detected in patients diagnosed with 
ductal carcinoma in situ of the breast', Breast Cancer Res Treat, 131: 801-8. 
Bauer, K. D., J. de la Torre-Bueno, I. J. Diel, D. Hawes, W. J. Decker, C. Priddy, B. Bossy, S. 
Ludmann, K. Yamamoto, A. S. Masih, F. P. Espinoza, and D. S. Harrington. 2000. 
'Reliable and sensitive analysis of occult bone marrow metastases using automated 
cellular imaging', Clin Cancer Res, 6: 3552-9. 
Behjati, S., M. Huch, R. van Boxtel, W. Karthaus, D. C. Wedge, A. U. Tamuri, I. Martincorena, 
M. Petljak, L. B. Alexandrov, G. Gundem, P. S. Tarpey, S. Roerink, J. Blokker, M. 
Maddison, L. Mudie, B. Robinson, S. Nik-Zainal, P. Campbell, N. Goldman, M. van de 
Wetering, E. Cuppen, H. Clevers, and M. R. Stratton. 2014. 'Genome sequencing of 
normal cells reveals developmental lineages and mutational processes', Nature, 513: 
422-25. 
Bidard, F. C., C. Proudhon, and J. Y. Pierga. 2016. 'Circulating tumor cells in breast cancer', 
Mol Oncol, 10: 418-30. 
Biezuner, T., A. Spiro, O. Raz, S. Amir, L. Milo, R. Adar, N. Chapal-Ilani, V. Berman, Y. Fried, E. 
Ainbinder, G. Cohen, H. M. Barr, R. Halaban, and E. Shapiro. 2016. 'A generic, cost-
effective, and scalable cell lineage analysis platform', Genome Res, 26: 1588-99. 
Bill, R., and G. Christofori. 2015. 'The relevance of EMT in breast cancer metastasis: 
Correlation or causality?', FEBS Lett, 589: 1577-87. 
Blomberg, O. S., L. Spagnuolo, and K. E. de Visser. 2018. 'Immune regulation of metastasis: 
mechanistic insights and therapeutic opportunities', Dis Model Mech, 11. 
Brabletz, T., D. Lyden, P. S. Steeg, and Z. Werb. 2013. 'Roadblocks to translational advances 
on metastasis research', Nat Med, 19: 1104-9. 
Braun, S., F. D. Vogl, B. Naume, W. Janni, M. P. Osborne, R. C. Coombes, G. Schlimok, I. J. 
Diel, B. Gerber, G. Gebauer, J. Y. Pierga, C. Marth, D. Oruzio, G. Wiedswang, E. F. 
 81 
Solomayer, G. Kundt, B. Strobl, T. Fehm, G. Y. Wong, J. Bliss, A. Vincent-Salomon, and 
K. Pantel. 2005. 'A pooled analysis of bone marrow micrometastasis in breast 
cancer', N Engl J Med, 353: 793-802. 
Bray, F., J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal. 2018. 'Global 
cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide 
for 36 cancers in 185 countries', CA Cancer J Clin, 68: 394-424. 
Brenton, J. D., L. A. Carey, A. A. Ahmed, and C. Caldas. 2005. 'Molecular classification and 
molecular forecasting of breast cancer: ready for clinical application?', J Clin Oncol, 
23: 7350-60. 
Carlson, K. D., P. H. Sudmant, M. O. Press, E. E. Eichler, J. Shendure, and C. Queitsch. 2015. 
'MIPSTR: a method for multiplex genotyping of germline and somatic STR variation 
across many individuals', Genome Res, 25: 750-61. 
Chambers, A. F., A. C. Groom, and I. C. MacDonald. 2002. 'Dissemination and growth of 
cancer cells in metastatic sites', Nat Rev Cancer, 2: 563-72. 
Chatterjee, M., and K. L. van Golen. 2011. 'Farnesyl transferase inhibitor treatment of breast 
cancer cells leads to altered RhoA and RhoC GTPase activity and induces a dormant 
phenotype', Int J Cancer, 129: 61-9. 
Chu, J. E., and A. L. Allan. 2012. 'The Role of Cancer Stem Cells in the Organ Tropism of 
Breast Cancer Metastasis: A Mechanistic Balance between the "Seed" and the 
"Soil"?', Int J Breast Cancer, 2012: 209748. 
Chu, J., S. Sadeghi, A. Raymond, S. D. Jackman, K. M. Nip, R. Mar, H. Mohamadi, Y. S. 
Butterfield, A. G. Robertson, and I. Birol. 2014. 'BioBloom tools: fast, accurate and 
memory-efficient host species sequence screening using bloom filters', 
Bioinformatics, 30: 3402-4. 
Collins, V. P., R. K. Loeffler, and H. Tivey. 1956. 'Observations on growth rates of human 
tumors', Am J Roentgenol Radium Ther Nucl Med, 76: 988-1000. 
Cristofanilli, M., D. F. Hayes, G. T. Budd, M. J. Ellis, A. Stopeck, J. M. Reuben, G. V. Doyle, J. 
Matera, W. J. Allard, M. C. Miller, H. A. Fritsche, G. N. Hortobagyi, and L. W. 
Terstappen. 2005. 'Circulating tumor cells: a novel prognostic factor for newly 
diagnosed metastatic breast cancer', J Clin Oncol, 23: 1420-30. 
Cserni, G., E. Chmielik, B. Cserni, and T. Tot. 2018. 'The new TNM-based staging of breast 
cancer', Virchows Arch, 472: 697-703. 
Curtis, C., S. P. Shah, S. F. Chin, G. Turashvili, O. M. Rueda, M. J. Dunning, D. Speed, A. G. 
Lynch, S. Samarajiwa, Y. Yuan, S. Graf, G. Ha, G. Haffari, A. Bashashati, R. Russell, S. 
McKinney, Metabric Group, A. Langerod, A. Green, E. Provenzano, G. Wishart, S. 
Pinder, P. Watson, F. Markowetz, L. Murphy, I. Ellis, A. Purushotham, A. L. Borresen-
Dale, J. D. Brenton, S. Tavare, C. Caldas, and S. Aparicio. 2012. 'The genomic and 
transcriptomic architecture of 2,000 breast tumours reveals novel subgroups', 
Nature, 486: 346-52. 
Czyz, Z. T., M. Hoffmann, G. Schlimok, B. Polzer, and C. A. Klein. 2014. 'Reliable single cell 
array CGH for clinical samples', PLoS One, 9: e85907. 
Czyz, Z. T., and C. A. Klein. 2015. 'Deterministic Whole-Genome Amplification of Single Cells', 
Methods Mol Biol, 1347: 69-86. 
Domschke, C., I. J. Diel, S. Englert, S. Kalteisen, L. Mayer, J. Rom, J. Heil, C. Sohn, and F. 
Schuetz. 2013. 'Prognostic value of disseminated tumor cells in the bone marrow of 
patients with operable primary breast cancer: a long-term follow-up study', Ann Surg 
Oncol, 20: 1865-71. 
 82 
Eckhardt, B. L., P. A. Francis, B. S. Parker, and R. L. Anderson. 2012. 'Strategies for the 
discovery and development of therapies for metastatic breast cancer', Nat Rev Drug 
Discov, 11: 479-97. 
Endo, H., and M. Inoue. 2019. 'Dormancy in cancer', Cancer Sci, 110: 474-80. 
Engel, J., R. Eckel, J. Kerr, M. Schmidt, G. Furstenberger, R. Richter, H. Sauer, H. J. Senn, and 
D. Holzel. 2003. 'The process of metastasisation for breast cancer', Eur J Cancer, 39: 
1794-806. 
Evrony, G. D., E. Lee, B. K. Mehta, Y. Benjamini, R. M. Johnson, X. Cai, L. Yang, P. Haseley, H. 
S. Lehmann, P. J. Park, and C. A. Walsh. 2015. 'Cell lineage analysis in human brain 
using endogenous retroelements', Neuron, 85: 49-59. 
Eyles, J., A. L. Puaux, X. Wang, B. Toh, C. Prakash, M. Hong, T. G. Tan, L. Zheng, L. C. Ong, Y. 
Jin, M. Kato, A. Prevost-Blondel, P. Chow, H. Yang, and J. P. Abastado. 2010. 'Tumor 
cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a 
mouse model of melanoma', J Clin Invest, 120: 2030-9. 
Fallahpour, S., T. Navaneelan, P. De, and A. Borgo. 2017. 'Breast cancer survival by 
molecular subtype: a population-based analysis of cancer registry data', CMAJ Open, 
5: E734-E39. 
Fehm, T., S. Braun, V. Muller, W. Janni, G. Gebauer, C. Marth, C. Schindlbeck, D. Wallwiener, 
E. Borgen, B. Naume, K. Pantel, and E. Solomayer. 2006. 'A concept for the 
standardized detection of disseminated tumor cells in bone marrow from patients 
with primary breast cancer and its clinical implementation', Cancer, 107: 885-92. 
Foulkes, W. D., I. E. Smith, and J. S. Reis-Filho. 2010. 'Triple-negative breast cancer', N Engl J 
Med, 363: 1938-48. 
Frieda, K. L., J. M. Linton, S. Hormoz, J. Choi, K. K. Chow, Z. S. Singer, M. W. Budde, M. B. 
Elowitz, and L. Cai. 2017. 'Synthetic recording and in situ readout of lineage 
information in single cells', Nature, 541: 107-11. 
Frumkin, D., A. Wasserstrom, S. Itzkovitz, T. Stern, A. Harmelin, R. Eilam, G. Rechavi, and E. 
Shapiro. 2008. 'Cell lineage analysis of a mouse tumor', Cancer Res, 68: 5924-31. 
Frumkin, D., A. Wasserstrom, S. Kaplan, U. Feige, and E. Shapiro. 2005. 'Genomic variability 
within an organism exposes its cell lineage tree', PLoS Comput Biol, 1: e50. 
Gay, L. J., and B. Felding-Habermann. 2011. 'Contribution of platelets to tumour metastasis', 
Nat Rev Cancer, 11: 123-34. 
Ghajar, C. M., H. Peinado, H. Mori, I. R. Matei, K. J. Evason, H. Brazier, D. Almeida, A. Koller, 
K. A. Hajjar, D. Y. Stainier, E. I. Chen, D. Lyden, and M. J. Bissell. 2013. 'The 
perivascular niche regulates breast tumour dormancy', Nat Cell Biol, 15: 807-17. 
Giannakeas, V., V. Sopik, and S. A. Narod. 2018. 'A comparison of two models for breast 
cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis', 
Breast Cancer Res Treat, 169: 587-94. 
Giuliano, A. E., S. B. Edge, and G. N. Hortobagyi. 2018. 'Eighth Edition of the AJCC Cancer 
Staging Manual: Breast Cancer', Ann Surg Oncol, 25: 1783-85. 
Gomis, R. R., and S. Gawrzak. 2017. 'Tumor cell dormancy', Mol Oncol, 11: 62-78. 
Goodenough, D. A., and N. B. Gilula. 1974. 'The splitting of hepatocyte gap junctions and 
zonulae occludentes with hypertonic disaccharides', J Cell Biol, 61: 575-90. 
Grujovic, Ana. 2019. 'Regulation of cellular dormancy in disseminated breast cancer cells', 
Doctoral Thesis, University of Regensburg. 
Guo, T., E. Stankiewicz, X. Mao, and Y. J. Lu. 2019. 'The Isolation and Analysis of Circulating 
Tumor Cells', Methods Mol Biol, 2054: 115-28. 
 83 
Guzvic, M., B. Braun, R. Ganzer, M. Burger, M. Nerlich, S. Winkler, M. Werner-Klein, Z. T. 
Czyz, B. Polzer, and C. A. Klein. 2014. 'Combined genome and transcriptome analysis 
of single disseminated cancer cells from bone marrow of prostate cancer patients 
reveals unexpected transcriptomes', Cancer Res, 74: 7383-94. 
Haffty, B. G., Q. Yang, M. Reiss, T. Kearney, S. A. Higgins, J. Weidhaas, L. Harris, W. Hait, and 
D. Toppmeyer. 2006. 'Locoregional relapse and distant metastasis in conservatively 
managed triple negative early-stage breast cancer', J Clin Oncol, 24: 5652-7. 
Hammond, M. E., D. F. Hayes, M. Dowsett, D. C. Allred, K. L. Hagerty, S. Badve, P. L. 
Fitzgibbons, G. Francis, N. S. Goldstein, M. Hayes, D. G. Hicks, S. Lester, R. Love, P. B. 
Mangu, L. McShane, K. Miller, C. K. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. 
Sasano, J. N. Schwartz, F. C. Sweep, S. Taube, E. E. Torlakovic, P. Valenstein, G. Viale, 
D. Visscher, T. Wheeler, R. B. Williams, J. L. Wittliff, and A. C. Wolff. 2010. 'American 
Society of Clinical Oncology/College Of American Pathologists guideline 
recommendations for immunohistochemical testing of estrogen and progesterone 
receptors in breast cancer', J Clin Oncol, 28: 2784-95. 
Harbeck, N., and M. Gnant. 2017. 'Breast cancer', Lancet, 389: 1134-50. 
Harper, K. L., M. S. Sosa, D. Entenberg, H. Hosseini, J. F. Cheung, R. Nobre, A. Avivar-
Valderas, C. Nagi, N. Girnius, R. J. Davis, E. F. Farias, J. Condeelis, C. A. Klein, and J. A. 
Aguirre-Ghiso. 2016. 'Mechanism of early dissemination and metastasis in Her2(+) 
mammary cancer', Nature, 540: 588-92. 
Hartkopf, A. D., F. A. Taran, M. Wallwiener, M. Hahn, S. Becker, E. F. Solomayer, S. Y. 
Brucker, T. N. Fehm, and D. Wallwiener. 2014. 'Prognostic relevance of disseminated 
tumour cells from the bone marrow of early stage breast cancer patients - results 
from a large single-centre analysis', Eur J Cancer, 50: 2550-9. 
Hartkopf AD, Brucker SY, Taran F-A, Harbeck N, von Au A, Naume B, Pierga J-Y, Hoffmann O, 
Beckmann MW, Rydén L, Fehm T, Aft R, Montserrat S, Walter V, Rack B, Schuetz F, 
Borgen E, Ta M-H, Bittner A-K, Fasching P, Fernö M, Krawczyk N, Weilbaecher K, 
Margelí M, Hahn M, Jueckstock J, Domschke C, Bidard F-C, Kasimir-Bauer S, 
Schoenfisch B, Kurt AG, Wallwiener M, Gebauer G, Wallwiener D, Janni W, Pantel K. 
2018 'Abstract GS5-07: International pooled analysis of the prognostic impact of 
disseminated tumor cells from the bone marrow in early breast cancer: Results from 
the PADDY study', Proceedings of the 2018 San Antonio Breast Cancer Symposium, 
79. 
Havas, K. M., V. Milchevskaya, K. Radic, A. Alladin, E. Kafkia, M. Garcia, J. Stolte, B. Klaus, N. 
Rotmensz, T. J. Gibson, B. Burwinkel, A. Schneeweiss, G. Pruneri, K. R. Patil, R. Sotillo, 
and M. Jechlinger. 2017. 'Metabolic shifts in residual breast cancer drive tumor 
recurrence', J Clin Invest, 127: 2091-105. 
Hecht, Eva-Maria. 2016. 'Optimizing Laser Pressure Catapulting Of Single Cells While 
Preserving The DNA Integrity', Master Thesis, University of Regensburg  
Heitzer, E., M. Auer, C. Gasch, M. Pichler, P. Ulz, E. M. Hoffmann, S. Lax, J. Waldispuehl-
Geigl, O. Mauermann, C. Lackner, G. Hofler, F. Eisner, H. Sill, H. Samonigg, K. Pantel, 
S. Riethdorf, T. Bauernhofer, J. B. Geigl, and M. R. Speicher. 2013. 'Complex tumor 
genomes inferred from single circulating tumor cells by array-CGH and next-
generation sequencing', Cancer Res, 73: 2965-75. 
Hogan, M. P., D. A. Goldman, B. Dashevsky, C. C. Riedl, M. Gonen, J. R. Osborne, M. 
Jochelson, C. Hudis, M. Morrow, and G. A. Ulaner. 2015. 'Comparison of 18F-FDG 
 84 
PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus 
Invasive Ductal Carcinoma', J Nucl Med, 56: 1674-80. 
Hognas, G., K. Kivinummi, H. M. L. Kallio, R. Hieta, P. Ruusuvuori, A. Koskenalho, J. Kesseli, T. 
L. J. Tammela, J. Riikonen, J. Ilvesaro, S. Kares, P. P. Hirvikoski, M. Laurila, T. Mirtti, 
M. Nykter, P. M. Kujala, T. Visakorpi, T. Tolonen, and G. S. Bova. 2018. 'Feasibility of 
Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: 
Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues', Am J Surg Pathol, 42: 
103-15. 
Hosseini, H., M. M. Obradovic, M. Hoffmann, K. L. Harper, M. S. Sosa, M. Werner-Klein, L. K. 
Nanduri, C. Werno, C. Ehrl, M. Maneck, N. Patwary, G. Haunschild, M. Guzvic, C. 
Reimelt, M. Grauvogl, N. Eichner, F. Weber, A. D. Hartkopf, F. A. Taran, S. Y. Brucker, 
T. Fehm, B. Rack, S. Buchholz, R. Spang, G. Meister, J. A. Aguirre-Ghiso, and C. A. 
Klein. 2016. 'Early dissemination seeds metastasis in breast cancer', Nature. 
Howlader, N., S. F. Altekruse, C. I. Li, V. W. Chen, C. A. Clarke, L. A. Ries, and K. A. Cronin. 
2014. 'US incidence of breast cancer subtypes defined by joint hormone receptor 
and HER2 status', J Natl Cancer Inst, 106. 
Husemann, Y., J. B. Geigl, F. Schubert, P. Musiani, M. Meyer, E. Burghart, G. Forni, R. Eils, T. 
Fehm, G. Riethmuller, and C. A. Klein. 2008. 'Systemic spread is an early step in 
breast cancer', Cancer Cell, 13: 58-68. 
Inman, J. L., C. Robertson, J. D. Mott, and M. J. Bissell. 2015. 'Mammary gland development: 
cell fate specification, stem cells and the microenvironment', Development, 142: 
1028-42. 
Irlbeck, Christoph. 2019. 'Molecular characterization of disseminated cancer cells isolated 
from patients with luminal B type breast cancer', PhD Thesis, University of 
Regensburg. 
Ishaque, N., M. L. Abba, C. Hauser, N. Patil, N. Paramasivam, D. Huebschmann, J. H. Leupold, 
G. P. Balasubramanian, K. Kleinheinz, U. H. Toprak, B. Hutter, A. Benner, A. 
Shavinskaya, C. Zhou, Z. Gu, J. Kerssemakers, A. Marx, M. Moniuszko, M. Kozlowski, 
J. Reszec, J. Niklinski, J. Eils, M. Schlesner, R. Eils, B. Brors, and H. Allgayer. 2018. 
'Whole genome sequencing puts forward hypotheses on metastasis evolution and 
therapy in colorectal cancer', Nat Commun, 9: 4782. 
Jaffer, S., and I. J. Bleiweiss. 2002. 'Histologic classification of ductal carcinoma in situ', 
Microsc Res Tech, 59: 92-101. 
Janni, W., S. Gastroph, F. Hepp, C. Kentenich, D. Rjosk, C. Schindlbeck, T. Dimpfl, H. Sommer, 
and S. Braun. 2000. 'Prognostic significance of an increased number of 
micrometastatic tumor cells in the bone marrow of patients with first recurrence of 
breast carcinoma', Cancer, 88: 2252-9. 
Janni, W., F. D. Vogl, G. Wiedswang, M. Synnestvedt, T. Fehm, J. Juckstock, E. Borgen, B. 
Rack, S. Braun, H. Sommer, E. Solomayer, K. Pantel, J. Nesland, K. Friese, and B. 
Naume. 2011. 'Persistence of disseminated tumor cells in the bone marrow of breast 
cancer patients predicts increased risk for relapse--a European pooled analysis', Clin 
Cancer Res, 17: 2967-76. 
Javed, A., and A. Lteif. 2013. 'Development of the human breast', Semin Plast Surg, 27: 5-12. 
Klein, C. A. 2000. 'The biology and analysis of single disseminated tumour cells', Trends Cell 
Biol, 10: 489-93. 
———. 2008. 'Cancer. The metastasis cascade', Science, 321: 1785-7. 
 85 
———. 2009. 'Parallel progression of primary tumours and metastases', Nat Rev Cancer, 9: 
302-12. 
———. 2013. 'Selection and adaptation during metastatic cancer progression', Nature, 501: 
365-72. 
Klein, C. A., T. J. Blankenstein, O. Schmidt-Kittler, M. Petronio, B. Polzer, N. H. Stoecklein, 
and G. Riethmuller. 2002. 'Genetic heterogeneity of single disseminated tumour cells 
in minimal residual cancer', Lancet, 360: 683-9. 
Klein, C. A., and D. Holzel. 2006. 'Systemic cancer progression and tumor dormancy: 
mathematical models meet single cell genomics', Cell Cycle, 5: 1788-98. 
Klein, C. A., O. Schmidt-Kittler, J. A. Schardt, K. Pantel, M. R. Speicher, and G. Riethmuller. 
1999. 'Comparative genomic hybridization, loss of heterozygosity, and DNA 
sequence analysis of single cells', Proc Natl Acad Sci U S A, 96: 4494-9. 
Klein, C. A., S. Seidl, K. Petat-Dutter, S. Offner, J. B. Geigl, O. Schmidt-Kittler, N. Wendler, B. 
Passlick, R. M. Huber, G. Schlimok, P. A. Baeuerle, and G. Riethmuller. 2002. 
'Combined transcriptome and genome analysis of single micrometastatic cells', Nat 
Biotechnol, 20: 387-92. 
Kretzschmar, K., and F. M. Watt. 2012. 'Lineage tracing', Cell, 148: 33-45. 
Kroigard, A. B., M. J. Larsen, C. Brasch-Andersen, A. V. Laenkholm, A. S. Knoop, J. D. Jensen, 
M. Bak, J. Mollenhauer, M. Thomassen, and T. A. Kruse. 2017. 'Genomic Analyses of 
Breast Cancer Progression Reveal Distinct Routes of Metastasis Emergence', Sci Rep, 
7: 43813. 
Kuipers, J., K. Jahn, B. J. Raphael, and N. Beerenwinkel. 2017. 'Single-cell sequencing data 
reveal widespread recurrence and loss of mutational hits in the life histories of 
tumors', Genome Res, 27: 1885-94. 
Lambert, A. W., D. R. Pattabiraman, and R. A. Weinberg. 2017. 'Emerging Biological 
Principles of Metastasis', Cell, 168: 670-91. 
Lemoine, F., J. B. Domelevo Entfellner, E. Wilkinson, D. Correia, M. Davila Felipe, T. De 
Oliveira, and O. Gascuel. 2018. 'Renewing Felsenstein's phylogenetic bootstrap in the 
era of big data', Nature, 556: 452-56. 
Leung, M. L., A. Davis, R. Gao, A. Casasent, Y. Wang, E. Sei, E. Vilar, D. Maru, S. Kopetz, and 
N. E. Navin. 2017. 'Single-cell DNA sequencing reveals a late-dissemination model in 
metastatic colorectal cancer', Genome Res, 27: 1287-99. 
Li, C. I., B. O. Anderson, J. R. Daling, and R. E. Moe. 2003. 'Trends in incidence rates of 
invasive lobular and ductal breast carcinoma', JAMA, 289: 1421-4. 
Li, C. I., D. J. Uribe, and J. R. Daling. 2005. 'Clinical characteristics of different histologic types 
of breast cancer', Br J Cancer, 93: 1046-52. 
Linde, N., G. Fluegen, and J. A. Aguirre-Ghiso. 2016. 'The Relationship Between Dormant 
Cancer Cells and Their Microenvironment', Adv Cancer Res, 132: 45-71. 
Lodato, M. A., M. B. Woodworth, S. Lee, G. D. Evrony, B. K. Mehta, A. Karger, S. Lee, T. W. 
Chittenden, A. M. D'Gama, X. Cai, L. J. Luquette, E. Lee, P. J. Park, and C. A. Walsh. 
2015. 'Somatic mutation in single human neurons tracks developmental and 
transcriptional history', Science, 350: 94-98. 
Luker, K. E., and G. D. Luker. 2006. 'Functions of CXCL12 and CXCR4 in breast cancer', Cancer 
Lett, 238: 30-41. 
Lyons, W. R. 1958. 'Hormonal synergism in mammary growth', Proc R Soc Lond B Biol Sci, 
149: 303-25. 
 86 
Magbanua, M. J., E. V. Sosa, R. Roy, L. E. Eisenbud, J. H. Scott, A. Olshen, D. Pinkel, H. S. 
Rugo, and J. W. Park. 2013. 'Genomic profiling of isolated circulating tumor cells 
from metastatic breast cancer patients', Cancer Res, 73: 30-40. 
Magbanua, M. J., E. V. Sosa, J. H. Scott, J. Simko, C. Collins, D. Pinkel, C. J. Ryan, and J. W. 
Park. 2012. 'Isolation and genomic analysis of circulating tumor cells from castration 
resistant metastatic prostate cancer', BMC Cancer, 12: 78. 
Malhotra, G. K., X. Zhao, H. Band, and V. Band. 2010. 'Histological, molecular and functional 
subtypes of breast cancers', Cancer Biol Ther, 10: 955-60. 
Malladi, S., D. G. Macalinao, X. Jin, L. He, H. Basnet, Y. Zou, E. de Stanchina, and J. Massague. 
2016. 'Metastatic Latency and Immune Evasion through Autocrine Inhibition of 
WNT', Cell, 165: 45-60. 
Martelotto, L. G., T. Baslan, J. Kendall, F. C. Geyer, K. A. Burke, L. Spraggon, S. Piscuoglio, K. 
Chadalavada, G. Nanjangud, C. K. Ng, P. Moody, S. D'Italia, L. Rodgers, H. Cox, A. da 
Cruz Paula, A. Stepansky, M. Schizas, H. Y. Wen, T. A. King, L. Norton, B. Weigelt, J. B. 
Hicks, and J. S. Reis-Filho. 2017. 'Whole-genome single-cell copy number profiling 
from formalin-fixed paraffin-embedded samples', Nat Med, 23: 376-85. 
McDonough, S. J., A. Bhagwate, Z. Sun, C. Wang, M. Zschunke, J. A. Gorman, K. J. Kopp, and 
J. M. Cunningham. 2019. 'Use of FFPE-derived DNA in next generation sequencing: 
DNA extraction methods', PLoS One, 14: e0211400. 
McKenna, A., G. M. Findlay, J. A. Gagnon, M. S. Horwitz, A. F. Schier, and J. Shendure. 2016. 
'Whole-organism lineage tracing by combinatorial and cumulative genome editing', 
Science, 353: aaf7907. 
McMaster Pathophysiology Review. 2012-2018. 'Breast cancer'. 
http://www.pathophys.org/breast-cancer/. 
Mitra, A., L. Mishra, and S. Li. 2013. 'Technologies for deriving primary tumor cells for use in 
personalized cancer therapy', Trends Biotechnol, 31: 347-54. 
Muller, P., D. Weckermann, G. Riethmuller, and G. Schlimok. 1996. 'Detection of genetic 
alterations in micrometastatic cells in bone marrow of cancer patients by 
fluorescence in situ hybridization', Cancer Genet Cytogenet, 88: 8-16. 
Muzumdar, M. D., K. J. Dorans, K. M. Chung, R. Robbins, T. Tammela, V. Gocheva, C. M. Li, 
and T. Jacks. 2016. 'Clonal dynamics following p53 loss of heterozygosity in Kras-
driven cancers', Nat Commun, 7: 12685. 
Narod, S. A., J. Iqbal, V. Giannakeas, V. Sopik, and P. Sun. 2015. 'Breast Cancer Mortality 
After a Diagnosis of Ductal Carcinoma In Situ', JAMA Oncol, 1: 888-96. 
Navin, N., J. Kendall, J. Troge, P. Andrews, L. Rodgers, J. McIndoo, K. Cook, A. Stepansky, D. 
Levy, D. Esposito, L. Muthuswamy, A. Krasnitz, W. R. McCombie, J. Hicks, and M. 
Wigler. 2011. 'Tumour evolution inferred by single-cell sequencing', Nature, 472: 90-
4. 
Nguyen, D. X., P. D. Bos, and J. Massague. 2009. 'Metastasis: from dissemination to organ-
specific colonization', Nat Rev Cancer, 9: 274-84. 
Nilsson, M., H. Malmgren, M. Samiotaki, M. Kwiatkowski, B. P. Chowdhary, and U. 
Landegren. 1994. 'Padlock probes: circularizing oligonucleotides for localized DNA 
detection', Science, 265: 2085-8. 
O'Shaughnessy, J. 2005. 'Extending survival with chemotherapy in metastatic breast cancer', 
Oncologist, 10 Suppl 3: 20-9. 
O'Sullivan, B., J. Brierley, D. Byrd, F. Bosman, S. Kehoe, C. Kossary, M. Pineros, E. Van Eycken, 
H. K. Weir, and M. Gospodarowicz. 2017. 'The TNM classification of malignant 
 87 
tumours-towards common understanding and reasonable expectations', Lancet 
Oncol, 18: 849-51. 
Oh, H., C. E. Boeke, R. M. Tamimi, S. A. Smith-Warner, M. Wang, W. C. Willett, and A. H. 
Eliassen. 2015. 'The interaction between early-life body size and physical activity on 
risk of breast cancer', Int J Cancer, 137: 571-81. 
Paget, S. 1989. 'The distribution of secondary growths in cancer of the breast. 1889', Cancer 
Metastasis Rev, 8: 98-101. 
Pan, H., R. Gray, J. Braybrooke, C. Davies, C. Taylor, P. McGale, R. Peto, K. I. Pritchard, J. 
Bergh, M. Dowsett, D. F. Hayes, and Ebctcg. 2017. '20-Year Risks of Breast-Cancer 
Recurrence after Stopping Endocrine Therapy at 5 Years', N Engl J Med, 377: 1836-
46. 
Pantel, K., and M. von Knebel Doeberitz. 2000. 'Detection and clinical relevance of 
micrometastatic cancer cells', Curr Opin Oncol, 12: 95-101. 
Perou, C. M., T. Sorlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. Pollack, D. T. 
Ross, H. Johnsen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. 
E. Lonning, A. L. Borresen-Dale, P. O. Brown, and D. Botstein. 2000. 'Molecular 
portraits of human breast tumours', Nature, 406: 747-52. 
Polyak, K., and O. Metzger Filho. 2012. 'SnapShot: breast cancer', Cancer Cell, 22: 562-62 e1. 
Polzer, B., G. Medoro, S. Pasch, F. Fontana, L. Zorzino, A. Pestka, U. Andergassen, F. Meier-
Stiegen, Z. T. Czyz, B. Alberter, S. Treitschke, T. Schamberger, M. Sergio, G. Bregola, 
A. Doffini, S. Gianni, A. Calanca, G. Signorini, C. Bolognesi, A. Hartmann, P. A. 
Fasching, M. T. Sandri, B. Rack, T. Fehm, G. Giorgini, N. Manaresi, and C. A. Klein. 
2014. 'Molecular profiling of single circulating tumor cells with diagnostic intention', 
EMBO Mol Med, 6: 1371-86. 
Prat, A., M. C. Cheang, M. Martin, J. S. Parker, E. Carrasco, R. Caballero, S. Tyldesley, K. 
Gelmon, P. S. Bernard, T. O. Nielsen, and C. M. Perou. 2013. 'Prognostic significance 
of progesterone receptor-positive tumor cells within immunohistochemically defined 
luminal A breast cancer', J Clin Oncol, 31: 203-9. 
Prat, A., E. Pineda, B. Adamo, P. Galvan, A. Fernandez, L. Gaba, M. Diez, M. Viladot, A. 
Arance, and M. Munoz. 2015. 'Clinical implications of the intrinsic molecular 
subtypes of breast cancer', Breast, 24 Suppl 2: S26-35. 
Price, M. N., P. S. Dehal, and A. P. Arkin. 2010. 'FastTree 2--approximately maximum-
likelihood trees for large alignments', PLoS One, 5: e9490. 
Psaila, B., R. N. Kaplan, E. R. Port, and D. Lyden. 2006. 'Priming the 'soil' for breast cancer 
metastasis: the pre-metastatic niche', Breast Dis, 26: 65-74. 
Psaila, B., and D. Lyden. 2009. 'The metastatic niche: adapting the foreign soil', Nat Rev 
Cancer, 9: 285-93. 
Rabbani, S. A., and A. P. Mazar. 2007. 'Evaluating distant metastases in breast cancer: from 
biology to outcomes', Cancer Metastasis Rev, 26: 663-74. 
Rakha, E. A., J. S. Reis-Filho, F. Baehner, D. J. Dabbs, T. Decker, V. Eusebi, S. B. Fox, S. 
Ichihara, J. Jacquemier, S. R. Lakhani, J. Palacios, A. L. Richardson, S. J. Schnitt, F. C. 
Schmitt, P. H. Tan, G. M. Tse, S. Badve, and I. O. Ellis. 2010. 'Breast cancer prognostic 
classification in the molecular era: the role of histological grade', Breast Cancer Res, 
12: 207. 
Raz, O., T. Biezuner, A. Spiro, S. Amir, L. Milo, A. Titelman, A. Onn, N. Chapal-Ilani, L. Tao, T. 
Marx, U. Feige, and E. Shapiro. 2019. 'Short tandem repeat stutter model inferred 
from direct measurement of in vitro stutter noise', Nucleic Acids Res, 47: 2436-45. 
 88 
Reizel, Y., N. Chapal-Ilani, R. Adar, S. Itzkovitz, J. Elbaz, Y. E. Maruvka, E. Segev, L. I. Shlush, N. 
Dekel, and E. Shapiro. 2011. 'Colon stem cell and crypt dynamics exposed by cell 
lineage reconstruction', PLoS Genet, 7: e1002192. 
Reizel, Y., S. Itzkovitz, R. Adar, J. Elbaz, A. Jinich, N. Chapal-Ilani, Y. E. Maruvka, N. Nevo, Z. 
Marx, I. Horovitz, A. Wasserstrom, A. Mayo, I. Shur, D. Benayahu, K. Skorecki, E. 
Segal, N. Dekel, and E. Shapiro. 2012. 'Cell lineage analysis of the mammalian female 
germline', PLoS Genet, 8: e1002477. 
Riethdorf, S., H. Wikman, and K. Pantel. 2008. 'Review: Biological relevance of disseminated 
tumor cells in cancer patients', Int J Cancer, 123: 1991-2006. 
Robson, M., S. A. Im, E. Senkus, B. Xu, S. M. Domchek, N. Masuda, S. Delaloge, W. Li, N. 
Tung, A. Armstrong, W. Wu, C. Goessl, S. Runswick, and P. Conte. 2017. 'Olaparib for 
Metastatic Breast Cancer in Patients with a Germline BRCA Mutation', N Engl J Med, 
377: 523-33. 
Romond, E. H., E. A. Perez, J. Bryant, V. J. Suman, C. E. Geyer, Jr., N. E. Davidson, E. Tan-Chiu, 
S. Martino, S. Paik, P. A. Kaufman, S. M. Swain, T. M. Pisansky, L. Fehrenbacher, L. A. 
Kutteh, V. G. Vogel, D. W. Visscher, G. Yothers, R. B. Jenkins, A. M. Brown, S. R. 
Dakhil, E. P. Mamounas, W. L. Lingle, P. M. Klein, J. N. Ingle, and N. Wolmark. 2005. 
'Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast 
cancer', N Engl J Med, 353: 1673-84. 
Rosen, J. M. 2012. 'On hormone action in the mammary gland', Cold Spring Harb Perspect 
Biol, 4. 
Rosen, R. D., and A. Sapra. 2020. 'TNM Classification.' in, StatPearls (Treasure Island (FL)). 
Salipante, S. J., A. Kas, E. McMonagle, and M. S. Horwitz. 2010. 'Phylogenetic analysis of 
developmental and postnatal mouse cell lineages', Evol Dev, 12: 84-94. 
Sanborn, J. Z., J. Chung, E. Purdom, N. J. Wang, H. Kakavand, J. S. Wilmott, T. Butler, J. F. 
Thompson, G. J. Mann, L. E. Haydu, R. P. Saw, K. J. Busam, R. S. Lo, E. A. Collisson, J. 
S. Hur, P. T. Spellman, J. E. Cleaver, J. W. Gray, N. Huh, R. Murali, R. A. Scolyer, B. C. 
Bastian, and R. J. Cho. 2015. 'Phylogenetic analyses of melanoma reveal complex 
patterns of metastatic dissemination', Proc Natl Acad Sci U S A, 112: 10995-1000. 
Sanger, N., K. E. Effenberger, S. Riethdorf, V. Van Haasteren, J. Gauwerky, I. Wiegratz, K. 
Strebhardt, M. Kaufmann, and K. Pantel. 2011. 'Disseminated tumor cells in the bone 
marrow of patients with ductal carcinoma in situ', Int J Cancer, 129: 2522-6. 
Schardt, J. A., M. Meyer, C. H. Hartmann, F. Schubert, O. Schmidt-Kittler, C. Fuhrmann, B. 
Polzer, M. Petronio, R. Eils, and C. A. Klein. 2005. 'Genomic analysis of single 
cytokeratin-positive cells from bone marrow reveals early mutational events in 
breast cancer', Cancer Cell, 8: 227-39. 
Schlimok, G., I. Funke, B. Holzmann, G. Gottlinger, G. Schmidt, H. Hauser, S. Swierkot, H. H. 
Warnecke, B. Schneider, H. Koprowski, and G. Riethmuller. 1987. 'Micrometastatic 
cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo 
labeling with anti-17-1A monoclonal antibodies', Proc Natl Acad Sci U S A, 84: 8672-
6. 
Schmidt-Kittler, O., T. Ragg, A. Daskalakis, M. Granzow, A. Ahr, T. J. Blankenstein, M. 
Kaufmann, J. Diebold, H. Arnholdt, P. Muller, J. Bischoff, D. Harich, G. Schlimok, G. 
Riethmuller, R. Eils, and C. A. Klein. 2003. 'From latent disseminated cells to overt 
metastasis: genetic analysis of systemic breast cancer progression', Proc Natl Acad 
Sci U S A, 100: 7737-42. 
 89 
Schwartz, A. M., D. E. Henson, D. Chen, and S. Rajamarthandan. 2014. 'Histologic grade 
remains a prognostic factor for breast cancer regardless of the number of positive 
lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the 
SEER Program', Arch Pathol Lab Med, 138: 1048-52. 
Seely, J. M., and T. Alhassan. 2018. 'Screening for breast cancer in 2018-what should we be 
doing today?', Curr Oncol, 25: S115-S24. 
Senft, D., and Z. E. Ronai. 2016. 'Adaptive Stress Responses During Tumor Metastasis and 
Dormancy', Trends Cancer, 2: 429-42. 
Shapiro, E. 2018. 'On the journey from nematode to human, scientists dive by the zebrafish 
cell lineage tree', Genome Biol, 19: 63. 
Shariff-Marco, S., J. Yang, E. M. John, A. W. Kurian, I. Cheng, R. Leung, J. Koo, K. R. Monroe, 
B. E. Henderson, L. Bernstein, Y. Lu, M. L. Kwan, R. Sposto, C. L. Vigen, A. H. Wu, T. H. 
Keegan, and S. L. Gomez. 2015. 'Intersection of Race/Ethnicity and Socioeconomic 
Status in Mortality After Breast Cancer', J Community Health, 40: 1287-99. 
Shlush, L. I., N. Chapal-Ilani, R. Adar, N. Pery, Y. Maruvka, A. Spiro, R. Shouval, J. M. Rowe, 
M. Tzukerman, D. Bercovich, S. Izraeli, G. Marcucci, C. D. Bloomfield, T. Zuckerman, 
K. Skorecki, and E. Shapiro. 2012. 'Cell lineage analysis of acute leukemia relapse 
uncovers the role of replication-rate heterogeneity and microsatellite instability', 
Blood, 120: 603-12. 
Sieuwerts, A. M., J. Kraan, J. Bolt, P. van der Spoel, F. Elstrodt, M. Schutte, J. W. Martens, J. 
W. Gratama, S. Sleijfer, and J. A. Foekens. 2009. 'Anti-epithelial cell adhesion 
molecule antibodies and the detection of circulating normal-like breast tumor cells', 
J Natl Cancer Inst, 101: 61-6. 
Slamon, D., W. Eiermann, N. Robert, T. Pienkowski, M. Martin, M. Press, J. Mackey, J. 
Glaspy, A. Chan, M. Pawlicki, T. Pinter, V. Valero, M. C. Liu, G. Sauter, G. von 
Minckwitz, F. Visco, V. Bee, M. Buyse, B. Bendahmane, I. Tabah-Fisch, M. A. Lindsay, 
A. Riva, J. Crown, and Group Breast Cancer International Research. 2011. 'Adjuvant 
trastuzumab in HER2-positive breast cancer', N Engl J Med, 365: 1273-83. 
Sluka, P., L. O'Donnell, R. I. McLachlan, and P. G. Stanton. 2008. 'Application of laser-capture 
microdissection to analysis of gene expression in the testis', Prog Histochem 
Cytochem, 42: 173-201. 
Sorlie, T., C. M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. B. Eisen, M. 
van de Rijn, S. S. Jeffrey, T. Thorsen, H. Quist, J. C. Matese, P. O. Brown, D. Botstein, 
P. E. Lonning, and A. L. Borresen-Dale. 2001. 'Gene expression patterns of breast 
carcinomas distinguish tumor subclasses with clinical implications', Proc Natl Acad 
Sci U S A, 98: 10869-74. 
Sosa, M. S., P. Bragado, and J. A. Aguirre-Ghiso. 2014. 'Mechanisms of disseminated cancer 
cell dormancy: an awakening field', Nat Rev Cancer, 14: 611-22. 
Sotiriou, C., and L. Pusztai. 2009. 'Gene-expression signatures in breast cancer', N Engl J 
Med, 360: 790-800. 
Spiro, A., and E. Shapiro. 2016. 'Accuracy of Answers to Cell Lineage Questions Depends on 
Single-Cell Genomics Data Quality and Quantity', PLoS Comput Biol, 12: e1004983. 
Stoecklein, N. H., A. Erbersdobler, O. Schmidt-Kittler, J. Diebold, J. A. Schardt, J. R. Izbicki, 
and C. A. Klein. 2002. 'SCOMP is superior to degenerated oligonucleotide primed-
polymerase chain reaction for global amplification of minute amounts of DNA from 
microdissected archival tissue samples', Am J Pathol, 161: 43-51. 
 90 
Stoecklein, N. H., S. B. Hosch, M. Bezler, F. Stern, C. H. Hartmann, C. Vay, A. Siegmund, P. 
Scheunemann, P. Schurr, W. T. Knoefel, P. E. Verde, U. Reichelt, A. Erbersdobler, R. 
Grau, A. Ullrich, J. R. Izbicki, and C. A. Klein. 2008. 'Direct genetic analysis of single 
disseminated cancer cells for prediction of outcome and therapy selection in 
esophageal cancer', Cancer Cell, 13: 441-53. 
Sturm, D., L. Marselli, F. Ehehalt, D. Richter, M. Distler, S. Kersting, R. Grutzmann, K. Bokvist, 
P. Froguel, R. Liechti, A. Jorns, P. Meda, G. B. Baretton, H. D. Saeger, A. M. Schulte, P. 
Marchetti, and M. Solimena. 2013. 'Improved protocol for laser microdissection of 
human pancreatic islets from surgical specimens', J Vis Exp. 
Suhail, Y., M. P. Cain, K. Vanaja, P. A. Kurywchak, A. Levchenko, R. Kalluri, and Kshitiz. 2019. 
'Systems Biology of Cancer Metastasis', Cell Syst, 9: 109-27. 
Sulston, J. E., and H. R. Horvitz. 1977. 'Post-embryonic cell lineages of the nematode, 
Caenorhabditis elegans', Dev Biol, 56: 110-56. 
Sulston, J. E., E. Schierenberg, J. G. White, and J. N. Thomson. 1983. 'The embryonic cell 
lineage of the nematode Caenorhabditis elegans', Dev Biol, 100: 64-119. 
Svaren, J., S. Inagami, E. Lovegren, and R. Chalkley. 1987. 'DNA denatures upon drying after 
ethanol precipitation', Nucleic Acids Res, 15: 8739-54. 
Tao, Liming, Ofir Raz, Zipora Marx, Tamir Biezuner, Shiran Amir, Lilach Milo, Rivka Adar, 
Amos Onn, Noa Chapal-Ilani, Veronika Berman, Ron Levy, Barak Oron, Ruth Halaban, 
and Ehud Shapiro. 2018. 'A biological-computational human cell lineage discovery 
platform based on duplex molecular inversion probes', bioRxiv: 191296. 
Tjensvoll, K., O. Nordgard, M. Skjaeveland, S. Oltedal, E. A. M. Janssen, and B. Gilje. 2019. 
'Detection of disseminated tumor cells in bone marrow predict late recurrences in 
operable breast cancer patients', BMC Cancer, 19: 1131. 
Tjensvoll, K., S. Oltedal, R. K. Farmen, F. V. Shammas, R. Heikkila, J. T. Kvaloy, B. Gilje, R. 
Smaaland, and O. Nordgard. 2010. 'Disseminated tumor cells in bone marrow 
assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical 
outcome in operable breast cancer patients', Clin Breast Cancer, 10: 378-84. 
Torre, L. A., R. L. Siegel, E. M. Ward, and A. Jemal. 2016. 'Global Cancer Incidence and 
Mortality Rates and Trends--An Update', Cancer Epidemiol Biomarkers Prev, 25: 16-
27. 
Valastyan, S., and R. A. Weinberg. 2011. 'Tumor metastasis: molecular insights and evolving 
paradigms', Cell, 147: 275-92. 
van de Moosdijk, A. A., N. Y. Fu, A. C. Rios, J. E. Visvader, and R. van Amerongen. 2017. 
'Lineage Tracing of Mammary Stem and Progenitor Cells', Methods Mol Biol, 1501: 
291-308. 
van de Wouw, A. J., M. L. Janssen-Heijnen, J. W. Coebergh, and H. F. Hillen. 2002. 
'Epidemiology of unknown primary tumours; incidence and population-based 
survival of 1285 patients in Southeast Netherlands, 1984-1992', Eur J Cancer, 38: 
409-13. 
van der Toom, E. E., J. E. Verdone, and K. J. Pienta. 2016. 'Disseminated tumor cells and 
dormancy in prostate cancer metastasis', Curr Opin Biotechnol, 40: 9-15. 
Vandewoestyne, M., K. Goossens, C. Burvenich, A. Van Soom, L. Peelman, and D. Deforce. 
2013. 'Laser capture microdissection: should an ultraviolet or infrared laser be 
used?', Anal Biochem, 439: 88-98. 
Visvader, J. E., and J. Stingl. 2014. 'Mammary stem cells and the differentiation hierarchy: 
current status and perspectives', Genes Dev, 28: 1143-58. 
 91 
Vogel, A., K. Lorenz, V. Horneffer, G. Huttmann, D. von Smolinski, and A. Gebert. 2007. 
'Mechanisms of laser-induced dissection and transport of histologic specimens', 
Biophys J, 93: 4481-500. 
von Minckwitz, G., A. du Bois, M. Schmidt, N. Maass, T. Cufer, F. E. de Jongh, E. Maartense, 
C. Zielinski, M. Kaufmann, W. Bauer, K. H. Baumann, M. R. Clemens, R. Duerr, C. 
Uleer, M. Andersson, R. C. Stein, V. Nekljudova, and S. Loibl. 2009. 'Trastuzumab 
beyond progression in human epidermal growth factor receptor 2-positive advanced 
breast cancer: a german breast group 26/breast international group 03-05 study', J 
Clin Oncol, 27: 1999-2006. 
Vondeling, G. T., G. L. Menezes, E. P. Dvortsin, F. G. A. Jansman, I. R. Konings, M. J. Postma, 
and M. H. Rozenbaum. 2018. 'Burden of early, advanced and metastatic breast 
cancer in The Netherlands', BMC Cancer, 18: 262. 
Waks, A. G., and E. P. Winer. 2019. 'Breast Cancer Treatment: A Review', JAMA, 321: 288-
300. 
Weckermann, D., B. Polzer, T. Ragg, A. Blana, G. Schlimok, H. Arnholdt, S. Bertz, R. 
Harzmann, and C. A. Klein. 2009. 'Perioperative activation of disseminated tumor 
cells in bone marrow of patients with prostate cancer', J Clin Oncol, 27: 1549-56. 
Weigelt, B., F. L. Baehner, and J. S. Reis-Filho. 2010. 'The contribution of gene expression 
profiling to breast cancer classification, prognostication and prediction: a 
retrospective of the last decade', J Pathol, 220: 263-80. 
Wen, H. Y., and E. Brogi. 2018. 'Lobular Carcinoma In Situ', Surg Pathol Clin, 11: 123-45. 
Werner-Klein, M., S. Scheitler, M. Hoffmann, I. Hodak, K. Dietz, P. Lehnert, V. Naimer, B. 
Polzer, S. Treitschke, C. Werno, A. Markiewicz, K. Weidele, Z. Czyz, U. Hohenleutner, 
C. Hafner, S. Haferkamp, M. Berneburg, P. Rummele, A. Ulmer, and C. A. Klein. 2018. 
'Genetic alterations driving metastatic colony formation are acquired outside of the 
primary tumour in melanoma', Nat Commun, 9: 595. 
Willems, T., M. Gymrek, G. D. Poznik, C. Tyler-Smith, Y. Group Genomes Project 
Chromosome, and Y. Erlich. 2016. 'Population-Scale Sequencing Data Enable Precise 
Estimates of Y-STR Mutation Rates', Am J Hum Genet, 98: 919-33. 
Woelfle, U., E. Breit, K. Zafrakas, M. Otte, F. Schubert, V. Muller, J. R. Izbicki, T. Loning, and 
K. Pantel. 2005. 'Bi-specific immunomagnetic enrichment of micrometastatic tumour 
cell clusters from bone marrow of cancer patients', J Immunol Methods, 300: 136-45. 
Wolff, A. C., M. E. Hammond, D. G. Hicks, M. Dowsett, L. M. McShane, K. H. Allison, D. C. 
Allred, J. M. Bartlett, M. Bilous, P. Fitzgibbons, W. Hanna, R. B. Jenkins, P. B. Mangu, 
S. Paik, E. A. Perez, M. F. Press, P. A. Spears, G. H. Vance, G. Viale, D. F. Hayes, 
Oncology American Society of Clinical, and Pathologists College of American. 2013. 
'Recommendations for human epidermal growth factor receptor 2 testing in breast 
cancer: American Society of Clinical Oncology/College of American Pathologists 
clinical practice guideline update', J Clin Oncol, 31: 3997-4013. 
Woodworth, M. B., K. M. Girskis, and C. A. Walsh. 2017. 'Building a lineage from single cells: 
genetic techniques for cell lineage tracking', Nat Rev Genet, 18: 230-44. 
Yates, L. R., S. Knappskog, D. Wedge, J. H. R. Farmery, S. Gonzalez, I. Martincorena, L. B. 
Alexandrov, P. Van Loo, H. K. Haugland, P. K. Lilleng, G. Gundem, M. Gerstung, E. 
Pappaemmanuil, P. Gazinska, S. G. Bhosle, D. Jones, K. Raine, L. Mudie, C. Latimer, E. 
Sawyer, C. Desmedt, C. Sotiriou, M. R. Stratton, A. M. Sieuwerts, A. G. Lynch, J. W. 
Martens, A. L. Richardson, A. Tutt, P. E. Lonning, and P. J. Campbell. 2017. 'Genomic 









First of all, I would like to express my sincere gratitude towards my PI Dr. Christoph A. Klein 
for allowing me to work in his laboratory and for supervising my doctoral research. I would like 
to thank him for being such a great mentor, under his guidance I have acquired valuable 
insights on how to address scientific questions and plan experiments with a reductionist 
approach. Also, I am grateful to him for allowing me to design my experiments independently 
but also guiding me whenever I needed. I would like to thank him for helping me sharpen my 
presentation skills and also allowing me to visit various conferences. A special thanks for 
organizing the FOR2127 “Meet the Experts” Seminar Series, where we were able to closely 
interact with renowned scientists in the field. I would like to mention that I have learnt to be  
logically optimistic and to be persistent with my efforts from him which he explained with an 
example of the human genome project that “Progress curve is exponential” and I found out 
that it actually is like that! 
 
I would like to thank Stefanie Paush for helping me settle in Regensburg and till date helping 
me with my dumb administrative queries. 
 
Next, I would like to thank DFG for financing me and my project. A bundle of gratitude towards 
the patients whose consent made this research possible. Many thanks to our clinical partner 
Dr Andreas Hartkopf and especially Vincent Walter without whose dedicated efforts I could 
not have imagined building the triplet cohort of patient samples.  
 
I would like to thank our collaborators, Dr Ehud Shapiro and his team, especially Ofir Raz and 
Tzipora Marx for helping us with our research and promptly addressing our naive questions. 
Furthermore, I would like to thank our lineage tree team for their cooperation, Julia G. 
Junghans, Sandra Huber, Dr Melanie Werner Klein, and especially Dr. Zbigniew Czyż for the 
technical help.  
 
Next, I want to thank Dr. Elisabeth Schneider, Oliver Schmidt, Dr. Miodrag Gužvić, Dr 
Sebastian Scheitler, Dr. Hedayatollah Hosseini, Dr Ana Grujovic for their insights and 
guidance during the course of my study. I would like to thank Dr. Giancarlo Feliciello for 
training me for LowPass analysis and helping me whenever I needed. Many thanks to ITEM-
R members especially Dr. Bernhard Polzer and Dr. Stefan Kirsch for helping me with the 
contamination experiment, Dr Martin Hoffman for the CNA analysis from my data. 
 
I would like to thank Dr. Courtney König, Dr Christoph Irlbeck and Dr Christoph Klein for proof 
reading parts of my thesis and my examiners Dr Gunter Meister and Dr Stephan Schneuwly. 
 
I would also like to thank our SL-DTC team for introducing me to the methods in the lab and 
helping me with the patient samples. Special thanks to Manfred Meyer for his help with the 
arrayCGH experiments, and Isa always till date helps me with my DCC screening related 
questions (it is sometimes difficult to identify DCCs on cytospins!). 
 93 
 
A special thanks to my students Eva Maria Hecht, Vincent Walter, Annina Grieff without whom 
I would have never finished my PhD. 
 
I would like to thank all members of LEX and ITEM-R for the friendly atmosphere. 
I am grateful to my RIGEL mentors Dr Gunter Meister and Nikolas Stoecklein for their time 
and valuable suggestions during progress reports. 
 
From personal life, I would like to thank my friends Dr Amrita Das, Swarupa Chatterjee, Dr 
Rohit Menon, Dr Somnath Das, Dr. Zbigniew Czyż, Regina Hoheisel who made life fun in 
Regensburg. Special thanks to my Zumba instructor Virginia. Many thanks to my long-distance 
friends Poonam Kumari, Trishtina Hembram, Sujith Naik, Kireeti Bodduna, Dr Harshit 
Lakhotia, Ankan Bag, Artitra Mukhopadhyaya, John Jose, Mamata Vats and Shipra Gupta for 
always being there. 
 
Lastly, I would like to thank my lovely, parents; Rupali and Ashutosh Ghosh, brother; Anirban 




































1. Single cell DNA quality of archived frozen cytospins. (see chapter 4.1.1.) 
 
  
BM Sample ID BM isolation date Age of cytospin at isolation No. of picked cells Cells with GII>2 Percentage of  cells with GII>2
113 01.06.18 0 10 9 90
114 01.06.18 0 5 3 60
115 01.06.18 0 10 9 90
116 01.06.18 0 4 4 100
123 01.06.15 0 8 5 62.5
120 01.06.14 1 5 5 100
122 01.06.14 1 5 5 100
92 01.06.13 2 3 3 100
78 01.06.15 3 5 2 40
98 01.06.12 3 9 9 100
107 01.06.13 3 10 4 40
109 01.06.15 3 2 2 100
119 01.06.12 3 5 5 100
1 11.09.13 4 5 5 100
71 13.05.11 4 10 10 100
83 01.06.12 4 9 6 66.6
97 01.06.11 4 10 8 80
104 01.06.12 4 10 6 60
110 01.06.14 4 2 0 0
79 01.06.13 5 10 4 40
88 01.06.10 5 4 2 50
96 01.06.10 5 7 1 14
2 24.08.11 6 4 1 25
3 16.08.11 6 1 1 100
77 01.06.10 6 8 8 100
80 01.06.12 6 10 5 50
87 01.06.09 6 5 5 100
90 01.06.09 6 1 1 100
91 01.06.09 6 5 3 60
93 01.06.09 6 8 8 100
99 01.06.10 6 14 10 71.4
100 01.06.10 6 9 2 20
103 01.06.10 6 5 0 0
105 01.06.10 6 18 18 100
111 01.06.12 6 2 1 50
112 01.06.12 6 4 4 100
81 01.06.11 7 9 4 44.4
85 01.06.09 7 10 9 90
95 01.06.08 7 10 6 60
101 01.06.09 7 10 9 90
102 01.06.09 7 10 5 50
108 01.06.10 7 10 7 70
117 01.06.11 7 2 1 50
4 12.05.10 8 4 3 75
5 28.04.10 8 5 5 100
6 20.01.10 8 4 3 75
7 14.07.09 8 4 0 0
75 09.07.08 8 4 0 0
82 01.06.10 8 10 5 50
84 01.06.10 8 10 7 70
89 01.06.07 8 3 3 100
94 01.06.07 8 9 9 100
118 01.06.10 8 4 2 50
121 01.06.08 8 9 9 100
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BM Sample ID BM isolation date Age of cytospin at isolation No. of picked cells Cells with GII>2 Percentage of  cells with GII>2
8 22.04.09 9 3 0 0
9 21.04.09 9 4 0 0
10 21.04.09 9 4 4 100
11 13.01.09 9 4 0 0
12 09.12.08 9 15 5 33
13 03.12.08 9 4 2 50
14 25.11.08 9 4 0 0
15 05.11.08 9 3 0 0
16 14.10.08 9 11 11 100
17 15.07.08 9 5 3 60
18 04.06.08 9 3 3 100
72 20.05.08 9 8 6 75
86 01.06.09 9 10 7 70
19 29.01.08 10 5 5 100
20 16.01.08 10 5 4 80
21 15.01.08 10 10 4 40
22 05.12.07 10 8 6 75
23 30.10.07 10 5 5 100
24 23.10.07 10 5 1 20
25 19.06.07 10 4 1 25
73 22.05.07 10 8 6 75
74 14.03.07 10 10 3 30
26 16.05.07 11 5 4 80
27 15.05.07 11 5 0 0
28 18.04.07 11 5 5 100
29 04.04.07 11 5 3 60
30 27.03.07 11 5 3 60
31 21.03.07 11 5 2 40
32 28.02.07 11 5 3 60
33 23.01.07 11 9 7 78
34 17.01.07 11 3 3 100
35 06.12.06 11 5 3 60
36 21.11.06 11 5 3 60
37 21.11.06 11 5 3 60
38 15.11.06 11 3 1 33
39 26.09.06 11 10 5 50
40 20.09.06 11 4 0 0
41 18.08.06 11 9 8 89
42 04.08.06 11 8 3 37
43 04.04.06 12 5 3 60
44 10.02.06 12 3 1 33
45 29.07.05 12 4 0 0
46 27.07.05 12 8 3 37.5
47 01.07.05 12 11 5 45.5
48 29.06.05 12 11 2 18
49 28.06.05 12 4 3 75
50 21.06.05 12 8 2 25
106 01.06.04 12 7 4 57
51 04.05.05 13 4 1 25
52 28.04.05 13 4 1 25
53 23.02.05 13 5 1 20
54 21.02.05 13 5 4 80
55 26.01.05 13 5 1 20
56 12.08.04 13 3 0 0
57 18.05.04 14 9 2 22
76 01.06.04 14 10 4 40
58 04.12.02 15 4 3 75
59 24.09.02 15 9 4 44.5
60 17.09.02 15 4 0 0
61 06.09.02 15 5 2 40
62 16.07.02 15 10 6 60
63 27.06.02 15 5 4 80
64 12.06.02 15 5 0 0
65 04.06.02 16 5 3 60
66 15.05.02 16 6 2 33
67 08.05.02 16 4 3 75
68 06.05.02 16 5 2 40
69 10.04.02 16 5 2 40
70 08.02.00 18 5 4 80
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2. CNA profiles of single cells isolated from FFPE tumor sections (see chapter 
4.2.2.1). 
 




























































3. CNA profiles of all cells from patient 01.  
 
Tree IDs are the numbers corresponding to cells on the lineage trees shown in in Chapter 
4.5.5.1, Figure 33 and Figure 34. Cell IDs are unique IDs for each single cell. Cells IDs 
corresponding to cells from respective groups are mentioned below. 
 
Primary tumor cells: Cell IDs 6119-6143  
 
M0-DCC: Cell IDs 6144-6145 
 
M1-CTC: Cell IDs 6146-6163 
 
Macrophages: Cell IDs 6164-6188 
 
T-cells: Cell IDs 6189-6213 
 
















































































































































































































































































































































































































































4. Hierarchical clustering of cells with CNA data 
 
CNA data obtained by Ampli 1TM Lowpass-Sequencing of all the cancer cells of patient 01 
were used by Dr Martin Hoffman at ITEM-R to obtain a heatmap of genome wide aberrations 
(Figure 36A). The heatmap and denodogram is based on segmentation files from LowPass 
sequencing (Silicon Biosystems pipeline) which provide integer copy numbers. The 
dendogram showing hierarchical clustering of the cancer cells on the basis of CNAs can be 
seen in figure below. It can be noted that majority of the metastatic M1-CTCs are clustering 
separately from the primary tumor cells. From the heatmap (Figure 36A) it can be seen that 
two M1-CTCs and one M0-DCC (marked by arrows) have fewer aberrations compared to the 
rest of M1-CTCs and are clustering separately from the rest of the M1-CTCs (Figure 36B). 
Interestingly, the same cells are also clustered away from the M1-CTC cluster in the STR 
based cell lineage tree (ID40248, ID40249, ID40240 in Figure 34).  
 
Cell lineage tree reconstruction using CNV data is an ongoing project and is under 
development, however this preliminary hierarchical clustering gives us a qualitative and 
quantitative overview of the heterogeneity in the distribution of CNAs across all the tumor cells 






























Figure 36: Hierarchical clustering of cells with CNA data. A: Heatmap of CNAs, X axis shows the 
chromosome numbers, samples are denoted on the Y axis, CNAs are color coded for various intensities 
according to the legend, where deep blue indicates loss of 2 copies of a chromosomal locus and deep red 
indicates gain of >6 copies. B. Dendogram from the heatmap in A; blue, PT cell; orange, CTC; green; DCC. 
Sample ordering and dendrogram are derived from complete linkage hierarchical clustering using Euclidean 
distance 
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